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ABSTRACT  
 
Introduction 
Olfactory loss is a common non-motor symptom of Parkinson’s disease (PD), 
which has the potential to have a negative effect on quality of life.  However, 
research examining PD patients with varying degrees of loss of sense of 
smell and whether they are clinically distinct and the implications of the loss 
of sense of smell when nursing a patient with PD appears to be poorly 
explained.  
 
Objective 
To investigate whether patients with PD who have either mild/moderate 
microsmia, severe microsmia or anosmia (as measured by the University of 
Pennsylvania Smell Identification Test (UPSIT)) were clinically different when 
compared across a range of motor, non-motor and quality of life domains.  
 
 Methodology 
This is an open cross-sectional observational study, involving 112 patients (of 
both genders) who have a diagnosis of PD.  Tools and scales used include 
the motor rating subscales in the Unified Parkinson’s Disease Rating Scale 
(UPDRS), the Non-motor Symptoms Questionnaire (NMSQ), the PDQ39 
Quality of Life Questionnaire (PDQ39), the Hoehn and Yahr scale (H&Y), the 
Rapid Eye Movement Behaviour Disorder Screening Questionnaire, (RBD) 
and the Montreal Cognitive Assessment (MoCA). 
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Results 
Seventy-two males and forty females have been recruited for this study.  Age 
ranged from 49 - 89 years (mean age 71 years).  Eight-five (77%) of the PD 
patients were at stage 1 or 2 Hoehn and Yahr staging highlighting the study 
sample mainly consisted of PD patients with minimal or no functional 
impairment, without impairment of balance. Disease duration ranged from 6 
months to 19 years (mean duration 5.5 years).  All PD patients (except two) 
were considered to have either normal cognition or mild cognitive 
impairment, defined by the MoCA (mean MoCA 26.1).   
 
All the PD patients recruited for this study had loss of sense of smell and 
91% had -in fact- severe microsmia or anosmia.  Seventy-nine (70.5%) PD 
patients correctly detected a reduced sense of smell.  Twenty-nine out of the 
33 PD patients (97%) (self-reporting a normal sense of smell) had, in fact, a 
severe degree of loss of sense of smell (Mean UPSIT 16) without realising it.   
 
Overall loss of sense of smell was not correlated with severity or stage of PD, 
duration of disease, medication, smoking, the environment in which the PD 
patient was tested, whether they had phantosmia (persistent pleasant or 
disgusting smell) or taste problems.  There was also no correlation between 
the motor, non-motor, rapid eye movement disorder and quality of life themes 
during whole group analysis. However, on sub-group analysis,  a positive 
correlation was noted between sense of smell  score and PD patients with 
normal cognition compared to those with mild cognitive impairment using 
MoCA ( =0.213, p=0.024)  and non-motor symptom dribbling of saliva 
during the day (p=0.003),  There was also a negative correlation in PDQ39 
cognition theme (score =-0.012 p=0.036), minutes since last PD 
medication taken ( =-0.2634, p=0.008), timing of levodopa dose ( =-
0.1875, p=0.015), and individual domains of the UPDRS motor scores, 
including posture ( = -.231 p=0.014) facial expression ( =-0.207 p=0.029) 
and arising from a chair ( =-0.190 p=0.045). 
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Conclusion 
This study raises three important points; (i) all the PD patients in this study 
had abnormal sense of smell, highlighting that loss of sense of smell in PD is 
very common, (ii) PD patients need to be formally tested to assess their 
degree of smell loss as their ability to recognise this cannot be relied upon 
and (iii) olfactory loss can be profound even in in the early stage and duration 
of PD. 
However, there were several limitations to the present PhD study due to a 
possible sample size effect and some aspects of this study relied on self-
reported data in the form of questionnaires which could be a potential source 
of bias.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 OVERVIEW 
 
The clinical diagnosis of Parkinson’s disease (PD) is currently outlined by the 
UK Parkinson’s Disease Brain Bank Clinical Diagnostic Criteria and relies on 
the presence of bradykinesia (slowness of initiation of voluntary movement 
with progressive reduction in speed and amplitude of repetitive actions) and 
at least one of the following:-  muscular rigidity, 4-6 Hz rest tremor and 
postural instability, not caused by primary visual, vestibular, cerebellar, or 
proprioceptive dysfunction (Hughes et al 1992).  Despite these diagnostic 
criteria, the accuracy of such a diagnosis, even after long term follow-up 
(applied by experts), has at its best 84%-90% sensitivity (Rizzo et al 2016, 
Brooks 2012, Hughes et al 2001).  
 
It is now known however, that non-motor symptoms as well as the typical 
motor features are well recognised in PD (Chaudhuri et al 2006).  These 
include sensory disturbances such as visual contrast sensitivity, colour 
perception, and sensations associated with proprioception (such as 
numbness and tingling) (Doty et al 1995).  However, the most consistent 
sensory deficit in PD is olfactory impairment (Tissingh et al 2001).  The 
neuropathological basis of this dysfunction is neuronal damage in the 
olfactory system, including the olfactory bulb and the anterior olfactory 
nucleus (Braak et al 2003).  
 
Impairment of olfaction in PD was first recognised in the 1970s (Ansari and 
Johnson 1975, Constandinidia et al 1970).  There is now good research 
evidence that the ability to smell is significantly affected in PD compared to 
the general population (Cajuns et al 2013, Latvian et al 2003, Artmaker et al 
2002, Hawkes et al 1999, Hawkes and Shephard 1998, Mesholam et al 
1998, Hawkes et al 1997, Doty et al 1988, Quinn et al 1987) and affects at 
least 80% of PD patients (Double et al 2003, Mesholam et al 1998, Hawkes 
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et al 1997).  There is also evidence that impaired olfaction may precede the 
classical motor manifestations by several years (Ross et al 2008, Haehner et 
al 2007, Stiasny-Kolster et al 2005, Pones et al 2004, Hawkes 2003, 
Berendsen et al 2001, Doty et al 1988), suggesting that neuronal damage 
occurs early in the diagnosis before the classical motor signs are evident 
(Braak et al 2003). 
 
Although olfactory deficits are now considered a highly characteristic feature 
of PD (Katzenschlarger and Lees 2004), several studies suggest that 
olfactory deficits in PD are unrelated to factors such as disease stage and 
duration (Haehner et al 2009, Hawkes et al 1997, Doty et al 1988, Quinn et al 
1987, Ward et al 1983).  However, a study by Tissingh et al (2001) 
highlighted that smell discrimination scores were related to disease severity, 
suggesting that at least some aspects of olfactory dysfunction in PD patients 
may be secondary to ongoing degenerative processes in PD.   
 
Interest in the phenomenon has grown markedly in the past few years, driven 
by the hope of developing neuroprotection treatment for patients in the early 
stage of the disorder.  This PhD study however, aims to explore the 
relationship between olfactory dysfunction in PD and disease severity, within 
the motor, non-motor and quality of life domains.  Patients with PD were 
divided (depending on their sense of smell scores) into three sub-groups 
(mild/moderate microsmia, severe microsmia and anosmia) to see if they are 
clinically different.  This study also addresses the implications of the loss of 
sense of smell for nursing a patient with PD.  
 
1.1.1. Prevalence of PD 
 
Parkinson’s disease is the second most common chronic neurodegenerative 
condition in older people especially beyond the age of sixty (Office for 
National Statistics. Age structure: Census 2001, Spillantini and Goedert 
2000, De Rijk et al 1997).  It occurs because of the progressive loss of 
dopamine-producing nerve cells in a region of the brain called the substantia 
nigra.  
26 
 
There are a limited number of prevalence studies that have been carried out 
in various United Kingdom (UK) regions over the last two decades (Walker et 
al 2010, Wickremaratchi et al 2009, Porter et al 2006, Hobson et al 2005, 
Schrag et al 2000, Mutch et al 1986).  Their results on prevalence ranged 
from 105 to 178 persons with Parkinson’s per 100,000 of the population.  The 
possible reasons for such a varied range of prevalence may be attributed to 
the fact that all these studies have been performed in specific regions, biased 
by the characteristics of the populations studied.  Therefore, access to and 
quality of health care services and the accuracy of diagnosis at local level 
may be factors affecting the differences in prevalence (Parkinson’s UK 2009)  
A relatively more recent study (Parkinson’s UK 2009) calculated the 
prevalence of PD (using the clinical practice research datalink) as 
27.4/10,000 which is equivalent to 126,893 cases when scaled up to the total 
UK population of whom 69,850 were males and 57,043 were females (males 
are 1.5:1 times more likely to develop PD than females (Wooten et al 2004).  
The highest prevalence rate of Parkinson’s was among those aged > 80 
years.  Future trends suggest the number of people with Parkinson’s will 
increase to 162,000 in 2020 which represents a 28% increase on the 2009 
figure with particular increase in the older age group (Parkinson’s prevalence 
in the UK 2012).  Currently, over 500 people with a diagnosis of PD are 
registered on the local PD Trust database. 
 
1.1.2. Socio-Economic Burden of PD 
 
Few studies have examined the cost of PD in the UK.  An early study 
conducted by West (1991) reported an annual cost to the National Health 
Service of £126 million.  This figure was based on national statistics and 
considered direct costs only.  A more recent study (Findley et al 2003), used 
a cross-sectional, survey-based approach through interviews and study 
questionnaires to 432 PD patients, in which three categories of direct costs 
were included: NHS costs, social service costs and private PD-related 
expenditures.  Costs were analysed according to age and disease severity 
(Hoehn and Yahr stage) of PD.  Direct costs in the UK were estimated at 
£5993 per patient per year, NHS costs (38%) social services costs (35%) and 
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private expenditure (27%).  This equates to £288 million annual costs to the 
National Health Service, £266 million annual costs to social services and 
£205 million annual costs to private expenditure.  In clinical practice, the rise 
in social services costs is particularly influenced by the degree of disability 
(Hoehn and Yahr stage).  Findley et al (2003) in their study identified that 
disease severity was a crucial factor associated cost.  Thus, total cost of PD 
in the UK, using the recent Parkinson’s disease UK (2006) prevalence study 
on direct costs might be as high as £760 million annually.  
 
Therefore, the cost of PD is extremely high in both economic terms and in 
terms of the impact on patients’ lives.  For these reasons, strategies that 
maximise quality of life, while minimising the impact of disease progression, 
are paramount.  This can be achieved by not only optimising therapies to 
treat motor symptoms but also by addressing non-motor complications and 
quality of life issues, such as those that are (and might be) associated with a 
reduced sense of smell. 
 
1.1.3 Implications for Nursing   
 
The sense of smell is an important chemical warning system that regulates 
food intake and is involved in social and personal interactions and 
relationships and is linked to our memories and places.  Consequently, 
adverse effects in patients with olfactory disorders have been reported with 
regards to poor safety, difficulties cooking and detecting spoiled food, 
decreased food enjoyment and poor appetite, change in body weight, worries 
about personal hygiene, depression and mood changes, feelings of 
vulnerability, and deterioration in work life, social interactions and sexual life 
(Hummel and Nordin 2005). This highlights that reduced sense of smell is 
associated with reduced quality of life. 
 
There appears, at this present time, no evidence in the literature that any 
treatment exists to reverse, protect or slow down the loss of sense of smell 
seen in PD and therefore coping strategies play a vital role in dealing with 
everyday problems.  Nurses, not only due to their expertise in the bio-
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psychosocial approach to care, but also because they are direct care 
providers are in an ideal position to advise on coping strategies and refer to 
other members of the multi-disciplinary team.  
 
As a nurse consultant working with patients with Parkinson’s disease and 
allied conditions, the role, although diverse, is also firmly grounded in direct 
care provision or clinical work with patients and families.  However, unlike 
general nurses this involves regular reviews via nurse led clinics, home visits, 
in-patient visits, and telephone consultations.  The role requires advanced 
skills in physical examinations, interpreting diagnostic tests, communication, 
prescribing medication and monitoring the effectiveness of therapeutic 
interventions.  The ability to comprehensively assess patients for risk factors 
and early signs of illness due to the complex and unpredictable care events 
that PD patients encounter is paramount.  
 
 
1.2. GENERAL REVIEW OF THE LITERATURE EXPLORING THE GAPS 
IN CURRENT KNOWLEDGE AROUND THE LOSS OF SENSE OF SMELL 
IN PD 
 
The major objectives of this literature review were to: (i) explore the sense of 
smell in relation to PD and the significance of this for PD patients, (ii) identify 
gaps in the current body of knowledge and (iii) identify a place where a new 
contribution could be made.   This helped to set the scene for the main 
research question itself and the most appropriate methodology (see figure 
1.1 for elements of literature review). 
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Figure 1.1 Elements of Literature Review 
 
An initial search was conducted between August 2010 and January 2011 
using electronic citation databases, CINAHL, BNI Medline, PubMed, and 
PubMed Related Articles’ (this includes PubMed Central, Medline, Embase 
and the Cochrane central trials Registry). Subsequent major literature 
searches were performed between July 2012 and December 2012 after the 
study proposal was accepted, between June 2014 and December 2014 prior 
to voice viva to transfer to PhD and between April 2016 and August 2016 
prior to final voice viva. However, this was an ongoing process throughout 
this study. 
   
There was a variety of search terms used for each section. For example, 
“olfaction” “olfactory” “smell” “anosmia,” “hyposmia”, “microsmia” and “odour” 
were all used to look for smell and smoking, smokers, cigarette, nicotine 
Parkinson’s disease, PD, sense of smell, olfaction, smell and odour for one 
Literature Review 
Explore exsisting 
information/research 
on sense of smell and 
Parkinson's disease  
Locate major works on 
this topic and acertain 
key researchers 
working on thsi topic.  
Identify tools and 
assesments used in the 
work of other 
researchers 
Notice main 
methodologies and 
research tecniques 
Identify gaps in 
exsisting research and 
establish  context  for 
this PhD study 
Show relationships 
between previous 
studies/theories and 
establish  similarities 
and diferences 
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section (see section 3.1.4). The thesaurus of synonyms was also used to 
expand on search terms. 
 
Some research articles offered links to the full-text material. In addition, web-
based search engines, i.e., Google and Google Scholar were also accessed 
as well as accessing papers through ResearchGate.  However, if any core 
journal references were unavailable in full text from the databases searched 
the Online Library was accessed to see if the full text of the article is 
available from any other database by using Article Linker or through the 
Trusts library service.  
 
When searching these databases, emphasis was given to primary articles 
where possible, such as expert's new evidence, proposals, case reports, 
clinical trials and conference papers, although secondary articles such as 
peer reviews were also considered an important part of the analysis.  The 
researcher also became a member of respected journals on movement 
disorders, neurology and olfaction to eliminate any frustrations encountered 
by being denied access to scholarly papers.  The researcher also discussed 
with colleagues and eminent researchers in the field of PD and olfaction the 
topic under investigation and the most appropriate tools to use for data 
collection and the most appropriate method to disseminate this information.   
 
Also, several frequently cited variables that could affect a patient’s perceived 
or actual sense of smell were noted during initial analysis, (see sections 1.2.2 
to 1.2.7).  
 
The researcher initially started with the most recently published papers and 
worked backwards until the earliest records of smell loss was found. This 
was to establish current issues. However, it was soon apparent who the 
important authors were in this field and therefore some searches included 
looking for specific authors and sense of smell. 
  
The researcher looked for rigour, credibility, relevance’ and particularly the 
number of citations and started looking at references cited in highly relevant 
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articles. The researcher also combined keywords, for example, “Parkinson’s 
and olfaction”. Furthermore, the link entitled ‘Related Articles’ in PubMed was 
used to searches for similar citations which scans titles, abstracts and 
Medical Subject headings.  
 
Firstly, all study titles and abstracts were screened and studies that clearly 
did not meet the inclusion criteria were excluded (i.e.  loss of sense of smell 
reported for other known conditions besides PD such as post-viral or post-
traumatic injury or since birth). The articles were then grouped into; A= must 
read (highly relevant, high quality), B = unsure, probably relevant, but not yet 
sure how and C= probably irrelevant, not what you thought it was when you 
read the title. Throughout the study all articles were then filed into sub-
sections. For example, folders were named, smoking, cognition, tools for 
assessment, pathology and put into alphabetical order of first author’s 
surname. A language criterion was not set. However, all the papers found 
were available in the English or American language.  
It is important to highlight that due to a plethora of information on PD and 
sense of smell, those authors that consider their argument, are most 
convincing of their opinions and make the greatest contribution to the 
understanding and development of this area, have been referenced.  This 
was achieved by working systematically through each article using Holland 
and Rees (2010) critiquing framework for both qualitative (see appendix 1) 
and quantitative (see appendix 2) research.   
 
The literature revealed that although there were wide variations in the 
prevalence of smell loss, the consensus now is that at least 80% of people 
with PD do have some degree of smell loss (Haehner et al 2009, Double et al 
2003, Mesholam et al 1998, Hawkes et al 1997).  This means that 101,000 
out of the 127,000 PD patients in the UK have a loss of sense of smell.  
Given the significance of this, it was deemed important to establish whether 
the sense of smell progresses alongside the natural history of PD, in the 
motor, non-motor and quality of life domains.  The literature review revealed 
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that although the sense of smell in PD has been extensively explored, 
particularly trying to establish a link between the loss of sense of smell and 
the well-known motor aspects of PD (Casjens et al 2013, Litvan et al 2003, 
Ramaker et al 2002, Hawkes et al 1999, Hawkes and Shephard 1998, 
Mesholam et al 1998, Hawkes et al 1997, Doty et al 1988, Quinn et al 1987), 
no studies were found so far, that have explored the link between the sense 
of smell and other non-motor or quality of life symptoms frequently seen in 
patients with PD.  Therefore, such a narrow focus may not fully explain the 
link between the sense of smell and the diverse symptoms seen in PD.  This 
PhD study addresses this by looking at the correlation between the sense of 
smell and other non-motor and quality of life symptoms, as well as re-
examining the typical individual motor symptoms seen in PD.  Clarifying the 
link with the motor, non-motor and quality of life symptoms and degree of 
smell loss could not be justified with the present available evidence as no 
research -to date- had further sub-divided patients per their degree of smell 
loss.  The researcher therefore divided the patients’ sense of smell into three 
sub-groups (mild/moderate microsmia, severe microsmia and anosmia) to 
see if they were clinically different.  This will also allow the researcher to 
establish whether the degree of smell loss might predict symptoms likely to 
be encountered by people with PD. 
 
1.2.1. Impairment in Olfaction 
 
Olfactory dysfunction (or disorders) can be generally classified into: (i) 
conductive disorders caused by the interference with the access of odorants 
to the olfactory receptors, (ii) peripheral sensorineural disorders resulting 
from injury to the olfactory receptors and (iii) central neural disorders of the 
olfactory bulb or tract or related parts of the central nervous system such as 
the temporal lobe (Doty 2003). 
 
1.2.1.1. Terminology 
 
Olfactory dysfunction is defined in terms of its severity, using a wide range of 
terminology.  Anosmia is the inability to perceive odour or a lack of 
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functioning olfaction (also called olfactory anaesthesia).  Microsmia (also 
called hyposmia) is defined as a reduced or lessened ability to detect odours 
and normosmia is defined as normal sense of smell. 
 
For this study, a specific classification scoring system and terminology were 
used (see section 2.4.6).  This classification scheme has been developed by 
Doty in 2003 for establishing an adult patient’s olfactory diagnosis using the 
40 item University of Pennsylvania Smell Identification Test (UPSIT) (Doty 
2003). 
In this classification scheme (Doty 2003), anosmia is defined as total inability 
to perceive odour sensations, whereas microsmia is defined operationally as 
decreased smell ability.  The term microsmia was chosen for this study to 
specifically relate to the scores on the Smell Identification Test (UPSIT) (Doty 
2003) (see section 2.4.6) and does not draw a distinction between “Partial 
Anosmia” and “Hyposmia”.  Doty (2003) further subdivides the microsmia 
category into “severe”, “moderate” and “mild” classes.   
 
1.2.1.2. Pathophysiology of Olfaction in PD 
As previously stated, olfaction is markedly reduced in PD compared to the 
general population (Casjens et al 2013, Litvan et al 2003, Ramaker et al 
2002, Hawkes et al 1999, Hawkes and Shephard 1998, Mesholam et al 
1998, Barz et al 1997, Hawkes et al 1997, Hawkes and Shephard 1993, 
Hummel et al 1993, Doty et al 1988, Quinn et al 1987, Ward et al 1983).  
There is also evidence that olfactory dysfunction is more prevalent than the 
cardinal sign of a resting tremor (approximately 70%) of PD patients (Alves et 
al 2008) and equal to rigidity and bradykinesia (Alves et al 2008, Hawkes et 
al 1999, Hoehn and Yahr 1967).  There is also evidence that olfactory loss 
significantly affects quality of life (Politis et al 2010).  Indeed, according to 
Politis et al (2010), olfactory loss belongs to the top five most prevalent 
symptoms (both from a motor and non-motor perspective) that have affected 
the quality of life of PD patients.  This highlights the importance of smell loss 
in PD not only as a biomarker and as an aid to diagnosis, but also the effect 
this has on the PD patient’s quality of life.  This concurs with the results of a 
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case-control study on 90 PD patients and healthy controls by Bohnen et al 
(2010) who found that the accuracy of smell testing in PD diagnosis 
outweighs the accuracy of motor test batteries, and other non-motor tests of, 
for example, depression and anxiety. 
The cause of impairment of olfaction in PD is likely to be due to the presence 
of Lewy bodies (abnormal aggregates of protein that develop inside nerve 
cells in PD and other Lewy body pathologies) and neuritis in the olfactory 
bulb and its projections through the olfactory tract to the anterior olfactory 
nucleus (Kranick and Duda 2008, Braak et al 2003, Pearce et al 1995).  It is, 
therefore, more likely to be a central neural disorder than a peripheral 
disorder (Haehner et al 2011, Hummel et al 2010, Witt et al 2009, Silveira-
Moriyama et al 2009, Westermann et al 2008, Muller et al 2005).  However, 
there is also some debate as to whether PD related olfactory deficit is directly 
associated with specific changes at the peripheral level of the olfactory 
system (such as the olfactory mucosa).  Crino et al (1995) in their research 
conclude PD sufferers show dystrophic axons in the lamina propria of the 
olfactory mucosa but this is not specific for PD and occurs also in Alzheimer’s 
disease (AD) and even in healthy individuals.  Furthermore, Witt et al (2009) 
found no specific changes in the nasal mucosa of PD patients compared with 
patients who had microsmia for other reasons.  Therefore, PD-related 
olfactory impairment does not seem to be directly associated with specific 
changes in the olfactory mucosa, further clarifying that it is likely to be a 
central neural disorder and therefore irreversible. 
However, most olfactory studies in PD have used clinical diagnostic criteria 
and none have post mortem validation to confirm the diagnosis.  This is 
reasonable, considering particularly the ethical, scientific, legal and cost 
implications associated with post-mortem procedures (Brain Procurement 
Programme 2015).  However, post-mortem validation is of considerable 
relevance in PD as it has been estimated that the diagnostic error rate made 
in the community by non-experts, currently diagnosing PD is usually in the 
range of a 25% (Brooks 2012); this can be reduced to a 10% error rate if the 
established brain bank criteria is applied by experts (Brooks 2012, Hughes et 
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al 2001, Hughes et al 1992).  Despite this, it is reasonable to propose that 
patients with PD have profound disorder of olfactory function.  This 
observation is based on pathological abnormality, psychophysical tests, and 
evoked potential studies (Hummel et al 2013, Litvan et al 2003, Ramaker et 
al 2002, Hawkes et al 1999, Hawkes and Shephard 1998, Doty et al 1988, 
Quinn et al 1987, Ward et al 1983).  This means that testing a patient’s sense 
of smell may reduce the diagnostic error rate and may need to be considered 
as part of the brain bank criteria. 
 
Although, research suggests approximately 80% of PD patients have 
olfactory loss (Haehner et al 2009, Herting et al 2008, Double et al 2003, 
Muller et al 2002, Daum et al 2000, Meshholam et al 1998, Hawkes and 
Shephard 1998, Hawkes et al 1997, Hummel et al 1997, Wenning et al 1995, 
Doty et al 1988, Quinn et al 1987), two other studies concluded that 100% of 
PD patients had olfactory loss (Herting et al 2008, Hummel et al 1997).  
Hummel et al (1997) states the diagnosis of PD should be reconsidered if 
olfaction is normal on testing by reliable methods such as University of 
Pennsylvania Smell Identification Test (UPSIT) or the Brief Smell 
Identification Test (BSIT). (Doty et al 1984). 
 
Furthermore, olfactory deficits are now considered a highly characteristic 
feature of PD (Katzenschlarger and Lees 2004), several studies suggest that 
olfactory deficits in PD are unrelated to factors such as disease stage and 
duration, and are therefore non-progressive (Meusel et al 2010, Stern et al 
1994, Doty et al 1992, Doty et al 1988, Quinn et al 1987, Ward et al 1983) 
(see table 1.1).  However, three later studies highlighted that odour 
discrimination scores correlate well with disease stage and severity, and 
therefore sense of smell loss may be progressive (Deeb et al 2010, 
Boesveldt et al 2008, Tissingh et al 2001) (see table 1.2).  In addition, odour 
discrimination performance (in patients with PD) improves concurrent with 
clinical motor improvement after stereotactic neurosurgical treatment using 
deep brain stimulation (Hummel et al 2005).  This possibly indicates that at 
least some aspects of olfactory dysfunction in PD may be secondary to on-
going degenerative processes in PD.  As this study is an open cross-
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sectional study (and not a longitudinal study), this issue was not assessed. 
However, none of the above studies investigated patients according to 
severity of smell loss which this PhD study addresses. 
 
Table 1.1 Studies that Show Loss of Sense of Smell does not Correlate 
with Disease Stage or Duration 
 
Author-
Year 
Study Number of 
Cases 
Follow-
up 
Assessment Conclusion 
Meusel et 
al 2010 
Retrospective, 
Longitudinal 
19 PD 
patients 
5 years Psychophysical 
tests including 
“Sniffin Sticks”,  
Fluctuations seen in 
olfactory loss but did 
not predict the course 
of PD. 
Doty et al 
1992 
Comparative 
Study 
40 PD 
patients (20 
early-stage 
non-treated 
and 20 
early-stage 
treated) and 
20 controls  
NA UPSIT No relation was 
present between the 
olfactory test scores 
and the degree of 
tremor, rigidity and 
bradykinesia or gait 
disturbance at the 
time of testing.  
Doty et al 
1988 
Longitudinal 
Study 
81 PD 
patients 
5-39 
months. 
Re-test 
24 
patients 
UPSIT 40 
Phenyl ethyl 
alcohol odour 
detection test  
Consistent and 
marked olfactory 
impairment. 
No evidence of 
longitudinal change.  
Stern et al 
1994 
Comparative 
Study 
118 PD 
patients  
NA UPSIT 40 No significant 
correlation. 
Hawkes et 
al 1997 
Case Control 96 PD 
patients, 96 
controls 
NA UPSIT 
Olfactory Evoked 
Potentials,  
Olfactory damage in 
Parkinson’s disease is 
consistent and severe. 
 
Table 1.2 Studies that Show Loss of Sense of Smell Correlates with 
Disease Severity/Duration 
 
Author-
Year 
Study Number 
of Cases 
Follow
-up 
Assessment Conclusion 
Tissingh et 
al 2001 
Case Control 41 PD 
patients, 
18 healthy 
controls 
NA Odour Detection, 
Discrimination and 
Identification Test 
Odour discrimination 
measures were related to 
disease severity. 
Boesveldt 
et al 2008 
Comparative 
Study 
404 PD 
patients  
150 
controls 
NA Sniffin Sticks 
Battery 
The impairment in odour 
discrimination appears to 
increase with disease 
duration whereas odour 
identification did not. 
Deeb et al 
2010 
Longitudinal  73 early 
PD 
patients 
15 
months 
(mean) 
UPDRS, DaTSCAN, 
Electrogustometry 
(EGM), UPSIT, 
Olfactory Event-
Related Potentials 
(OERP) 
Early PD patients have a 
frequent and severe 
olfactory deficit that 
correlates with disease 
severity, symptom 
duration and DaTSCAN 
but not EGM. 
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1.2.2. Why do Clinicians Need to Test for Sense of Smell Formally in PD 
Patients? 
 
According to some clinical studies, PD patients frequently complain of 
impaired sense of smell years prior to the appearance of motor impairments 
(Wolters et al 2000, Hawkes et al 1999, Mesholam et al 1998, Hawkes et al 
1997).  However, self-reporting of smell dysfunction is regarded as too 
unreliable as between 40% and up to 76% of PD patients with smell 
dysfunction on formal smell testing have failed to notice it (Muller et al 2002, 
Doty et al 1988, Doty et al 1992, Hawkes and Doty 2009).  Hawkes and Doty 
(2009) reported in their study, that those who are unaware of their smell 
dysfunction probably have mild/moderate microsmia.  Regardless of this, the 
evidence highlights that simply asking a patient about their sense of smell is 
unreliable and it must be properly measured.  This is important in counselling 
the patient and ensuring that the patient is aware of the dangers faced from 
compromised smell function (Doty et al 1988), which include fire risk and 
food poisoning (Santos et al 2004). 
 
Smell tests are cheap and quick (Deeb et al 2010, Hummel et al 2001, 
Davidson et al 1998) and therefore suited for routine use in everyday clinical 
practice (presently The University of Pennsylvania Smell Identification Test 
(UPSIT 40) costs £2.50 each compared to approximately £1,500 for a 
DaTSCAN in 2017.  The UPSIT 40 can have up to 86% sensitivity and 82% 
specificity (Picillo et al 2014).  In contrast, dopamine transporter imaging 
(DaTSCAN) can have up to 92% sensitivity and 100% specificity in the 
demonstration of nigrostriatal dopamine deficiency in individuals with 
suspected pre-synaptic Parkinsonism (Picillo et al 2014, Jennings et al 
2004).  Although, the DaTSCAN may be more sensitive and specific than 
smell tests, in practice, they are expensive to perform and not readily 
available.  There are also still technical issues with these scans which can 
lead to difficulties with interpretation of findings in borderline cases. It is also 
important to recognise that patients who are claustrophobic refuse to have 
these scans.  In fact, although not specific to dopamine transporter imaging, 
estimates highlight that between 4–37% of patients refuse to go through with 
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any form of brain scan, (MRI, DaTSCAN, PET Scan) for precisely this reason 
(Dewey et al 2007).   
 
1.2.3. Ageing and Olfaction 
 
The incidence of olfactory dysfunction in the general population is a matter of 
debate (Murphy et al 2002, Hoffman et al 1994, Wysocki et al 1989). 
However, most authors reported frequencies of 1% to 3%.  At least 1% of the 
general population have total inability to perceive odour sensations (anosmia) 
and approximately 5-10% has reduced olfactory function (microsmia) 
(Wysocki and Gilbert 1989).  It is known that ageing is among the factors that 
put an individual at risk of developing olfactory dysfunction (Hawkes 2008, 
Doty 1995, Doty et al 1984) and about 25% of people  older than 53 years 
exhibit varying degrees of loss of sense of smell (Murphy et al 2002).  The 
decrease in the olfactory ability with age is in part attributed to structural 
modifications in the olfactory system, particularly due to age-related 
decreases in the number of olfactory receptor cells (Jafari et al 2008).  This 
can be due to vascular or metabolic insufficiency, loss of specific 
neurotrophic factors (leading to age related atrophy of the olfactory 
receptors), viral damage (Rombaux et al 2012, Jafek et al 1990, Douek et al 
1975), nutritional deficiencies, air pollution (Hudson et al 2006), as well as 
several age-related diseases (Rombaux et al 2009, Doty 1989). 
 
However, recent research has found that some impaired olfaction in old age 
is associated with post-mortem evidence of neurodegenerative disease, 
including Lewy bodies, the pathological hallmark for PD (Ross et al 2006).  
Using statistics from the UK, it is noted that 2 million people in the UK exhibit 
varying degrees of smell loss (The Ageing Population, Key Issues for the 
2010 Parliament).  Out of these 2 million, neurodegenerative diseases, 
particularly synucleinopathies such as Parkinson's disease (PD), dementia 
with Lewy bodies (DLB) and multiple system atrophy (MSA) could account for 
224,000 people over the age of 65 with significant smell loss.  These can be 
broken down into 121,000 people with DLB (Dementia with Lewy bodies - 
Alzheimer's Research UK 2016), 3,000 people with MSA (MSA Trust 
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Research Strategy  2016) and 127,000 with PD (Parkinson’s UK 2009). (See 
table 1.3). 
 
Table1.3: UK Population of People with Varying Degrees of Smell Loss and 
Those with a Synucleinopathology 
People with varying 
degrees of smell 
loss (UK) 
Parkinson’s 
disease 
Dementia with 
Lewy Bodies 
Multiple System 
Atrophy 
2,000,000 127,000 121,000 3,000 
Taken from The Ageing Population.  Key Issues for the 2010 Parliament and calculated from the 
findings of Murphy et al (2002) by the researcher. 
 
Also, when specifically looking at PD, Hawkes (2008) suggests it is unlikely 
that the PD olfactory defect is due to simple ageing and suggests a healthy 
person would need to live until the age of 106 to 160 years to exhibit the 
degree of smell loss shown by a typical PD patient aged 60 years. 
 
1.2.4. Sniff Vigour and Olfaction 
 
Sniffing enhances smell detection and, apart from redirection of airflow to the 
olfactory neuroepithelium, functional magnetic resonance imaging studies 
have shown that it activates the pyriform and orbitofrontal cortices of the 
brain (Sobel et al 1998). 
 
In PD, mechanical aspects of sniffing may also play a role in the odour 
sensory deficits.  Indeed, Sobel et al (2001) showed that sniffing caused a 
slight reduction in patients with PD performance on identification (using 
UPSIT 40) and detection thresholds, (using the odourants vanillin and 
protonic acid and a two-alternative forced-choice paradigm during which sniff 
parameters were recorded with a pneomatotachograph-coupled spirometre. 
Practically, this is said to equate to a mean reduction of around two to three 
points on the 40-odour University of Pennsylvania smell Identification 
(UPSIT-40) test (Doty et al 1984) in PD patient.  Studies have not allowed for 
this effect and therefore may exaggerate slightly the severity of any smell 
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defect, especially where bulbar function is involved.  However, Sobel et al 
(2001) observed that olfactory function improved with increased sniff vigour. 
 
1.2.5. Parkinson’s Disease Medication and Olfaction 
 
Most present anti-parkinsonian medication works on the dopaminergic 
system (for a list of present UK drugs used to treat PD see Appendix 3).  
These drugs aim to increase dopamine in the brain, by increasing its 
production or altering its metabolism.  (See figure 1.2 for drugs that affect the 
metabolism of levodopa). 
 
 
Figure 1.2 Drugs Affecting the Metabolism of Levodopa. 
Key:  Enzymes in bold.  COMT = Catechol-O-methyltransferase.  MAO-B = monoamine 
oxidase B.  Drugs with alter metabolism in boxed red italics.  (Fung et al 2001). 
 
As far back as 1975 when Ansari and Johnson (1975) first recognised 
impairment in olfaction in PD, it appeared unlikely that PD medications affect 
or restore olfactory function, even in patients who were taking drugs with 
anticholinergic effects with the possible drying up effect of the olfactory 
mucosa.  However, no firm conclusions could be made -at that time- due to 
the small number of patients recruited (22 males with PD). 
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Since then, several studies have explored this phenomenon and reported 
that olfactory function remains unaffected by anti-parkinsonian medication 
(Doty et al 1992, Quinn et al 1987, Ward et al 1983), including the potent 
dopamine agonist Apomorphine (Roth et al 1998). 
 
However, although there are several types of interneurons in the olfactory 
bulb, most of them are dopaminergic.  As most PD symptoms are due to a 
lack of dopaminergic neurons (Braak et al 2003), you would expect that there 
would be a reduction in dopaminergic neurons in the olfactory bulb.  
However, in 2004 Huisman et al (2004) noted a significant increase (more 
than 100%) of Tyrosine Hydroxylase-expressing cells in the olfactory bulb of 
PD patients.  Tyrosine Hydroxylase is the enzyme responsible for catalysing 
the conversion of the amino acid L-tyrosine to L-3, 4-dihydroxphenlalanine 
(L-DOPA).  L-DOPA is the precursor to the neurotransmitters dopamine, 
norepinephrine (noradrenaline) and epinephrine (adrenaline), collectively 
known as catecholamines (Nakashima et al 2009).  See figure 1.3 
 
 
 
Figure 1.3: Role of N-terminus of Tyrosine Hydroxylase in the Biosynthesis of 
Catecholamines (Nakashima et al 2009). 
The increase in the number of dopaminergic neurons (that inhibit olfaction) in 
the olfactory bulbs in PD patients (as shown in Huisman et al 2004 study), 
makes it understandable why olfaction is not improved in PD patients treated 
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with L-dopa (as dopamine is known to inhibit olfactory transmission in the 
olfactory bulb) (Hsia et al 1999, Koster et al 1999, Duchamp-Viret 1997, 
Wilson and Sullivan 1995, Doty et al 1992).  This proposes that the increase 
in dopaminergic neurons in the olfactory bulbs may be responsible for the 
olfactory dysfunction seen in PD patients.  However, results of a follow-up 
study (Huisman et al 2008) indicated that although the number of tyrosine 
hydroxylase cells in control females is significantly lower than those in control 
males, the number of dopaminergic (inhibitory) cells in the olfactory bulbs of 
both male and female Parkinson's patients equals that of healthy males of 
the same age group, concluding that the hyposmia in Parkinson's disease 
patients cannot simply be ascribed to dopamine in the olfactory bulb. 
 
Therefore, perhaps impaired olfactory threshold in PD patients might be due 
to cholinergic rather than dopaminergic disturbance, not only because of the 
increased dopamine levels in the olfactory bulb but also because in AD there 
is reduced choline acetyltransferase activity in the olfactory tubercle 
(Simpson et al 1984) and in AD and Parkinson’s Disease Dementia (PDD), 
defective olfactory recognition has been reported (Serby et al 1985).  
However, to date the lack of olfactory response to L-Dopa treatment remains 
inconclusive. 
 
1.2.6. Cognition and Olfaction 
 
Odour identification has been linked in some studies to language, verbal 
memory, and processing speed in healthy elderly (Westervelt et al 2005, 
Swan and Carmelli 2002), whilst in other studies this has not been found 
(Hawkes et al 1997, Doty et al 1989, Quinn et al 1987).  However, this link 
between cognitive impairment and olfactory loss remains poorly explored in 
PD.  Postuma and Gagnon (2010) have recently reported significant 
correlations between verbal and nonverbal memory and olfactory loss in PD.  
Furthermore, Bohnen et al (2010) found a positive correlation between odour 
identification scores and verbal memory in patients with PD who have 
olfactory loss.  Bohnen et al (2010) implicated limbic cholinergic denervation 
and suggests that this cholinergic denervation may be more pronounced in a 
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subset of PD patients with early emerging cognitive deficits and that greater 
deficits in odour identification may identify patients at risk of clinically 
significant cognitive impairment (Bohnen et al 2010, Bohnen and Albin 2010). 
 
1.2.7. Gender and Olfaction 
 
In general, women have a better sense of smell than men (Oliveira-Pinto et al 
2014, Liu et al 1995).  The discussion as to why these effects should occur is 
inconclusive.  So far, the increased olfactory sensitivity has been speculated 
to be attributed to numerous factors including hormonal effects (Doty 1986), 
verbal skills (Larsson et al 2004), congenital factors (Schaal et al 2004) or 
more recently the discovery that women have more olfactory bulb cells than 
men (Olveria-Pinto et al 2014).  This observation has been made by 
numerous investigators using psychophysical, electrophysical and imaging 
techniques (Lundstrom et al 2006, Dalton et al 2002, Brand and Millot 2001, 
Cain 1982).   
 
The superiority of women’s sense of smell can be observed very early on in 
childhood, even as early as 4 years of age, and is evidenced by several 
cultures (Liu et al 1995).  This superiority in women also increases with age 
(Liu et al 1995).  This agrees with normative data for the UPSIT-40 in the 
United States showing considerable influence of gender (Doty 1995).  This 
was also supported by the Silveria-Moriyama et al (2008) study which found 
that gender was an independent predictor of the UPSIT-40 score.  (The 
UPSIT 40 has allowed for both male and female percentile scores and can 
be seen in appendix 4). 
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1.3. LOSS OF SENSE OF SMELL NOTED IN OTHER PARKINSONIAN 
DISORDERS 
 
1.3.1. Conditions that can be misdiagnosed as Parkinson’s disease 
 
Parkinsonian disorders include Lewy Body Dementia (LBD), Multi System 
Atrophy (MSA), Progressive Supranuclear Palsy (PSP), Drug-Induced PD 
(DIPD) and Essential Tremor (ET).  These conditions have been chosen as 
they are the most likely conditions to be referred to a PD clinic and the most 
likely conditions that can be misdiagnosed as PD.  They will now be 
discussed individually. 
 
1.3.1.1. Lewy Body Dementia (LBD) 
 
In comparison to PD, this parkinsonian disorder is characterised by a more 
rapid course, early onset of confusion, hallucinations, drug sensitivity, and 
dementia.  However, it is a disorder with synuclein pathology and therefore 
the pathology differs only quantitatively from typical PD.  In one study of 
clinically defined LBD, severe impairment of olfactory identification and 
detection threshold was observed, and test scores were independent of 
disease stage and duration (Liberini et al 2000, Liberini et al 1999).  In 
another study (McShane et al 2001), simple smell perception to one odour 
(lavender water) was examined in 92 patients with dementia (confirmed on 
post mortem) of whom 22 had LBD and 43 had AD; they were compared to 
94 age-matched controls.  The main finding was of impaired smell perception 
in the LBD group and little or no defect in the AD patients.  Although only one 
odorant was used for perception tests, the study confirms at clinical and 
pathological level the clinically based conclusions (Liberini et al 2000, Liberini 
et al 1999) that impairment of smell is significant in LBD.  Those who 
consider LBD to be no more than severe PD would not be surprised by this 
observation.  Therefore, reduced olfaction may be associated with Lewy 
bodies (McShane et al 2001). 
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1.3.1.2. Multiple System Atrophy (MSA). 
 
This is a rapidly progressive form of Parkinsonism in which autonomic 
dysfunction predominates, particularly affecting bladder and orthostatic blood 
pressure control.  In the only study of identification in 29 patients with a 
clinical diagnosis of MSA, mild impairment of UPSIT-40 score was 
demonstrated.  The mean UPSIT score was 26.7 compared to the control 
mean of 33.5 (Wenning et al 1993). 
 
The discovery of alpha-synuclein in MSA has provided an elusive link with 
Parkinson’s disease. Nevertheless, MSA is distinguished from other 
neurodegenerative diseases by the prominent, if not primary, involvement of 
the glial cells.  Glial cytoplasmic inclusions (GCIs) are present in all the 
olfactory bulbs from MSA cases and are a diagnostic hallmark.  Additionally, 
neuronal loss is present in the Anterior Olfactory Nucleus.  These 
pathological changes might be responsible for the olfactory dysfunction seen.  
This may well have significance when testing the sense of smell. 
 
1.3.1.3. Progressive Supranuclear Palsy (PSP). 
 
The classic clinical features of Progressive Supranuclear Palsy (PSP) include 
supranuclear vertical ophthalmoplegia, severe postural instability with early 
falls, (Steele and Richardson 1964, Richardson et al 1963) and subcortical 
dementia (Albert et al 1974) most commonly developing in the seventh 
decade of life. 
 
PSP-P (PSP-parkinsonism), an atypical clinical presentation of PSP-type 
tauopathy which presents with less cognitive decline (O’Sullivan et al 2008, 
Williams et al 2005), is more likely to be confused with PD and shares many 
common features with PD (Williams et al 2005, Hughes et al 2002). 
 
Previous studies have suggested that microsmia is not present in PSP-P 
(Wenning et al 1995, Doty et al 1993).  A later study suggests smell tests 
might differentiate PSP-P from PD (Silveria-Moriyama et al 2010) particularly 
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when UPSIT scores are lower than 14/40 (a cut-off that provides a sensitivity 
of 97.3%) although they do conclude, as a generalization, smell sense is 
better preserved in PSP-P than PD.   
 
1.3.1.4. Drug-Induced Parkinsonism (DIP). 
 
There are reported to be 261 suspected drugs that might cause DIP, most 
involve central dopaminergic antagonists, followed by antidepressants, 
calcium channel blockers, peripheral dopaminergic antagonists and H1 
antihistamines that cause DIP (see appendix 5). 
 
Clinically, drug induced parkinsonism is almost indistinguishable from PD 
(Bondon-Guitton et al 2011, Benito-Leon et al 2004, de Lau et al 2004), 
which constitutes 15 - 60% of all parkinsonism cases and represents the 
second most frequent cause of akinetic rigid syndromes in the western world, 
with a prevalence nearly approaching that of PD due to the increased use of 
polypharmacotherapy (Mena and de Yebenes 2006). 
 
Although it can be serious, it is often reversible once the drug is withdrawn in 
90% of cases (Bondon-Guitton et al 2011).  However, DIP is not always 
reversible; it has been reported that PD can develop after apparent recovery 
from DIP (Burn and Brooks 1993, Hardie and Lees 1988, Stephen and 
Williamson 1984). 
 
From the research available, it appears this subset of patients could well 
have subclinical PD (Morley et al 2014, Lee et al 2007) and the offending 
drug has simply unmasked emerging PD.  It could be argued then the results 
of these research studies suggest that the presence of smell deficits in DIP 
patients might be more associated with dopaminergic loss rather than with a 
drug-mediated dopamine receptor blockade. 
 
These preliminary results might have prognostic and therapeutic implications, 
as abnormalities in these individuals may be suggestive of an underlying PD-
like neurodegenerative process (Bovi et al 2010).  Indeed, in a recent study, 
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Morley et al (2014) highlight that olfactory testing may offer a simple and 
inexpensive method to help predict outcomes in drug-induced parkinsonism 
and, potentially, identify a cohort of pre-motor Parkinson's disease. 
 
1.3.1.5. Essential Tremor. 
 
Classical essential tremor is usually diagnosed easily but there are problems 
when the tremor seems to be dystonic or there is co-existing rigidity.  In one 
small study of odour identification ability in 15 patients with benign essential 
tremor, all were normal (Busenbark et al 1992).  If this phenomenon is 
correct, it might be useful in distinguishing essential tremor from parkinsonian 
tremor although females (with tremor dominant PD) are thought to be less 
liable to have olfactory impairment (Stern et al 1994).  However, In Louis et al 
(2002) study of 37 patients with essential tremor, modestly impaired olfaction 
was noted.  This may relate to the newly claimed function of the cerebellum 
in olfactory processing.  Once more, the diagnosis in this present study was 
not established by reference to agreed criteria, and confirmation from 
imaging (e.g., DaTSCAN, PET) or post mortem was not undertaken.  
Accordingly, their finding must be regarded as provisional. 
 
 
1.4. RATIONALE 
Although sense of smell in PD has been extensively explored; particularly 
with regards to the motor aspects of PD, the researcher was unable to find 
any studies that have explored the link between the sense of smell and a 
majority of other non-motor and quality of life symptoms frequently seen in 
patients with PD.  This PhD study addresses this by looking at the correlation 
between the sense of smell and other non-motor and quality of life symptoms 
as well as re-examining the typical individual motor symptoms seen in PD.  
Therefore, this study will add new evidence to this topic and support or refute 
previous research. 
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This study also addresses the link between varying degrees of loss of sense 
of smell (mild/moderate microsmia, severe microsmia and anosmia), both in 
the motor, non-motor and quality of life symptoms and whether the degree of 
smell loss itself might predict symptoms likely to be encountered by people 
with PD.   
Testing loss of sense of smell may also  provide a supportive diagnostic tool 
for PD, which is of great interest when examining the literature and in clinical 
practice, particularly for specialists working in the field of PD.  This is 
because aalthough less severe, olfactory loss may be found in multiple 
system atrophy  (Shah et al 2008) and dementia with Lewy bodies (DLB) 
(Olichney et al 2005), but uncommonly in progressive supranuclear palsy 
(PSP/PSP-P) (Silveria-Moriyama et al 2010), drug-induced parkinsonism 
(DIP) (Kruger et al 2008) and essential tremor (ET) (Shah et al 2008).  
Therefore, from the evidence so far, data does suggest that olfactory function 
may be a useful tool for the discriminative diagnosis of PD from other 
parkinsonian disorders.  This is extremely important when a patient with 
parkinsonian symptoms is assessed, as the sense of smell may well be a 
significant indicator as to what type of parkinsonian condition the patient has, 
as atypical symptoms may come much later in the disease progression.  
 
This research will also address implications of the loss of sense of smell for 
nursing a patient with PD as there is no preceding evidence that this has 
been explored before.  This is to raise awareness of the prevalence and 
implications of smell loss in PD, including the increased risk of hazards, and 
to ensure the nurse implements or advises on coping mechanisms required 
to improve safety, well-being and quality of life.  
This study also explores whether there is a link between the sense of smell 
and Rapid Eye Movement Behavioural Disorder (RBD) (Yoritaka et al 2009, 
Gjerstad et al 2008, De Cock et al 2007).  This is because both symptoms 
are known to be early biomarkers for a diagnosis of PD and loss of sense of 
smell alone would not be specific to PD.  
Therefore, if there is a statistically significant link between the degree of smell 
loss seen in PD patients and certain motor and non-motor symptoms this 
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may then support the need to review the Parkinson’s Disease National 
Institute for Health and Clinical Excellence Guideline Number 35 (NICE) 
(2006) on treatment and management for Parkinson’s disease which could 
have improved outcomes for patients with PD. 
 
Also, if smell function is associated with a certain PD phenotype or 
prognosis, this can pave the way for a (bio)marker that can be obtained 
easily and relatively cheaply at the bedside. 
 
Finally, the researcher is best placed to conduct this study having worked in 
the field of PD as a clinician for two decades.  The exsisting knowledge and 
expereince of assessing and interpreting tests will be of significant value not 
only for other clinicians but to the PD patients themselves.  The researcher is 
also in a prime position to disseminate and act upon the research findings, 
particularly in the field of nursing. 
 
 
1.5 AIMS OF THIS STUDY 
 
This study will investigate whether patients with PD who have mild/moderate 
microsmia, severe microsmia or anosmia are clinically different when 
comparing their  PD in terms of the motor, non-motor, disease stage and 
quality of life domains, using a range of validated scales and questionnaires. 
This study will also analyse tremor dominant PD compared to akinetic-rigid 
type PD (which presents with little or no tremor but increased bradykinesia 
and rigidity) as tremor dominant PD is said to have a more preserved sense 
of smell (Quinn 1995) and whether PD patients with RBD (or not) have a 
more preserved sense of smell.   
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1.6. OBJECTIVES OF THE RESEARCH 
 
 The objectives of the research are to establish:The prevalence of 
mild/moderate microsmia, severe microsmia or anosmia in this study 
group. (See chapter 3).  
 
 Whether gender, age, smoking or disease duration has an impact on 
the sense of smell. (See chapter 3). 
 
 Whether taste is related to the degree of smell loss in this PD study 
group. (See chapter 3). 
 
 Whether cognition has an impact on the sense of smell (N.B.  PD 
patients with significant cognitive problems have been excluded from 
this study). (See chapter 3). 
 
 Whether there is a link between motor function, (as measured by 
UPDRS III (see appendix 7)) and the degree of loss of sense of smell 
(mild/moderate microsmia, severe microsmia or anosmia) in this study 
group. (See chapter 4). 
 
 Whether there is a link between disease severity (using Hoehn and 
Yahr Staging) (see appendix 10)) and the degree of loss of sense of 
smell in this study group. (See chapter 4). 
 
 Whether PD patients with mild/moderate microsmia are less(or --more 
likely to have a rapid eye movement behaviour disorder (see chapter 
4) in comparison with PD patients who have severe microsmia or 
anosmia (using Rapid Eye Movement Behaviour Sleep Disorder 
Questionnaire. See appendix 11). 
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 Whether PD patients with tremor dominant PD are less (or more) likely 
to have reduced sense of smell compared with PD patients who have 
akinetic-rigid type PD. 
 
 Whether PD patients with mild/moderate microsmia are less  (or more) 
likely to have prominent non-motor features (such as hallucinations, 
sleep disturbance, cognitive or autonomic features) (see chapter 5) in 
comparison with PD patients who have severe microsmia or anosmia 
(using the Non-Motor Symptoms Questionnaire. See appendix 8). 
 
 Whether PD patients with mild/moderate microsmia are less(or more) 
likely to have prominent quality of life features, indicating the impact of 
PD (such as emotional well-being, activities of daily living or stigma) 
(see chapter 5) in comparison with PD patients who have severe 
microsmia or anosmia (using the PDQ39. See appendix 9). 
 
 Whether different classes of PD medication, the timing of medication ,  
the environment (in which the smell test was conducted) and 
handedness has an impact on sense of smell. (See chapter 6). 
 
 Whether sniff vigour fatigues during the UPSIT 40 smell test which 
may contribute to lower UPSIT scores seen in patients with PD in this 
study group. (See chapter 6). 
 
 Whether PD patients in this study group are aware of any impairment 
of their sense of smell (i.e. perceived sense of smell) and whether PD 
patients reporting a recovery or fluctuation of their sense of smell 
affects UPSIT scores. (See chapter 7 (See chapter 7). 
 
 If there is any evidence of phantosmia and whether phantosmia 
affects UPSIT scores. (See chapter 7).  
 
 The profile of the 40 odours presented and number/percentage of 
patients correctly identifying each individual odour. (See chapter 7).   
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CHAPTER 2  
METHODOLOGY 
 
2.1. STUDY DESIGN AND SAMPLE SIZE  
 
This is an open cross-sectional observational study, involving 112 patients (of 
both genders) who have a diagnosis of Parkinson’s disease.  This was 
considered the most appropriate study design in order to examine the 
relationship between the sense of smell and the motor, non-motor and quality 
of life domains in people with PD who had anosmia, severe microsmia or 
mild/moderate microsmia.  The intention was not to assign exposures or 
have a comparison between exposed and non-exposed groups and at this 
point this study does not want to establish whether the sense of smell 
progresses alongside the natural history of PD or how the sense of smell 
affects a patient with PD, over a period (i.e. no follow up). 
 
The individuals recruited for this study appear to represent  the general white 
British older PD population (as none of the PD patients recruited to this study 
were of ethnic minority race).  This is based on the fact that there is 33% 
higher than the national average of older people in the study area.  A majority 
of these have migrated, through retirement, from other parts of the United 
Kingdom, therefore, there is a mixture of patients who are either local to the 
area or from other regions of the UK. 
 
During the initial proposal it was estimated from the literature review that 
between 10 - 20% of PD patients have a preserved sense of smell.  
Therefore the original plan was to subdivide the patients into five groups (i) 
normosmia, (ii) mild microsmia  (iii) moderate microsmia (iv) severe 
microsmia (v) anosmia.  However, as no patients were found to be 
normosmic in this particular study, patients were divided into (i) 
mild/moderate microsmia, (ii) severe microsmia and (iii) anosmia sense of 
smell sub-groups. (For sense of smell test scores and therefore category of 
loss of sense of smell see section 2.4.6).  
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Patients were assessed, and data collected from March 2013 to November 
2013.  All patients provided written informed consent.  Data collection was 
performed on a convenient day for patients and included weekends and 
evenings.  Lone Worker Policy was adhered to (see appendix 6). 
 
2.1.1. Study sample recruitment process 
 
The preparatory work by the researcher during the recruitment process was 
to initially identify eligible patients from a local NHS PD Trust database. This 
was achieved by screening patient’s records to exclude patients who did not 
meet the inclusion or exclusion criteria (see section 2.2). Once eligible 
patients were found a list was compiled which contained the patient’s hospital 
number and telephone contact details. This list was then forwarded to two 
nursing colleagues, both covering different areas within the local trusts 
catchment area. The nursing colleagues then contacted these patients either 
via a telephone call, during an out-patient appointment or during a home visit. 
The researcher did not make the initial contact to avoid research bias. If the 
patient agreed the two nursing colleagues sent invitation letters (see 
appendix 16). All reply slips came directly back to the researcher and from 
then on, all tasks were the responsibility of the researcher. This included 
preparing appropriate recruitment material, completing all assessments and 
ensuring that the relevant clinicians were fully informed about the study 
(details of this process can be seen in Figure 2.1 flow diagram).   
 
As previously stated a sample size of 112 PD patients was required. This 
sample size was obtained by statistical analysis by the head statitician at the 
university that supported the researcher to complete this PhD study. This 
sample size was then agreed by the ethics committee. The process of 
gaining the is sample can be seen in figure 2.2.   Due to the researcher being 
the only person carrying out all the assessments it was agreed that patients 
would be contacted in batches of 40 at a time and to await response before 
contacting another 40 patients. As the two nursing colleagues shared an 
office with the researcher this was managable. The researcher started the 
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recruitment process as soon as a patient accepted. The aim was to ensure 
patients were seen in a timely manner rather than sending out information 
and then not being seen for some time afterwards.  Althogh there were 30 
remaining patients eleigible for the study the researcher would have needed 
to go back to the ethics committee for their approval and this would have 
been time consuming. Also the researcher was aware that there was going to 
be a significant amount of data collected and more patients in the study 
would have increased the researchers time carrying out all the assessments 
and arranging home visits or aseesment in an allocated research office. 
 
Figure 2.1 Parkinson’s disease out-patient’s recruitment chart   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
112 patients recruited for the study. 
Sample size required, and ethics committee 
agreed 112 patients to be recruited for this   
study 
344 patients excluded for the following 
reasons: 
237 patients unable to participate due to being 
cognitively impaired 
75 patients had other forms of parkinsonism 
32 patients had stroke disease or history of 
sinus problems   
51 patients excluded for following 
reasons:  
43 patients declined 
3 patients away 
3 patients contact details wrong 
2 people suffering from sinus problems 
142 patients eligible for the study 
Eligible to be included in the study  
N= 193 
Patients with a diagnosis of PD on local 
Trust database 
N= 537 
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2.2. INCLUSION AND EXCLUSION CRITERIA 
 
2.2.1. Inclusion criteria 
 Aged 18 years or above 
 Confirmed clinical diagnosis of Parkinson's disease 
 No other recognised causes of loss of sense of smell 
 No current medical history of using sedatives (or any other medication 
that may interfere with perception of symptoms or performance of 
measurements) 
 Able to provide informed consent 
 
2.2.2. Exclusion criteria 
 Known physical impairment (i.e.stroke/rheumatoid disease) that may 
influence compliance with protocol 
 Confirmed medical history of surgery or trauma to the nose resulting in 
the inability to smell properly 
 Known current infection (i.e. chest/sinus infections ) that may interfere 
with the sense of smell 
 Unable to provide informed consent. 
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2.3. STUDY PROTOCOL  
 
The flow chart highlighing the study protocol and methods used for data 
collection can be seen in Figure 2.2. 
 
FLOW DIAGRAM OF THE STUDY 
 
Potential patient receives invitation letter and information sheet 
 
Willing patient indicates by reply slip 
 
Willing patient invited to attend research room to receive further information, etc 
 
Patient fulfils criteria 
 
If still willing, patient signs consent form 
 
Researcher records age, gender and year of diagnosis 
 
Researcher conducts the The Montreal Cognitive Assessment (MoCA) 
 
Researcher examines and records subject’s Unified Parkinson’s Disease Rating 
Scale (UPDRS) motor component and Hoehn and Yahr scale (*) 
 
Patient completes Non-Motor Symptoms Questionnaire 
 
Patient completes PDQ39 Health Outcomes Questionnaire 
 
Patient completes REM Behaviour Disorder Screening Questionnaire 
 
Patient performs smell identification test 
 
End of study 
 
(*) Patients will be required to be examined in order to test their motor ability which 
is routine in clinical practice .This is a non invasive procedure 
 
Figure 2.2: Flow Diagram of the Study. 
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2.4. RATING SCALES AND TOOLS USED IN THE STUDY 
 
Specific scales and questionnaires that cover the different clinical symptoms 
noted in patients with PD have been chosen (see section 2.4.1 - 2.4.7).  This 
is to ensure that a wide variety of symptoms (present in PD), which 
particularly include the non-motor deficits, can be captured and analysed.  
This may highlight whether in fact the olfactory system is connected to or 
deteriorates parallel to a particular symptom.  This study will also investigate 
Rapid Eye Movement Behaviour Disorder and its correlation with olfactory 
dysfunction in PD patients.  These scales and questionnaires are discussed 
below. 
 
2.4.1. Unified Parkinson’s Disease Rating Scale 
 
The UPDRS developed by Fahn and Elton (1987) is a rating tool to follow the 
longitudinal course of Parkinson’s disease.  It is the most widely used 
standardised scale to assess parkinsonism (Rascol et al 2002, Mitchell et al 
2000).  The UPDRS demonstrates high internal consistency and inter-rater 
reliability, shows moderate construct validity and has stable factor structure 
(Stebbins and Gotez 1998, Nouzeilles and Merello 1997, Rabey et al 1997, 
Richards et al 1994). 
 
The motor subscales of the UPDRS provide a measure of key motor 
symptoms and examines speech, facial expression, tremor - both action and 
at rest, rigidity, finger taps, hand movements, hand pronation and supination, 
leg agility, arising from a chair, posture, gait, postural stability and body 
bradykinesia.  It contains fourteen questions, each measured on a 5-point 
scale (0 - 4) (see appendix 7).  The higher the score the worse the disability.   
 
There are three other muti modular scales containing both impairment and 
disability sections found in the literature.  These are the New York University 
Parkinson’s disease Evaluation (NYU) (Lieberman et al in Goldstien 1980 
pages 227-286), the University of California Los Angeles scale (UCLA) 
(Martinez-Martin et al 1988) and the Short Parkinson’s Disease Evaluation 
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Scale (SPES) (Rabey et al 1997).  Of these scales the SPES appears to be 
the most valid and reliable scale but none of these have been subjected to an 
extensive clinometric evaluation and have only been evaluated by their 
designers. Therefore, the researcher did not consider these scales for this 
particular research as no recommendations for the use of these scales is 
available. 
 
2.4.2 Non-Motor Symptoms Questionnaire 
 
The Non-motor Symptoms Questionnaire (Chaudhuri et al 2006)  is a 
validated questionnaire which shows modest association with indicators of 
motor symptom severity and disease progression but a high correlation with 
other measures of NMS (NMSQuest) and health-related quality of life 
measure (PDQ-8) (both,   = 0.70).  It has also been validated in several 
European and Asian languages (see Chaudhuri et al 2007).  It is a self 
reported questionnaire specifically designed for PD patients.  It comprises 30 
common non-motor symptoms and is designed to provide a rapid screen for 
problematic non-motor symptoms (see Appendix 8).  It is not a rating scale 
and is not intended to evaluate the effect of treatment.  In this research study, 
it will simply highlight if there is a link between any of the non-motor 
symptoms and degree of olfactory function.  It is now an integral part of the 
assessment of patients with Parkinson’s disease and contributes to the 
management of the disease.  This scale was chosen as there are no other 
non-motor symptoms questionnaires for PD available in practice. 
 
2.4.3. PDQ39 Quality of Life Questionnaire 
 
The PDQ39 Quality of Life Questionnaire (Jenkinson et al 2008, Peto et al 
1995) has been translated into more than 80 other languages.  The PDQ39 is 
a self reported questionnaire that is a disease-specific measure of subjective 
health status (see Appendix 9).  The PDQ-39 produces a profile of scores 
indicating the impact of Parkinson's disease in eight important areas of health 
status which are; 
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• mobility (10 items) 
• activities of daily living (6 items) 
• emotional well-being (6 items) 
• stigma (4 items) 
• social support (3 items) 
• cognition (4 items) 
• communication (3 items) 
• bodily discomfort (3 items) 
 
Patients are asked to think about their health and general well-being and to 
consider how often, in the last month, they have experienced certain events 
(e.g. difficulty walking 100 yards).  Patients are asked to indicate the 
frequency of each event by selecting one of 5 options (Likert Scale): 
never/occasionally/sometimes/often/always or cannot do at all. 
 
The PDQ 39 is shown to have high levels of reliability and validity (Damiano 
et al, 1999, Jenkinson et al, 1997, Peto et al 1998).  It is the most widely 
used specific health related quality of life scale and the most thoroughly 
tested and used in clinical studies.  Its disease specificity and the single 
summary index offer the opportunity to assess the overall impact of illness, 
and it is easy to interpret (Jenkinson et al 1997). 
 
There are other scales used to measure health related quality of life issues 
such as the Parkinson's Disease Questionnaire Short form (PDQ-8) 
(Jenkinson et al 1997), the Parkinson’s Disease Quality of Life (PDQL) (de 
Boer et al 1996), the Parkinson’s Impact Scale (PIMS) (Calne et al 1996) and 
Scales for Outcomes in Parkinson’s Disease - Psychosocial (SCOPA-PS) 
(Marinus et al 2003). 
 
The PDQ-8 is the short version of the PDQ-39.  However, it has lower 
reliability and validity than the PDQ-39 and was therefore not chosen.  The 
PDQL is the second most frequently used health related questionnaire 
specific for PD.  However, it does not adequately cover self-care, sleep, 
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cognition, close relationships and role functioning (Marinus et al 2002, 
Damiao et al 1999).  These are considered important to the researcher. 
The PIMS has very few independent and cross cultural validation studies 
(Serrano-Duenas et al 2008) and is rarely used in research and the SCOPA-
PS is focused on psychological adjustment rather than health related quality 
of life.  This is why PDQ39 was chosen. 
 
2.4.4. Hoehn and Yahr Scale 
 
Hoehn and Yahr scale (Hoehn and Yahr 1967) measures disease stage  (see 
Appendix 10).  There is no other scale available that provides a method of 
establishing the severity of PD with a simple staging assessment and this is 
why it has been chosen for this research.  Since its introduction, the Hoehn 
and Yahr scale has remained the most commonly and most widely used 
scale to describe severity of PD worldwide (Mitchell et al 2000).  It is the 
standard staging system used to describe patient populations enrolled in 
clinical trials of antiparkinsonian interventions and the second most frequently 
used outcome measure after the UPDRS in all randomly ordered drug trials 
for PD published between 1966 and 1998 (Mitchell et al 2000).  It provides an 
overall assessment of severity based on clinical features and functional 
disability (Diamond and Markham 1983) and is easy to apply,  quick to 
complete and practical  to use both in research and clinical practice.  The 
Hoehn and Yahr scale has been successfully used by raters with or without 
movement disorder expertise (Geminiani et al 1991). 
 
Most assessments of the validity and reliability of the Hoehn and Yahr scale 
have been limited to the assessment of reliability and report a moderate to 
significant level of inter-rater reliability (Geminiani et al 1991).  No formal 
assessments of test-retest reliability (intra-rater reliability) or validity could be 
found.  Most studies have used the Hoehn and Yahr scale as the gold 
standard against which the validity of other scales is assessed.  Although 
these studies cannot be considered examinations of Hoehn and Yahr scale 
validity, they do provide some assessment of the relationship between Hoehn 
and Yahr staging and other measures of PD impairment/disability.  Most 
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studies report significant correlations between Hoehn and Yahr stage and the 
UPDRS (van Hilten et al 1994), which is another reason for using this scale. 
 
Hoehn and Yahr staging is a quick, simple and commonly used tool both in 
research and clinical practice as an aid to assess the severity of PD.  The 
lower the score the less disability (for example 0= no signs of disease and 
5=Wheelchair bound or bedridden unless aided), (see Appendix 10).   
 
2.4.5 Rapid Eye Movement Behaviour Disorder Screening Questionnaire 
 
RBD Screening Questionnaire (Stiasny-Kolster et al 2007) is a relatively new 
screening questionnaire with high sensitivity.  This questionnaire was chosen 
as it specifically deals with RBD.  Other sleep scales are widely used in 
clinical practice such as the Pittsburgh Sleep Quality Index (PSQI) (Buysse et 
al 1989), and the Epworth Sleepiness Scale (ESS) (Johns 1991).  The PSQI 
is designed to assess sleep quality during the past month and has been 
used, for example, to measure sleep quality among truck drivers (Souza et al 
2005) and to test the effects of a drug on sleep quality in a randomized 
placebo controlled trial (Johnson et al 2005).  The ESS is an 8-item 
questionnaire designed to assess general level of daytime sleepiness, and 
has been used in studies that have examined daytime sleepiness in medical 
interns (Rosen et al 2006) and in patients with multiple sclerosis (Heesen et 
al 2006) and it was a main outcome measure of the effects of didgeridoo 
playing in patients with moderate obstructive sleep apnea (Puhan et al 2006).  
Both scales are highly reproducible (Knutson et al 2006) and reliable 
(Backhaus et al 2002, Johns 1992). 
 
However, RBD is a parasomnia, characterised by loss of normal skeletal 
muscle atonia during rapid eye movement sleep, thus enabling the patient to 
physically enact their dreams and, in some, vocalisations and abnormal 
movements are reported by bed partners (Comella et al 1993).  Many 
patients with PD complain of RBD.  Early detection of these patients is 
clinically relevant for long-term perspective as well as future neuroprotective 
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studies.  This present study will attempt to see if the degree of olfactory 
dysfunction correlates with the degree of severity of RBD. 
 
The questionnaire is a 10 item patient self rating instrument (maximum total 
score 13 points), covering the clinical features of RBD (spouse or carers 
observations can also be included during the assessment if appropriate).  
Items 1 to 4 address the frequency and content of dreams and their 
relationship to nocturnal movements and behaviour.  Item 5 asks about self-
injuries and injuries of the bed partner.  Item 6 consists of four sub items that 
assess nocturnal motor behaviour more specifically, e.g. questions about 
nocturnal vocalization, sudden limb movements, complex movements, or 
items around the bed that fell down.  Items 7 and 8 address nocturnal 
awakenings.  Item 9 focuses on disturbed sleep in general and item 10 on 
the presence of any neurological disorder.  A score of five points or more, 
based on The International Classification of Sleep Disorders (American Sleep 
Disorders Association 2001), is considered as a positive test result for a 
clinical diagnosis of RBD (see Appendix 11).  However, for a definite 
diagnostic decision, a polysomnography is required predominantly to 
definitely rule out differential diagnoses such as sleep related epileptic 
seizures, non-REM parasomnias (eg. sleep walking, obstructive sleep apnea 
or nocturnal periodic leg movements).  
 
2.4.6 University of Pennsylvania Smell Identification Test 
 
Numerous clinical olfactory tests have been described in the literature, 
including ones incorporating psychophysical, electrophysiological, and 
psychophysiological methods (for reviews, see Doty and Laing 2003, Kobal 
2003).  Such tests range from simple single-item odour identification 
screening tests to complex electrophysiological tests employing sophisticated 
olfactometers.  Briefly, these can be devided into three catogories; (i) 
psychophysical techniques (ii) electrophysiological techniques and (iii) 
imaging techniques. 
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(i) Psychophysical techniques are those where stimuli are varied in some 
manner (e.g., in concentration or quality) and the patient is required to 
indicate whether the stimulus is perceived (e.g., detection, discrimination and 
identification). 
 
(ii) Electrophysiological techniques evaluate either summated electrical 
activity at the surface of the olfactory receptor epithelium (i.e., the electro-
olfactogram or EOG) or integrated electrical activity at the surface of the 
scalp (e.g., odour event-related potentials or OERPs) (Hawkes and Doty 
2009). 
 
(iii) Imaging techniques assess stimulation of the left orbitofrontal region, right 
pyriform cortex or bilateral occipital cortex amongst other regions (see 
section 1.3.1).  
 
Olfactory perception was tested through a psychophysical test.  One 
advantage of this 'low-tech' approach over other methods is the speed of 
testing, allowing for rapid screening of olfactory function (Davidson et al 
1998, Hummel et al 2001).  There are three main psychophysical 
assessments highlighted in the literature: odour identification (Doty et al 
1984), odour discrimination (Hummel et al 1997) and odour thresholds. 
(Lotsch et al 2004, Ehrenstein and Ehrenstein 1999). 
 
Recent research (Lotsch et al (2008), Larron et al (2004) indicates that the 
three individual subtests describe different aspects of olfactory function.  
Lötsch et al (2008) found that odour thresholds can be separated from those 
of odour identification and odour discrimination.  Furthermore, Larsson et al 
(2004) report that odour discrimination is more strongly influenced by 
memory function than odour identification or odour thresholds. 
 
Thus, it would be best to perform all three subtests to obtain a maximum 
amount of reliable information.  However, this would be time consuming and 
involve storage of chemicals and equipment.  Furthermore, most olfactory 
psychophysical tests are positively correlated with one another and measure 
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common attributes (Frank et al 2003, Hummel et al 1997, Doty et al 1995, 
Cain and Rabin 1989, Doty et al 1985, Doty et al 1984).  For these reasons 
odour identification will be used to measure olfaction. 
 
Odour identification is the most frequently used measure of olfaction.  
Several test kits are commercially available, with the University of 
Pennsylvania Smell Identification Test (UPSIT) (Doty et al 1984) being the 
most widely used. It has well-validated psychometric properties (Doty et al 
1984, Doty et al 1995) This test will be used in this study and consists of 4 
booklets  each having 10 different odours to identify, which are 
microencapsulated in paper strips and are released by scratching with a 
pencil (see appendix 12).  A forced choice for each odour is required from 
four possible answers, even if no odour is perceived.  This forced-choice 
procedure controls the patient’s response bias. There is an answer column 
on the back of the test booklet, and the test is scored out of 40 items.  The 
score is compared to scores in a normative database from 4000 normal 
individuals.  This records the level of absolute smell function (Doty et al 
1984).  The score also indicates how the patient does in accordance to their 
age group and gender.  The test has been validated and normal age and 
sex-related values are available (Doty et al 1995). 
 
For this study, a specific classification scoring system and terminology were 
used. This classification scheme has been developed by Doty in 2003 for 
establishing an adult patient’s olfactory diagnosis using the 40 item University 
of Pennsylvania Smell Identification Test (UPSIT) (Doty 2003). (See table 
2.1). 
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Table 2.1. Classification Scoring System of UPSIT 40 
Test score                 Olfactory Diagnosis 
00-05                         Probable Malingering 
06-18                         Total Anosmia 
19-25                         Severe Microsmia 
26-29                         Moderate Microsmia (Males) 
26-30                         Moderate Microsmia (Females) 
30-33                         Mild Microsmia (Males) 
31-34                         Mild Microsmia (Females) 
34-40                         Normosmia (Males) 
35-40                         Normosmia (Females) 
(See appendix 4 for female and male percentile values). 
 
2.4.7. The Montreal Cognitive Assessment 
 
The Montreal Cognitive Assessment (MoCA) (Nasreddine et al 2005).  is a 
brief tool developed to detect mild cognitive impairment that assesses a 
broader range of domains frequently affected in Parkinson’s disease, in 
particular, executive functions (see appendix 13).  Although the Mini-Mental 
State Examination (MMSE) (Folsten et al 1975) is widely used in research 
and clinical practice, research highlights that the MMSE is particularly 
insensitive to mild cognitive impairment and lacks adequate sampling of 
executive functions.  It may therefore, not detect cognitive deficits common to 
Parkinson’s disease, especially in the early stages of disease (Zadikoff et al 
2008, Athey et al 2005, Tang-Wai et al 2003, Wind et al 1997, Tombaugh 
and Mcintyre 1992).  This is important because dementia is an important and 
increasingly recognised problem in PD and depending on the method of 
ascertainment of cases, 20 - 80% of patients with PD will develop dementia 
over time (Svenningsson et al 2012, Butler et al 2008, Aarsland et al 2001, 
Sutcliffe and Meara 1995). 
 
MoCA has been shown to have good validity, reliabilty and consistency by 
the original test authors (Nasreddine et al 2005) and since then has been 
shown to have a good test-retest reliabily, inter rater reliabilty, and 
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convergent validity with a neuropsychological battery in a small sample of 
patients with PD (Gill et al 2008). 
 
All these tools/scales used for data collection are presently used in clinical 
practice and provide simple, user friendly and inexpensive tools/scales 
across the field of PD ensuring colleagues can readily interpret data 
presented.  These tools/scales chosen from the researcher’s perspective 
particularly appealed to address the balance between the required 
information and the burden to the patients participating in this study. 
 
 
2.5. SAMPLE SIZE CALCULATIONS AND STATISTICAL ANALYSIS 
 
A sample size of 112 was required (Faul et al 2009) for 90% power, 
assuming a two-sided 0.05 significance level and a weak correlation 
coefficient of 0.3 (Swinscow, 1997).  Over-recruitment was not accounted for 
since there is no follow-up and missing data was anticipated to be negligible.  
Although there are four outcomes of interest, motor-skills are considered the 
most important and therefore are considered the primary outcome on which 
the sample size was based. 
 
Spearman’s Rank was the most appropriate statistical test to investigate the 
association between sense of smell and motor symptoms and disease stage; 
in the meantime Pearson’s correlation coefficient was the  most appropriate 
to investigate the association between sense of smell and quality of life and 
the sense of smell of those with and without the 30 non-motor symptoms was 
investigated using chi square test. 
Following on from the data collection, correlations were used to investigate 
the associations between sense of smell and most of the outcome variables. 
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2.6. ETHICAL CONSIDERATIONS 
 
Full NHS ethical approval was obtained from the National Research Ethics 
Service (NRES) Committee South Central Southampton B and The Royal 
Bournemouth and Christchurch NHS Foundation Trust Research and 
Development Department (IRAS project ID 87288 REC reference number 
12/SC/0705).  (See appendix 15). 
 
The study is based on voluntary participation.  Patients were posted an 
invitation letter (see appendix 16) and information sheet (see appendix 17) by 
the researcher following an initial telephone consultation, or face to face 
meeting from another member of the PD team (during routine follow-up 
appointments) or from a local research nurse working in the field of 
neurodegenerative conditions.  An attached reply slip and a self addressed, 
postage paid envelope was then sent to the patients.  This allowed patients 
time to digest the information and decide if they wished to participate.  It also 
gave them the opportunity to discuss it with others and ask if there was 
anything that was not clear or if they would like more information.  Therefore, 
further information would be provided prior to participation if requested. 
 
All procedures were explained before performing the tests.  All tests, apart 
from the smell test, were considered entirely free of risks.  There were some 
concerns as to whether the smell test could cause a migrane or nausea.  
This was not seen in the study or during routine clinical testing.  The only 
disadvantage to the patient was the donation of an hour of their time.  
Patients chose dates that were convenient to them for assessment. 
 
Written consent (see appendix 18) was obtained by the researcher from 
patients who were willing to participate in the study once they had read and 
understood the information that was given to them in advance, and they are 
made fully aware of the  expectations of them in the study and the researcher 
is satisfied they have understood.  Patients were informed that they were not 
likely to benefit personally from taking part in the research.  However 
because the research will give us a better understanding as to whether the 
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sense of smell and the progression of Parkinson’s disease may be linked this 
could influence our understanding and treatment of individual Parkinson’s 
disease patients in the future. 
 
Patients were consented in a quiet room away from the clinical areas or at 
their home.  This was to avoid patients feeling pressurised into consenting.  A 
statement highlighted that it was entirely up to the patient to decide whether 
or not to take part, and if that if they agreed to take part, they were free to 
withdraw at any time should they so decide.  The invitation letter also 
highlighted that the patient did not have to give any reasons for withdrawing 
and this would not affect the standard of care they receive or have any 
adverse effects on their treatment (see appendix  16).  Respect for human 
dignity and privacy was maintained at all times and patients were assured 
that their participation in the study was confidential.   All records remain 
anonymous and are stored in a secure place on a local hospital Trust site. 
 
All patients who participated agreed to their GP being informed and a letter 
was sent to the GP accordingly (see appendix 19). 
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CHAPTER 3 
SENSE OF SMELL AND THE DEMOGRAPHIC FEATURES OF THE 
PARKINSONS DISEASE PATIENTS PARTICIPATING IN THIS STUDY 
 
 
3.1 OVERVIEW 
This chapter will address the link between the sense of smell (as measured 
by UPSIT 40) and the typical characteristics and demographic features of the 
study group, including UPSIT 40 sense of smell scores, gender, age, 
smoking history, taste reported, disease duration and cognitive function in 
each sense of smell sub-group.  All these demographic features were chosen 
as they may contribute to loss of sense of smell seen in PD patients.  
 
3.1.1. Parkinson’s Disease and Sense of Smell 
 
There is now good research evidence that the ability to smell is significantly 
affected in PD compared to the general population (Casjens et al 2013, 
Litvan et al 2003, Ramaker et al 2002, Hawkes et al 1999, Hawkes and 
Shephard 1998, Mesholam et al 1998, Hawkes et al 1997, Doty et al 1988, 
Quinn et al 1987), with at least 80% of PD patients affected (Double et al 
2003, Mesholam et al 1998, Hawkes et al 1997) (see section 1.2.1.2.).  There 
is also evidence that impaired olfaction may precede the classical motor 
manifestations of PD by several years (Ross et al 2008, Haehner et al 2007, 
Stiasny-Kolster et al 2005, Ponsen et al 2004, Hawkes 2003, Berendse et al 
2001, Doty et al 1988) (see section 1.2.1.2), suggesting that neuronal 
damage occurs early in the diagnosis, even before the classical motor signs 
are evident (Braak et al 2003) (see section 8.1 figure 8.2).  Interest in the loss 
of sense of smell (seen in PD patients) has grown markedly in the past few 
years, driven by the hope of developing neuroprotection treatment for PD 
patients in the early stage of the disorder.  Therefore, one of the aims of this 
chapter is to study the pattern of distribution of mild/moderate microsmia, 
severe microsmia and anosmia in PD patients selected for this PhD study.  
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3.1.2. Gender and Sense of Smell 
 
In general, females have a better sense of smell than males (Liu et al 1995).  
This observation has been made by numerous investigators, using 
psychophysical, electrophysical and imaging techniques (Lundstrom et al 
2006, Dalton et al 2002, Brand and Millot 2001, Cain 1982).  The discussion 
as to why these effects should occur is inconclusive.  So far, the increased 
olfactory sensitivity in females has been speculated to be attributed to 
numerous factors including hormonal effects (Doty 1986), verbal skills 
(Larsson et al 2004) or congenital factors (Schaal et al 2004).  This agrees 
with normative data for the UPSIT-40 in the United States, showing 
considerable influence of gender (Doty 1995).  This was also supported by 
the Silveria-Moriyama et al (2008) study which found that gender was an 
independent predictor of the UPSIT-40 score.  The UPSIT-40 has therefore 
adjusted for this and both female and male percentile scores can be seen in 
appendix 4. Therefore, one of the objectives of this chapter is to confirm or 
refute whether females in this PD study group do -in fact- have a better 
sense of smell compared to males. 
 
3.1.3. Ageing and Sense of Smell 
 
As previously mentioned (in section 1.2.3.) ageing is among the factors that 
put an individual at risk of developing olfactory dysfunction (Hawkes 2008, 
Doty 1995, Doty et al 1984).  However, it is also known it is unlikely that the 
PD olfactory defect is simply due to ageing (Hawkes 2008).  Therefore, one 
of the objectives of this chapter is to confirm or refute whether ageing does 
have an impact on loss of sense of smell in PD and to what degree. 
 
3.1.4. Smoking and Sense of Smell 
 
Little is known about the effect of cigarette smoking on the ability to smell.  
Previous studies on this topic have led to inconsistent findings.  For example, 
Frye et al (1990) found that smoking causes long-term but reversible adverse 
effect on the ability to smell.  This was not replicated by Ishimaru and Fujii 
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(2007) research who found that although smoking reduces the sense of smell 
function, recovery of sense of smell after cessation of smoking appears to be 
exceptional.  Katotomichelakis et al. 2007, in their study found smoking to be 
adversely associated with the olfactory ability in a dose-related manner and 
that smokers were found to be nearly six times as likely to have evidence of 
an olfactory deficit as non-smokers.  This was supported by Vennemann et al 
(2008).  However, a study by Lucassen et al (2014) showed that a history of 
smoking was associated with better olfaction among PD.  Lucassen et al 
(2014) conclude that although the interaction between smoke and the 
olfactory system at a peripheral level is a very intriguing hypothesis, it is also 
possible that cigarette smoke may protect olfactory structures within the 
brain.  This is supported by the fact that more than 60 epidemiological 
studies are consistent in reporting that smokers have a lower risk for 
developing PD (Li et al 2015, Burton et al 2013, Hawkes et al 2007, Hawkes 
et al 2009, Allam et al 2004).  However, the mechanism(s) by which cigarette 
smoking may confer a protective effect in PD is unknown and warrants 
further study.  
 
3.1.5. Taste and Sense of Smell 
 
Since brain stem regions associated with early Parkinson's disease (PD) 
pathology encroach upon those involved in taste function (caudal 
orbitofrontal cortex and immediately adjacent agranular insula) (Welge-
Lussen et al 2005, De Araujo et al 2003), the ability to taste may be 
compromised in PD (Doty et al 2015).  However, studies regarding the link 
between taste and sense of smell generally have been contradictory.  
Sienkiewicz-Jarosz et al (2005) report in their study that taste is unaffected 
by PD, Shah et al (2008) suggest that up to 28% of patients with established 
disease also have taste problems but Deems et al (1991) in their early 
research reported that 87% of those who report a taste problem -in fact- have 
no measurable taste deficit (false-positive rate). 
 
Although it is suggested there can be a central cause of taste loss, Hawkes 
and Doty (2009) suggest this appears to be due to retro nasal olfaction as 
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odorants released from food escapes into the retropharyngeal space.  
Therefore, it appears any food entering the mouth will evoke a sensation of 
both taste and smell, unless it is pure odourless tastant evoking solely sweet, 
sour, salt, bitter or savoury taste qualities. 
 
Overall, at this present time, it appears the coexistence of taste impairment 
with PD is not typical of PD (Sienkiewicz-Jarosz et al 2005) and Fernando et 
al (2005) suggest if it does occur at all it is probably a late feature of PD.   
 
3.1.6. Disease Duration and Sense of Smell 
 
The question of whether olfactory deficits in PD are related or unrelated to 
factors such as disease duration has been of considerable debate over the 
last 40 years.  Some researchers report no associations (Haehner et al 2009, 
Hawkes et al 1997, Doty et al 1992, Doty et al 1988, Quinn et al 1987, Ward 
et al 1983), whilst others note associations (Cavaco et al 2015, Debb et al 
2010, Tissingh et al 2001, Stern et al 1994, Ansari and Johnson 1975).  
These inconsistent findings may be related to procedural differences in 
measuring olfactory dysfunction (e.g., use of different assessment 
instruments, different methods used in the interpretation of olfactory 
performance (see table 1.1 and 1.2 section 1.2.1.).  However, interestingly, 
odour discrimination performance (in patients with PD) improves concurrently 
with clinical motor improvement after stereotactic neurosurgical treatment 
using deep brain stimulation (Hummel et al 2005).  This possibly indicates 
that at least some aspects of olfactory dysfunction in PD may be secondary 
to on-going degenerative processes in PD. 
 
However, none of the above studies have divided patients according to their 
severity of smell loss and disease duration.  This section will address this by, 
firstly examining the whole group and then dividing the duration of disease 
into 5-year intervals.  The PD patients will then be analysed according to their 
degree of smell loss (mild/moderate microsmia, severe microsmia or 
anosmia). 
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3.1.7. Cognitive Function and Sense of Smell 
 
Odour identification has been linked in some studies to language, verbal 
memory, and processing speed in healthy elderly (Westervelt et al 2005, 
Swan and Carmelli 2002).  Whilst in other studies, this has not been 
proposed (Hawkes et al 1997, Doty et al 1989, Quinn et al 1987).  However, 
this link between cognitive impairment and olfactory loss remains poorly 
explored in PD, although, Postuma and Gagnon (2010) recently reported 
significant correlations between verbal and nonverbal memory and olfactory 
loss in PD.  Furthermore, Bohnen et al (2010) found a positive correlation 
between odour identification scores and verbal memory in patients with PD 
who have olfactory loss. Bohnen et al (2010) implicated limbic cholinergic 
denervation and suggests that this cholinergic denervation may be more 
pronounced in a subset of PD patients with early emerging cognitive deficits 
and that greater deficits in odour identification may identify patients at risk of 
clinically significant cognitive impairment (Bohnen et al 2010, Bohnen and 
Albin 2010).  
Part of this chapter aims to confirm or refute whether cognition has an impact 
on sense of smell in this PD patient study group. 
 
 
3.2. AIM  
 
The aim of this chapter is to establish the pattern of distribution of 
mild/moderate microsmia, severe microsmia and anosmia in PD patients in 
this PhD study and relate it to gender, age, smoking history, taste reported, 
disease duration and cognitive function. 
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3.3 OBJECTIVES 
  
(i) To establish the prevalence of mild/moderate microsmia, severe 
microsmia or anosmia in this study group.  
 
(ii) To establish whether females in this study group do in fact have a better 
sense of smell than males. 
 
(iii) To confirm or refute whether age has an impact on the sense of smell. 
 
(iv) To establish the smoking status of PD patients in this study group and to 
confirm or refute whether smoking status has an impact on the sense of 
smell. 
 
(v) To confirm or refute whether taste is related to the degree of smell loss in 
this PD study group. 
 
(vi) To confirm or refute whether disease duration has an impact on the 
sense of smell and degree of smell loss. 
 
(vii) To ascertain whether cognition has an impact on the sense of smell. 
 
 
3.4. OUTLINE OF THE METHODS 
 
(i) The sense of smell was evaluated using the 40 items University of 
Pennsylvania Smell Identification Test (UPSIT) (as detailed in section 2.4.6). 
 
(ii) Gender, age, smoking history, taste reported, and duration of disease 
were all recorded on the Odour Detection in Parkinson’s Disease Participants 
Questionnaire (see appendix 14).   
 
(iii) Cognition was measured using the Montreal Cognitive Assessment tool 
(MoCA), (see appendix 13), (as detailed in chapter 2.4.7). 
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3.5 RESULTS 
 
This study was performed on 112 PD patients.  All patients were enrolled 
from a local Trust PD database and had a confirmed diagnosis of PD, using 
the UK Parkinson’s Disease Brain Bank Clinical Diagnostic Criteria (Hughes 
et al 1992).  All patients were out-patients.  No in-patients were included in 
the study. All patients reported no olfactory system damage from any other 
cause at the time of testing.  No attempt was made to capture environmental 
exposures or family history of PD and none of the patients were related.  
 
Of the 112 PD patients, 72 were males and 40 were females which represent 
a ratio of 1.8:1, age ranged from 49-89 years (mean age 71 years).  Out of 
112 patients, 61 patients have never smoked, 47 patients were ex-smokers 
and 4 patients still smoke.  Thirty patients also reported a decrease in  taste. 
 
Disease duration ranged from 6 months to 19 years (mean duration 5.5 
years).  All patients (except two scoring less than 18 on The MoCA) were 
considered to have either normal or mild cognitive impairment (normal score 
for the MoCA questionnaire is 27 and above and mild cognitive impairment 
ranges from 18-26) (Nasreddine et al 2005). See table 3.1 for the 
demographics and clinical characteristics of PD patients in this study.  
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Table 3.1: Demographics and Clinical Characteristics of PD Patients in This 
Study 
Variable   All 
patients 
(N=112) 
Mild/Moderat
e Microsmia 
(N=10)  
Severe 
Microsmia 
(n=27) 
Anosmia 
(N=75) 
Total 
(N=112) 
Sense of 
smell 
(UPSIT) 
Score 
Mean  
Median 
(±SD) 
 
17 
16 
M=27 F=27 
M=27 F=27 
1.509 
 
M=22  F=22 
M=22 F=22 
1.884 
 
M=13 F=15 
M=16 F=16        
3.067 
 
 
Gender Males (N=72) 
Females (N=40) 
 4 
6 
17 
10 
51 
24 
 
Age 
(years) 
Males 
Males  
Mean  
Median 
(±SD)  
IQ  
N=72 
70 
 
7.951 
10.5 
 
66 
 
 
 
 
70 
 
 
  
 
72 
 
 
 
 
Age 
(years) 
Females 
Females  
Mean  
Median 
(±SD)  
IQ 
 
N=40 
70 
 
7.628 
10 
 
 
65 
 
 
 
 
 
66 
 
 
 
 
 
70 
 
 
 
 
 
Age 
(years) 
Males and 
Females 
Males and 
Females 
Mean 
Median 
(±SD) 
IQ 
71 
71 
 
 
7.820 
9.5 
 
65 
 
  
7.130  
 
69 
  
 
7.785 
 
72 
 
 
9.764 
 
Smoking Non-Smokers 
Ex-Smokers 
Current 
Smokers 
 7 
3 
- 
12 
13 
2 
42 
31 
2 
61 
47 
4 
Taste Mild 
Moderate 
Severe 
 1 
1 
- 
2 
3 
1 
7 
13 
2 
10 
17 
3 
Duration of 
Disease 
Mean 
Median 
(±SD) 
Range (IQ) 
 5  
4 
5.31 
7.5 
5  
3 
4.57 
5.5 
6  
5 
5.91 
5 
 
Cognition 
(MoCA) 
Score 
Mean 
Median 
(±SD)  
Range (IQ) 
 27.5 
27 
2.699 
3.75 
26 
23 
1.881 
2 
26 
26 
2.991 
3.5 
 
Data are presented in mean, medians, SD, IQ range. 
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3.5.1. Male to Female Ratio 
 
 
 
Figure 3.1: Male to Female Ratio 
72 patients were males (64%) and 40 were females (36%).  This represents a ratio of 1.8:1. 
 
3.5.2. Age Range and Gender of PD Patients 
 
 
Figure 3.2: Age of Patients Enrolled in this Study 
The distribution of age within this study group is roughly symmetric with no major outliers.  The mean 
age is 71 years and there is a cluster of patients around this age.  SD=7.821. 
 
 
 
 
40  
Females 
72  
Males 
Male to Female Ratio 
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Figure 3.3: Age Range, Gender and Numbers of Male and Females in Each 
Group. Most of the patients enrolled in this study are between 70-74 age groups (22%) in both 
genders.  Another peak in age can be seen among both genders in the 65-69 age groups (21%). PD 
patients between the age of 45-59 (6%) and 85-89 (> 1%) in both genders represent the smallest 
sample of age range in this study.  Males are predominantly more representative in the 80-84 age 
group (13%) compared to females (4%). 
 
 
 
3.5.3 Sense of Smell (UPSIT) Scores 
Of the 112 PD patients recruited to this study, 75 patients had anosmia, 27 
patients had severe microsmia, 9 had moderate microsmia and one patient 
had mild microsmia.  No PD patients had a normal sense of smell (figure 
3.4). 
 
 
Figure 3.4: Sense of Smell and Numbers of PD Patients in Each Sub-Group 
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Most PD Patients (75) have anosmia which is 67% of the study sample size.  The female and male 
normal percentile values per the age of patients and test scores can be seen in Appendix 4.   
 
Figure 3.5 UPSIT Scores in Anosmia Group 
The UPSIT 40 scores show a double peak distribution at 13 and 16.  Both represent 12 patients out of 
75 anosmic patients and therefore 9% each of the whole anosmic group.  The mean is 13.80 and 
SD=3.067. 
   
 
Figure 3.6: UPSIT Scores in Severe Microsmia Group 
Distribution of UPSIT 40 scores in 27 patients with severe microsmia.    The mean UPSIT is 22.37 and 
SD=1.884. 
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Figure 3.7 UPSIT Scores in the Mild/Moderate Microsmia Group 
Distribution of UPSIT 40 scores in 10 PD patients with mild to moderate microsmia.  There is a peak at 
UPSIT score 27 and represents 5 PD patients (50%) of the mild/moderate group.  Only one patient had 
mild microsmia possibly representing an outlier.  The mean UPSIT is 27.50 and SD=1.509. 
 
 
3.6. FACTORS AFFECTING SENSE OF SMELL 
 
In this section data will be analysed for the whole group as a continuous 
parameter to ascertain the effects of certain factors that might affect the 
sense of smell. 
 
3.6.1. Gender Differences and Sense of Smell 
 
Figure 3.8 demonstrates that females have a better sense of smell and an 
overall higher median UPSIT score than males in this group of PD patients. 
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Figure 3.8: UPSIT Scores and Gender 
Females have an overall higher median UPSIT score of 17.5 compared to males with a median UPSIT 
score of 16 in this group of PD patients, which is statistically significant (p= 0.024). (Number of males 
=72. Number of females = 40).   
 
An independent samples t-test has been conducted to provide further 
statistical analysis on gender differences regarding the sense of smell.  
These are statistically significant in females (M=18.68, SD 5.498) compared 
to males (M=16.21, SD 5.467: t (112) = 2.283. p=0.024. 
 
3.6.2 Age and Sense of Smell 
 
UPSIT scores of patients with PD according to their age are shown in Figure 
3.9.  The data show a trend of a reduction in the sense of smell as PD 
patients get older.  Furthermore, there is a negative correlation between age 
and UPSIT  = -0.210, which is statistically significant (p=0.026). 
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Figure 3.9: UPSIT Scores and Age of PD Patients 
Distribution of the UPSIT score for 112 PD patients age recruited for this study.  The mean age is 71 
years for both males and females.  SD=7.820 (see table 3.1). 
 
 
3.6.3. Smoking and Sense of Smell 
 
Figurer 3.10 shows UPSIT scores for non-smokers, ex-smokers and current 
smokers.  The median UPSIT of present smokers is less than ex-smokers 
and non-smokers. 
 
Figure 3.10: UPSIT Scores, Smoking and Sense of Smell 
Smoking status and median UPSIT score for each subgroup.  There are 61 non-smokers (median 
UPSIT 16), 47 ex-smokers (median UPSIT 16) and 4 current smokers (median UPSIT 14).   
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Figure 3.11 shows the years since 47 ex-smokers quit smoking.  This ranges 
from 1 year to 60 years and UPSIT scores range from 6-31.  A Spearman’s 
correlation was run to determine the relationship between number of years 
since ceasing smoking and the sense of smell using UPSIT 40 scores.  
There was a weak positive correlation between the years since ceasing 
smoking and the degree of smell loss ( =0.107, n=47), which did not reach 
statistical significance (p=0.472). 
 
 
Figure 3.11: UPSIT Scores and Years Since Last Smoked 
Distribution of 47 ex-smokers’ UPSIT scores and years since last smoked.  This ranges from 1 year to 
60 years and UPSIT scores range from 6-31.  It appears UPSIT scores improve alongside years from 
quitting smoking.  However, on further statistical analysis this did not reach statistical significance (
=0.107, n=47, p=0.472). 
 
 
3.6.4. Taste Perception and Sense of Smell 
 
Of the 112 PD patients recruited to this study, 82 patients (73%) self-reported 
no taste problems and 30 patients (27%) self-reported taste problems (figure 
3.12).  The median UPSIT is lower in patients with self-reported taste 
problems (14.5) and the mean is 15.70, compared to those PD patients with 
no taste problems (median 17, mean 17.60) (see figure 3.12). 
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Figure 3.12: Patients with or Without Self-Reported Taste Problems and 
UPSIT Scores. Eighty-two PD patients reported no taste problems and thirty PD patients had 
taste problems.  The median UPSIT is lower in patients with self-reported taste problems (14.5) and 
the mean is 15.70, compared to those PD patients with no taste problems (median 17. Mean 17.60).   
 
Further statistical analysis using independent-samples t-test was conducted 
to compare UPSIT scores with patients self-reporting loss or changes in taste 
perception or not and sense of smell.  There was not a significant difference 
in the scores for patients self-reporting no changes (M=17.60, SD 5.584) and 
those patients self-reporting changes (M=15.70, SD 5.421): t (110) =1.605, 
p=0.111 in their ability to taste.  These results suggest that the perceived 
ability to be aware of loss or change in ability to taste does not correlate with 
the degree of loss of sense of smell. 
 
Further subgroup analysis of the degree of self-reported taste loss by 30 PD 
patients and UPSIT scores is shown in figure 3.13 (mild, moderate or severe 
as per odour detection in Parkinson’s disease questionnaire), (see appendix 
14).  Figure 3.13 demonstrates those PD patients self-reporting mild taste 
loss appear to have an improved sense of smell.  
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Figure 3:13: Patients Self-Reported Degree of Taste Loss by 30 PD Patients 
in the Study Group and UPSIT Scores 
Ten PD patients reported mild taste problems, 17 PD patients reported moderate taste problems and 
three PD patients reported severe taste problems.  The median UPSIT is higher in PD patients 
reporting mild taste problems (21) than the PD patients reporting moderate (median 16.5) and severe 
(median 16) taste problems. 
 
An independent sample Kruskal-Wallis test was run to determine the 
relationship between self-reported mild, moderate and severe taste problems 
and the sense of smell (using UPSIT 40 scores). This did not reach statistical 
significance (p=0.570).  
 
3.6.5. Duration of PD and Sense of Smell 
 
The results showed that the duration of PD in the study group ranged from 6 
months to 19 years and that olfactory dysfunction is present to a relatively 
high degree even in early stages of the disease process (figure 3.14).  The 
mean duration is 5.5 years (SD=3.887), median is 4 years (IQ range=6).  
Further statistical analysis using Pearson’s correlation shows that there was 
no correlation between duration of PD and severity of olfactory dysfunction, 
(as measure by UPSIT score), ( =0.043, p=0.649). 
86 
 
0
5
10
15
20
25
30
35
0 5 10 15 20
U
P
S
IT
 S
c
o
re
s
 
PD Years  
UPSIT Scores and PD Years 
Figure 3.14: UPSIT and PD Years 
The duration of PD in the study group ranged from 6 months to 19 years.  On visual inspection, there 
appears to be a cluster of PD patients around two and six years with the widest range of UPSIT at one 
year (UPSIT range 6-28). 
 
 
 
Figure 3.15: Frequency of PD Years 
The mean duration is 5.5 years, median is 4 years, SD=3.887 and IQ range=6.  Further statistical 
analysis shows that duration of PD and UPSIT Scores did not reach statistical significance =0.043, 
p=0.649. 
 
Duration of the disease has been analysed further by dividing the years into 
5-year intervals (i.e., 0.6-5, 6-10, 11-15 and 16-19 years) since being initially 
diagnosed with PD.  These intervals were linked with UPSIT mean, median 
and range and can be seen in table 3.2. 
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Table 3.2 shows that most patients (61=54%) have PD for five years or less, 
with the next group of patients having PD between 6-10 years (35= 31%).  
The group least representative in this study is patients with PD for 16 years 
or more and only accounts for less than 2% of the overall sample size.  There 
appears to be a slight difference between the mean and median UPSIT 
scores in each 5-year duration of PD subgroup. 
 
Table 3.2: PD Years, Number of Patients, UPSIT Scores (Mean, Media and 
Range). 
PD Years 
(Since 
diagnosis) 
Number of 
Patients 
UPSIT  
(Mean) 
UPSIT  
(Median) 
UPSIT 
(Range) 
0.6-5  61 17 
(SD = 
8.602) 
16 
(IQR = 10) 
6-29 
6-10 35 18 
(SD = 
6.167) 
16 
(IQR = 7.25) 
8-31 
11-15 14 17 
(SD = 
3.701) 
17 
(IQR = 5) 
11-27 
16-19 2 15 
(SD = 2.061 
15 
(IQR = 1) 
14-16 
 
 
3.6.6. Cognitive Function and Sense of Smell 
 
MoCA was used to assess cognitive function in patients with PD in this study 
(see section 2.4.2).  The minimum recorded MoCA for this PD study group is 
16 and the maximum is 30.  The mean MoCA is 26.1 (SD=2.787).   
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Figure 3.16: Frequency of MoCA Scores 
Mean MoCA score is 26.1 SD=2.787.  Median is 26 and Mode is 28. 
 
Figure 3.17 shows the UPSIT and MoCA scores for the whole PD group.  
There appears to be a trend for UPSIT scores to increase alongside an 
increase in MoCA scores.  Therefore, a Spearman’s correlation was 
conducted on all PD patients MoCA and UPSIT scores.  There is a weak 
positive correlation between cognition and UPSIT which is statistically 
significant. ( =0.213 p=0.024). 
 
Figure 3.17: UPSIT and MoCA Scores of Study Group 
The mean MoCA is 26.1 (SD=2.787).  However, there appears, to be a trend for UPSIT scores to 
increase alongside an increase in MoCA scores.  On further analysis, there was a positive correlation 
between cognition and UPSIT ( =0.213), which is statistically significant (p=0.024). 
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Further sub-group analysis was conducted by dividing patients into those 
with normal and those with mild impaired cognition (figure 3.18).   
 
Figure 3.18: UPSIT Scores and Patients with Normal or Mild Cognitive 
Impairment 
Fifty-seven PD patients had normal cognitive function and 55 PD patients had mild impaired cognition 
(normal score for MoCA is 27 and above and mild cognitive impairment ranges from 18-26 (although 
two patients included in the study had MoCA’s of 16 and 17). (See Appendix 13).  Initial analysis 
appears to show UPSIT scores decrease alongside the degree of impaired cognition. 
 
 
Figure 3.18 demonstrates that UPSIT score are slightly less in fifty-seven PD 
patients with mild impaired cognition (median 15, mean 16, SD= 5.470) 
compared to the fifty-five PD patients with normal cognitive function (median 
18, mean 18 SD= 5.546).  An independent samples t-test showed a 
statistically significant difference in the sense of smell (p=0.049) between PD 
patients with normal cognitive impairment compared to PD patients with mild 
cognitive impairment. 
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3.7 DISCUSSION 
 
 
3.7.1. Demographic Features of the PD Study Group 
 
 
In this PhD study group, the male (64%, n=72) to female (36%, n=40) ratio 
(see figure 3.1) appears to be slightly higher at 1.8:1 ratio than that 
considered representative of the general PD population at 1.5:1 ratio 
(Wooten et al 2004).  This however, seems to vary throughout the PD 
research with Hearting et al (2008) study reported a 1.5:1 ratio but Doty et al 
1988 study reported a ratio of 1.3:1.  Most patients (44%) were between the 
65-74 age group in both genders and 80+ age group in the males (see figure 
3.2).  This is not surprising as the researcher has predominantly older 
patients on the Trust database.  This is not only due to predominantly 
working alongside an elderly care physician but also because local 
demographics of the area, where the study was conducted, holds the highest 
concentration of the elderly in the United Kingdom with 33.2% of its 
population over the age of 65.  This is almost double the existing UK figure of 
16.5%. (Office for National Statistics 2011).  However, it is also worth noting 
that the prevalence rate of PD is set to increase by 28% by 2020 particularly 
in the older age groups highlighted in this study (65-74 and 80 + years) 
(Parkinson’s Prevalence in the UK 2012) and therefore could also represent 
the general age of the PD population. 
 
The distribution of age of PD patients (in years) within this study group is 
roughly symmetric (Figure 3.2), with no major outliers.  The mean age is 71 
years and there is a cluster of patients around this age (SD=7.821). This is 
higher than Herting et al (2008) who examined 27 patients (5 women, 22 
men) and had a predominantly younger age range 27–64 years (mean age 
49 years), but lower than to Doty et al (1988), who examined 81 patients (46 
men 35 women using UPSIT 40) and had a slightly larger mean age at 77.2 
years. 
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3.7.2 The Link Between Sense of Smell and PD 
 
 
Although the UPSIT is a self-administered test and safe, a member of the 
ethics committee referred to potential side effects of the sniff test (such as 
nausea or headaches), which are very rare and have not been encountered 
in clinical practice. In view of this, the researcher administered the test to all 
PD patients in this study.  This has been done in previous research but for 
ease of data collecting and to reduce potential sources of variance rather 
than for possible side effects (Sobel et al 2001, Doty et al 1988). 
 
Results of this study show at least 90% of the patients recruited for this study 
have either anosmia or severe microsmia with the remainder of the patients 
having mild/moderate microsmia (figure 3.3).  This finding concludes that 
100% of this study sample had an abnormal sense of smell.  However, this is 
not mirrored by others.  For example, Haehner et al (2009) in their large-
scale study of 400 patients of 3 individual populations reported 96% of their 
PD patients had olfactory loss, however, when normative data in relationship 
to the subjects age and sex was applied 74.5% of the study population was 
diagnosed with olfactory loss, highlighting that olfactory loss needs to be 
qualified in terms of the olfactory test used and normative data being applied.  
Therefore, the reasons for these inconsistent findings may be due to 
procedural differences in measuring olfactory dysfunction (e.g., use of 
different assessment instruments, interpretation of olfactory performance and 
demographic confounding factors) (which varied between these 
investigations)  
 
Herting et al (2008) is the only other researcher who found no patients had 
normosmia.  They conducted a longitudinal study over 4.4 years rather than 
an open cross-sectional study.  Although the sample size was smaller (27 PD 
patients were examined of whom 5 were women and 22 were men) with a 
predominantly younger age range of 27–64 years their study had PD patients 
with similar duration of disease recorded in this PhD is study (0 to 19 years).  
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However, if between 80-100% of PD patients have a degree of loss of sense 
of smell, this further emphasises that testing a patient’s sense of smell may 
improve the diagnostic accuracy of PD and may need to be considered as 
part of the brain bank criteria.  The researcher believes the more cardinal 
symptoms associated with a diagnosis of PD can only contribute to a more 
accurate diagnosis particularly as (i) PD is a devastating relentless condition 
(ii) the diagnostic accuracy is at best 84%-90% accurate even by an expert 
(Rizzo et al 2016, Brooks 2012, Hughes et al 2001) and, (iii) in practice, 
some patients make drastic lifestyle changes and alter their upcoming plans 
based on the diagnosis. 
  
In practice, the UPSIT was a simple test to administer and took on average 5 
minutes to complete.  One patient however, did struggle to accept she could 
not smell anything and was determined to smell the odour presented (she 
was anosmic) and for this reason the test took 45 minutes to complete.  
There were also several patients who commented that they had not smelt the 
occasional odour presented on the cards such as liquorice or skunk but there 
were other odours on the card that were familiar to them.  None of the odours 
the patients had not smelt before were in fact the presenting odour which re-
assured the researcher that the test score was in fact correct.  Interestingly, 8 
patients commented that all the smells smelt of cardboard.  A couple of PD 
patients also commented that there were a lot of odours to sniff but in general 
it was received well. 
 
Interestingly, there is one major outlier in the groups and this is the only 
patient who had mild loss of sense of smell (UPSIT 31), who later went on to 
be diagnosed with PSP-P.  
 
Further clarification on the distribution of UPSIT scores in each sub-group 
can be found in figures 3.5-3.7 (see section 3.4.3). 
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 3.7.3. Age and Sense of Smell 
 
Results of this study showed that there is a trend in reduction in the sense of 
smell as PD patients get older (figure 3.9).  There are numerous theories on 
why the sense of smell deteriorates as we age (see section 3.1.3).  However, 
it is beyond this study to examine these theories in any detail.  Furthermore, 
there is a negative correlation between age and UPSIT (r=-0.210), which is 
statistically significant (p=0.026).  This is in support of the findings of not only 
PD patients but non-PD patients.  For example; Doty et al (1984), examined 
over 1600 subjects (see section 1.2.3) and noted age has an impact on 
sense of smell. Hawkes (2008) suggests it is unlikely that the PD olfactory 
defect is due to simple ageing and suggests a healthy person would need to 
live until the age of 106 to 160 years to exhibit the degree of smell loss 
shown by a typical PD patient aged 60 years.  However, it is worth 
remembering that although ageing (Jafari et al 2008, Murphy et al 2002) and 
PD (Casjens et al 2013, Litvan et al 2003, Ramaker et al 2002, Hawkes et al 
1999, Hawkes and Shephard 1998, Mesholam et al 1998, Barz et al 1997, 
Hawkes et al 1997, Hawkes and Shephard 1993, Hummel et al 1993, Doty et 
al 1988, Quinn et al 1987, Ward et al 1983) are among the factors that put an 
individual at risk of developing olfactory dysfunction, other factors can cause 
olfactory loss such as vascular and metabolic insufficiency, (e g  
hypothyroidism or cirrhosis of the liver) viral/ inflammatory  damage (e.g.  
allergic rhinitis) (Rombaux et al 2012, Jafek et al 1990, Douek et al 1975) 
nutritional deficiencies, (such as B12 and Zinc)  air pollution (such as paint 
solvents and acetone)  (Hudson et al 2006), as well as a number of age 
related diseases , e.g. PD and AD (Rombaux et al 2005, Doty 1989) (For a 
list of related medical conditions that affect sense of smell see appendix 20) 
and medications such as ampicillin to treat infections and dexamethasone to 
treat pain (see appendix 21) (Doty et al 2008, Seiberling and Conley 2004, 
Schiffman and Graham 2000), can affectsense of smell.  
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3.7.4. Gender Differences and Sense of Smell 
 
Results of this study showed that females have an overall higher median 
UPSIT score than males in this group of PD patients (figure 3.9). This 
difference was statistically significant (p= 0.024).  This is consistent with the 
published work by Silveria-Moriyama et al (2008), Doty (1995) and Liu et al 
(1995) in patients with PD and has also been observed in general by 
numerous investigators, using psychophysical, electrophysical and imaging 
techniques (Lundstrom et al 2006, Dalton et al 2002, Brand and Millot 2001, 
Cain 1982), (as briefly described in section 1.2.7.).  Therefore, this study 
agrees with normative data for the UPSIT-40 showing a considerable 
influence of gender (Silveria-Moriyama et al 2008, Doty 1995).  
 
It is also worth considering that gender differences are significant despite 
adjustment using percentile values allowed for by Doty (2003) (See Appendix 
4) and possibly suggest that percentile values are in fact much higher in 
females than previously stated. 
 
Many studies report females outperform males on tests of odour identification 
regardless if they have PD or not (Fusari et al 2008, Doty et al 1984, Cain 
1982).  These observations have been made by numerous investigators 
using psychophysical, electrophysical and imaging techniques (Lundstrom et 
al 2006, Dalton et al 2002, Brand and Millot 2001, Doty et al 1984, Cain 
1982), (see section 2.4.6).   For example, Doty et al 1984 found in a study of 
455 men and 742 women asked to identify each of 50 odours being 
evaluated for inclusion in a standardized smell identification test.  Women 
outperformed men on 45 of the 50 stimuli (90%).  However, this is not 
mirrored by all researchers and some studies fail to find any significant 
differences between male and females in sensitivity for some odours for 
example pyridine (spoiled-milk odour) (Dorries et al 1989) and phenyl ethyl 
alcohol (rose like), (Segal et al 1995).  However, these studies are rare.  The 
discussion as to why women outperform men is inconclusive.  So far, the 
increased olfactory sensitivity has been speculated to be attributed to 
numerous factors such as hormonal effects and verbal skills. 
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With regards to hormonal effects, well-known examples are the variations in 
the sensitivity of women during their menstrual cycle.  Olfactory performance 
reaches a peak during ovulation and then decreases during menstruation 
(Doty 1986).  However, this is also observed with women on the 
contraceptive pill, which suggests that the variations in sensitivity are not 
hormone dependent.  Therefore, the mechanisms underlying the correlations 
between odour perception and hormonal status still have to be clarified.  With 
regards to verbal skills, it is known that women perform better than men in 
verbal tasks and that there is sex differences in the functional organization of 
the brain for language (Shaywitz et al 1995).  Thus, the superiority of women 
in olfaction could reflect a type of cognitive advantage that is also found in 
the other senses or situations.  A strong similarity between odour and 
language perception has been advanced by Lorig (1999).  For this author, 
odour information processing shares some of the cortical resources used in 
processing language.  In this way, it would not be surprising if an advantage 
in verbal tasks is correlated with an advantage in olfactory perception 
(Larsson et al 2004).   
 
3.7.5. Smoking and Sense of Smell 
 
One in five adults (20%) aged 16 and over and one in 7.7 (13%) adults aged 
60 and over were smokers in the UK in 2012 (Office for National Statistics 
2013).  In this PhD study, there are 4 current smokers (see Table 3.1), this 
represents one in 28 (4%) of the PD population which is significantly lower 
than that of the general population, even if we only compare it to patients 
over 60 years of age (which is when PD is most likely to be diagnosed).  
Although smokers appear to be poorly represented in this study sample this 
is also mirrored in Checkoway et al (2002) study who had 7 smokers out of 
the 210 PD patients which is one in 29.4 adults (3%) which is lower than 
national figures again.  Therefore, this may well represent the general 
percentage of smokers in the PD population (For a systematic review further 
confirming low incidence rates of smokers in PD see Hernan et al 2002).  
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Within this study group, in addition to the 4 current smokers there are also 61 
non-smokers and 47 ex-smokers (see Table 3.1).  The mean UPSIT of 
present smokers is less than ex-smokers and non-smokers (figure 3.10).  
This is in support of Katotomichelakis et al (2007) who reported smokers to 
be nearly six times as likely to evidence an olfactory deficit as non-smokers, 
depending on the duration and the number of cigarettes smoked.  On the 
other hand, findings of this present PhD study are in contrast with the 
findings of Lucassen et al (2014) who also used UPSIT 40 and examined 76 
PD subjects (22 with a history of smoking (smokers), 54 who never smoked 
(non-smokers), and 70 Controls (17 smokers, 53 non-smokers) who in fact 
found a history of smoking is associated with better olfaction among PD.  
However, in this current study, results need to be interpreted with caution as 
there may be a sample size effect, as only 4 patients smoke.  It could 
therefore be argued that a larger sample size incorporating an even 
distribution of smokers compared to non-smokers would be required to 
confirm or refute the findings in this present study. 
 
There was a weak negative correlation (which was non statistically 
significant) between number of years since stopping smoking and the degree 
of smell loss ( =-0.107, n=47, p=0.472.).  Indirectly, some results are 
supported by Murphy et al (2002) study who found that only current smoking 
was associated with impaired olfaction.  They did not find any significant 
difference between persons who had never smoked and past smokers. In 
contrast, a recent study testing odour identification in a Japanese adult 
population (Ishimaru and Fujii 2007), demonstrated a decreased odour 
identification to both current and past smokers, thereby concluding that 
cessation of smoking may not provide recovery of olfactory function. 
 
3.7.6. Taste Perception and Sense of Smell 
 
Despite the key role of taste function in nutrition and health, little is known 
about changes in taste perception caused by PD, particularly as Cecchini et 
al (2014) suggest that taste dysfunction should be included in the list of non-
motor symptoms of PD. 
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In this PhD study group, 82 patients (72%) self-reported no taste problems 
and 30 patients (27%) self-reported taste problems.  This was mirrored by 
Shan et al (2009) study who also found impaired taste appreciation in about 
27% of PD patients.  However, in Shan et al (2009) study although they used 
the UPSIT to test loss of sense of smell they used a more robust way of 
measuring taste threshold using the Rion electrogustometer in 75 non-
demented PD patients and 74 controls.  
 
Although median UPSIT score is lower in patients with self-reported taste 
problems compared to those who self-reported no taste problems (figure 
3.17) this difference was not statistically significant (p=0.111).  These results 
suggest that the perceived ability to be aware of loss or change in ability to 
taste was not affected by the patient’s sense of smell.  This was mirrored in 
Kim et al (2011) study who also tested the taste function of 31 PD patients 
and 29 healthy controls using filter paper taste strip tests (TSTs).  Although 
the mean TST score was significantly lower in female (rather than male), 
once again TST scores in PD patients did not correlate with olfactory 
function. 
 
Further analysis of the degree of taste loss (mild, moderate or severe) self-
reported by 30 PD patients in this study group and the degree of loss of 
sense of smell did not reach statistical significance (p=0.570). However, this 
might not have reached statistical significance due to a small sample size as 
only 30 PD patients (27%) self-reported taste problems. 
 
3.7.7. Duration of PD and Sense of Smell 
 
The duration of PD in the study group ranged from 6 months to 19 years.  
This is identical to Herting et al (2008) study who conducted a longitudinal 
study over 4.4 years rather than an open cross-sectional study.  However, 
the duration of PD in other studies does vary considerably.  For example, 
duration of PD ranged from 3 months to 55 years in Doty et al (1988) study 
and 3-10 years in the Cavaco et al (2015) study.  
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Further analysis shows that most patients participating in this study 
(61=54%) have PD for five years or less, with the next group of patients 
having PD between 6-10 years (35= 31%).  The group least representative in 
this study are patients with PD for 16 years or more and accounts for less 
than 2% (2 patients) of the overall sample size (see table 3.1).  There is slight 
difference noted in the mean and median in each 5-year duration group 
(table 3.2) and the overall mean duration of PD in this PhD study group is 5.5 
years.  This is similar to Cavaco et al (2015) study with a mean duration of 6 
years but much lower than that of Doty et al (1988) study with a mean 
duration of 12.4 years. 
 
Regardless of the duration of PD, this PhD study highlights that duration of 
PD alone is not that relevant when correlated with the loss of sense of smell 
as loss of sense of smell was present to a relatively high degree even in 
initial stages of the disease process (see figure 3.12).  This suggests that 
there is no relationship between the duration of PD and loss of sense of 
smell.  This is consistent with several studies suggesting that olfactory 
deficits in PD are unrelated to factors such as disease duration.  For 
example, Doty et al (1988) (who examined 81 PD patients), Double et al 
(2003) (who examined 49 PD patients) and Haehner et al (2009) (who 
examined 400 PD patients from a large multicentre study) all concluded there 
was no association between loss of sense of smell and duration of disease.  
 
However, as loss of sense of smell can be profound even in the early stages 
of disease these findings may not apply to all patients in the earliest stages of 
the disease or indeed all patients  (Berendse et al 2011; Herting et al 2008; 
Siderowf et al 2005; Tissingh et al 2001).  Therefore, to establish whether 
this PhD study confirms or refutes whether duration of disease does or does 
not correlate with loss of sense of smell, the 10 patients who had 
mild/moderate loss of sense of smell would need to be re-tested in several 
years’ time.  This would be simple to perform and warrants further study. 
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3.7.8. Cognitive Function and Sense of Smell 
 
Results of this PhD study showed there is a trend for MoCA scores to 
decrease alongside the reduction in sense of smell (figure 3.18).  
Spearman’s correlation showed there was a positive correlation between 
cognition and UPSIT ( =0.213) which is statistically significant (p=0.024).  
Although the link between cognitive impairment and olfactory loss remains 
poorly explored in PD, these findings agree with the findings of Postuma and 
Gagnon (2010) and Bohnen et al (2010).  Bohnen et al (2010) implicated 
limbic cholinergic denervation and suggests that this cholinergic denervation 
may be more pronounced in a subset of PD patients with early emerging 
cognitive deficits and that greater deficits in odour identification may identify 
patients at risk of clinically significant cognitive impairment (Bohnen et al 
2010, Bohnen and Albin 2010). 
 
Further sub-group analysis demonstrates that the median UPSIT score was 
slightly less in patients with mild impaired cognition compared to those with 
normal cognitive function (figure 3.18) which was statistically significant 
(p=0.049).  This agrees with Parrao et al (2012) who suggested there is a 
significant association between olfactory deficits and impairments of 
executive functions in PD. 
 
There is evidence to suggest that patients with more pronounced olfactory 
loss are at increased risk of developing dementia (Baba et al 2012, 
Stephenson et al 2010).  However, as shown in this PhD study profound 
olfactory dysfunction is found in PD patients whom are cognitively intact.  
This suggests that the dementia may not be the primary basis of the olfactory 
problem (Doty et al 1989).  Therefore, it is not clear in this PhD study whether 
those patients with anosmia will eventually develop dementia.    
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3.8 SUMMARY 
 
 Results of this study showed that 100% of PD patients participating in 
this study had an abnormal sense of smell.  
 The most common UPSIT scores are 13 and 16 which are both in the 
anosmic group.  
 Male to female ratio appears to be slightly higher (1.8:1) than that 
considered representative of the general PD population (1.5:1).  
 There is a trend in reduction in the sense of smell as PD patients get 
older which is statistically significant.  
 Females have an overall higher median UPSIT score than males in 
this study which was statistically significant. 
 The mean UPSIT of present smokers is less than ex-smokers and 
non-smokers however, results need to be interpreted with caution as 
there may be due to a small sample size, as only 4 PD patients 
smoked in this study sample.  
 The number of years since stopping smoking did not correlates with 
an improvement in sense of smell.  
 Perceived ability to be aware of loss or change in ability to taste was 
not affected by the patient’s sense of smell. 
 The duration of PD in the study group has no effect on degree of smell 
loss and olfactory dysfunction was present to a relatively high degree 
even in initial stages of the disease process.  
 Median UPSIT scores are slightly less in patients with mild impaired 
cognition compared to those with normal cognitive function which was 
statistically significant.  
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CHAPTER 4 
SENSE OF SMELL AND MOTOR SYMPTOMS IN PARKINSON’S 
DISEASE 
 
 
4.1. OVERVIEW 
 
Motor symptoms of Parkinson’s disease vary from person to person and 
change over time.  For example, fluctuations in the symptoms of Parkinson's 
disease (PD), such as wearing-off and on-off effects, dyskinesias, dystonia 
and tremor are common and are related to a variety of factors, including 
duration and dosage of levodopa, age at onset, stress, sleep, food intake, 
and other pharmacokinetic and pharmacodynamic mechanisms (Weiner 
2006, Jankovic 2005).  These progressive fluctuating symptoms cause 
difficulty with walking and balance and have a significantly negative effect on 
quality of life (Dowding et al 2006).  This chapter will address the link 
between the sense of smell (as measured by UPSIT 40) and the disease 
severity and motor symptoms associated with patients with Parkinson’s 
disease.  This is to confirm or refute whether there is any link between 
degree of loss of sense of smell and any of the motor symptoms in these PD 
patients.   
 
4.1.1. Disease Severity of PD and Sense of Smell 
 
The question of whether olfactory deficits in PD are related (or unrelated) to 
disease severity has been of considerable debate over the last 40 years.  
Some researchers report no associations (Haehner et al 2009, Hawkes et al 
1997, Doty et al 1992, Doty et al 1988, Quinn et al 1987, Ward et al 1983), 
whilst others note positive associations (Cavaco et al 2015, Berendse et al 
2011, Debb et al 2010, Tissingh et al 2001, Stern et al 1994, Ansari and 
Johnson 1975).  However, as previously stated, these inconsistent findings 
may be related to procedural differences in measuring olfactory dysfunction 
(see tables 1.1 and 1.2; section 1.2.1).  Interestingly, Hummell et al (2005) 
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noted that odour discrimination performance in PD patients rather than odour 
detection (as examined in this study) improves concurrent with clinical motor 
improvement after stereotactic neurosurgical treatment using deep brain 
stimulation.  Boesveldt et al (2008) and Tissingh et al (2001) also noted that it 
was odour discrimination that was associated with disease severity.  This 
possibly indicates that -at least- some aspects of olfactory dysfunction in PD 
may be secondary to on-going degenerative processes in PD. 
 
However, none of the above studies divided PD patients according to the 
degree of their smell loss and therefore the correlation with disease severity 
of PD (measured by means of the Hoehn and Yahr scale and the UPDRS) 
and degree of smell loss appear to have never been analysed.  This chapter 
will address these issues. 
 
4.1.2. Motor Symptoms and Sense of Smell  
 
There is a plethora of research trying to establish a link between the well-
known motor domains aspects of PD and the loss of sense of smell (Casjens 
et al 2013, Litvan et al 2003, Ramaker et al 2002, Hawkes et al 1999, 
Hawkes and Shephard 1998, Mesholam et al 1998, Hawkes et al 1997, Doty 
et al 1988, Quinn et al 1987).  These motor domains using the UPDRS motor 
III examination consists of 14 domains each measured on a 5-point scale (0-
4) (see section 2.4.1).  The higher the score the more severe is the disability 
(see Appendix 7).  However, none of the above studies divided PD patients 
according to the degree of their smell loss and therefore the correlation with 
motor aspects and degree of smell loss appear to have never been analysed.  
This chapter will address these issues. 
 
4.1.3. Rapid Eye Movement Behaviour Disorder (RBD) and Sense of 
Smell 
RBD associated with Parkinson's disease (PD-RBD) is a common secondary 
form of RBD.  The frequency of RBD in PD patients has been estimated to 
range from 15 to 59% (Yoritaka et al 2009, Gjerstad et al 2008, De Cock et al 
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2007) depending on method of diagnosis.  PD patients with RBD are older, 
more likely to be male (Yoritaka et al 2009, Gjerstad et al 2008), sleepier 
(Yoritaka et al 2009), more likely to experience orthostatic hypotension 
(Postuma et al 2009) and less likely to have tremor-predominant PD (Kumeru 
et al 2008) than PD patients without RBD.  Importantly, RBD could be an 
early feature of neurodegenerative disease especially PD (Claassen et al 
2010, Postuma et al 2009, Scaglione et al 2005, Eisensehr et al 2003). Both 
RBD and PD are characterized by reduced striatal dopaminergic mediation 
(Poryazova and Zachariev 2005).  
Olfactory loss is also an early biomarker of PD (Casjens et al 2013, Litvan et 
al 2003, Ramaker et al 2002, Hawkes et al 1999, Hawkes and Shephard 
1998, Mesholam et al 1998, Hawkes et al 1997, Doty et al 1988, Quinn et al 
1987).  Therefore, one objective of this chapter is to establish whether there 
is a correlation between RBD and sense of smell in PD. 
 
4.2 AIM  
The main aim of this chapter is to establish whether any of the motor 
symptoms associated with Parkinson’s disease, disease severity or RBD 
correlate with the degree of loss of sense of smell.   
 
4.3. OBJECTIVES  
 
(i) To establish whether there is a link between motor function, (as measured 
by UPDRS III) and the degree of loss of sense of smell (mild/moderate 
microsmia, severe microsmia or anosmia) in this study group. 
 
(ii) To establish whether there is a link between disease severity ( using 
Hoehn and Yahr Staging) and the degree of loss of sense of smell in this 
study group. 
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(iii) To establish whether there is a correlation between RBD and loss of 
sense of smell in PD.  
 
(iv) To establish whether there is a correlation between tremor dominant PD 
compared to akinetic-rigid type PD (which presents with little or no tremor but 
increased bradykinesia and rigidity) in this study group.  
 
 
4.4 OUTLINE OF THE METHODS 
 
(i) The sense of smell was evaluated using the 40 items University of 
Pennsylvania Smell Identification Test (UPSIT) (as detailed in section 2.4.6). 
 
(ii) Motor function was evaluated using part III of the Unified Parkinson’s 
Disease Rating Scale, (see appendix 7), (as detailed in section 2.4.1). 
 
 
(iii) Assessment of severity of PD based on clinical features and functional 
disability was measured using Hoehn and Yahr Staging (0-5), (see appendix 
10), (as detailed in section 2.4.4). 
 
 
(iv) Rapid Eye Movement Behaviour Disorder was evaluated using the Rapid 
Eye Movement Behaviour Disorder Questionnaire (See appendix 11), (as 
detailed in Chapter 2.4.5).  
 
(v) Assessment of tremor was evaluated by assessing resting tremor in the 
UPDRS III motor section (see appendix 7).   
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4.5 RESULTS 
 
4.5.1. Unified Parkinson’s Disease Rating Scale (UPDRS) Motor Section 
III Scores and Sense of Smell 
 
The Link between the total score of the UPDRS motor section III and the 
sense of smell UPSIT score will now be analysed using; (i) a whole group 
analysis approach and (ii) a sub-group analysis.  
 
(i) Whole group analysis  
 
Figure 4.1 shows a very weak negative correlation r=-0.1192 which is not 
statistically significant (p= 0.203) between the motor function (as measured 
by the UPDRS III) score and sense of smell score. 
 
 
Figure 4.1: Patients UPSIT and Motor Unified Parkinson’s Disease Rating 
Scale Scores. There is a very weak negative correlation r/s=-0.1192 which was not statistically 
significant (p=0.203) between UPDRS motor scores and UPSIT scores. 
 
Further analysis of the 14 individual domains of the UPDRS motor scores 
shows a pattern indicative of decline in the sense of smell in association with 
an increase in the severity of certain motor disabilities, mainly in relation to 
speech (figure 4.2), facial expression (Figure 4.3), hand movement (figure 
4.4), arising from a chair (figure 4.5) and posture domains (figures 4.6). 
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These findings were also confirmed by further statistical analysis (see table 
4.1).  
 
However, the results did not show any association between decline of sense 
of smell and the increase in certain other motor disabilities; these are (i) 
tremor at rest, (ii) action/postural tremor, (iii) rigidity, (iv) finger tapping, (v) 
rapid hand movements, (vi) leg agility,(vii) gait, (viii) postural stability, (ix) 
body bradykinesia and hypokinesia (see figures 4.7-4-11). (For UPDRS III 
motor domains, correlation and level of significance see table 4.1.).  
 
 
Figure 4.2: UPSIT Scores and Speech.  
 Median UPSIT scores decrease alongside the degree of speech disability.  Further statistical analysis 
showed that it was close to being statistically significant ( = -0.163, p=0.085). 
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Figure 4.3: UPSIT Scores and Facial Expression.   
Median UPSIT scores decrease alongside the degree of facial expression disability.  Further statistical 
analysis showed that it was statistically significant ( = -0.207, p=0.029). 
  
 
 
Figure 4.4: UPSIT Scores and Hand Movements. 
Median UPSIT scores decrease alongside the degree of hand movement disability. Further statistical 
analysis showed that it was close to being statistically significant ( = -0.166, p=0.080). 
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Figure 4.5: UPSIT Scores and Arising from a Chair.  
Median UPSIT scores decrease alongside the degree of speech disability.  Further statistical analysis 
showed that it was statistically significant ( = -0.190, p=0.045). 
 
 
Figure 4.6: UPSIT Scores and Posture. 
Median UPSIT scores decrease alongside the degree of speech disability.  Further statistical analysis 
showed that it was statistically significant ( =-0.231, p=0.014). 
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Table 4.1 UPDRS III Motor Domains, Correlation and Level of 
Significance 
 
UPDRS III Motor Domains Correlation (
) 
Level of Significance 
(P Value) 
Posture -0.231 0.014 
Facial Expression  -0.207 0.029. 
Arising from a Chair -0.190 0.045 
Hand Movements -0.166 0.080 
Speech -0.163 0.085 
Postural Stability 
 
 0.213 0.197 
Gait -0.119 0.212 
Finger Taps -0.072 0.451 
Body Bradykinesia and 
Hypokinesia 
-0.066 0.490 
Action/Postural Tremor 
 
-0.57 0.553 
Leg Agility  0.035 0.711 
Rapid Alternating Movements of 
Hands 
-0.035 0.714 
Tremor at rest -0.010 0.920 
Rigidity -0.010 0.920 
 
 
 
 
 
 
Figure 4.7: UPSIT Scores and Tremor at Rest. 
Median UPSIT scores do not decrease alongside the degree of disability.  
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Figure 4.8: UPSIT Scores and Action/Postural Tremor.  
Median UPSIT Scores are equal to those PD patients with no or mild disability. 
  
 
Figure 4.9: UPSIT Scores and Rigidity. 
Median UPSIT scores do not decrease alongside the degree of smell loss. 
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Figure 4.10: UPSIT Scores and Finger Tapping. 
Median UPSIT scores do not decrease alongside the degree of smell loss. 
 
 
Figure 4.11: UPSIT Scores and Rapid Hand Movements. 
Median UPSIT scores do not decrease alongside the degree of smell loss. In fact, sense of smell is 
more preserved in those patients with worsening ability to do rapid hand movements. 
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Figure 4.12: UPSIT Scores and Leg Agility. 
Median UPSIT scores do not decrease alongside the degree of smell loss in fact the loss of sense of 
smell appears stable across the degree of leg agility. 
 
 
Figure 4.13: UPSIT Scores and Gait. 
Median UPSIT Scores appear to worsen alongside the degree of disability although this was not  
Further statistical analysis showed that it was not statistically significant ( = -0.119, p=0.212). 
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Figure 4.14: UPSIT Scores and Postural Stability. 
Median UPSIT Scores appear to worsen in more advanced postural instability.  Further statistical 
analysis showed that it was not statistically significant ( = -0.213, p=0.197). 
.  
 
Figure 4.15: UPSIT Scores and Body Bradykinesia and Hypokinesia.  
Median UPSIT appears to decrease alongside the degree of smell loss but due to the small number of 
patients in Hohen and Yahr stage 0.  However, this did not reach statistical ( = -0.066, p=0.490). 
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Further statistical analysis between the UPDRS 14 motor domains and sense 
of smell scores showed all of them have a weak negative correlation 
although some reached statistical significance.  As shown, correlation is 
significant on posture, facial expression and arising from a chair (see table 
4.1).  This agrees with figures 4.6, 4.3 and 4.5 and is close to being 
significant in motor domains; hand movements and speech (see figures 4.4 
and 4.2). 
 
4.5.2 Tremor and Loss of Sense of Smell  
 
Table 4.2 breaks down those patients with either no, slight and infrequent, 
mild and persistent and moderate and present most of the time tremor, 
(assessed by the UPDRS III ‘tremor at rest’ domain), the number of patients 
in each group and their range, mean and median scores to establish whether 
patients with a more tremor dominant PD, rather than those patients with 
akinetic rigid PD had a better sense of smell.  Although it appears those with 
more severe tremor have a better sense of smell a chi-square test was 
conducted and showed that there were no statistically significant differences 
between the groups (p=0.366), concluding there is no association between 
the degree of tremor and UPSIT scores in this study group. 
 
Table 4.2. PD Patients Degree of Tremor, Range, Mean and Median Scores.  
 
Tremor  Number of 
PD Patients  
UPSIT  
(Range) 
UPSIT 
(Mean) 
UPSIT 
(Median) 
Absent 39 7-27 17 17.5 
Slight and 
infrequent 
34 8-31 16 17.5 
Mild and 
persistent 
26 6-29 17 16 
Moderate and 
present most of 
the time.  
13 10-27 18 17.5 
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4.5.3 Hoehn and Yahr Staging and Sense of Smell 
 
 (i) Whole Group analysis  
Categorisation of patients in each of the Hoehn and Yahr stages, together 
with their UPSIT scores, can be seen in table 4.3.  Most patients are at stage 
1 with little or no functional impairment, followed by stage 2 and then stage 3 
(table 4.3).  Only 2 patients are categorised as stage 4. 
 
Table 4.3: Hoehn and Yahr Staging, Number of Patients in Each Stage, 
UPSIT Range and Mean. 
Hoehn and 
Yahr Staging 
Number of Patients in each Hoehn 
and Yahr Stage and Overall 
Percentage  
UPSIT 
(Range) 
UPSIT 
(Mean) 
 1 53 = 47% 6-29 18 
2 33 = 30% 7-26 17 
3 24 = 21% 8-31 17 
4 2= 2% 13-16 14.5 
 
 
 
 
Figure 4.16 UPSIT score and Hoehn and Yahr Staging 
Most patients are at stage 1 with little or no functional impairment, followed by stage 2 and then stage 3 
(table 4.6). Only 2 patients are categorised as stage 4. On further analysis, there was a negative 
correlation between the severity/stage of PD and the degree of smell loss ( =-0.062, n=112, p=0.514) 
which did not reach statistical significance. 
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 (ii)Sub-group analysis 
To answer the research question whether there is a link between degree of 
loss of sense of smell and the severity of PD (measured by Hoehn and Yahrr 
staging), further sub-group analysis was carried out;    
 
 Table 4.4 shows most patients (n= 53) are at stage 1. The overall 
percentage of patients represented decreases alongside the degree of 
olfactory loss.  
  Stage 2 represents the next highest group (n=33) showing bilateral 
disease without impairment of balance.  In this group, the opposite 
occurs, and percentage of patients represented increases alongside 
the degree of olfactory loss.  
  In stage 3, which is mild to moderate disease with impairment of 
balance, most have mild/moderate microsmia or anosmia.  Severe 
microsmia represents a lower overall percentage of patients.  
  Finally stage 4 which signify severe disability, only patients with 
anosmia are represented. 
 
Table 4.4: Sense of Smell and Hoehn and Yahr Staging and Percentage of 
Patients in Each UPSIT Group. 
Sense of Smell Stage 1 
47% 
(n=53) 
(((n=53) 
Stage 2  
30% 
(n=33)  
Stage 3 
21% 
(n=24) 
Stage 4 
2% 
(n=2) 
Total 
100% 
(n=112)   
Mild/Moderate 
Microsmia 
(n=6) (n=1) (n=3) - 10 
Severe Microsmia (n=15) (n=8) (n=4) - 27 
Anosmia (n=32) (n=24) (n=17) (n=2) 75 
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4.5.4 Rapid Eye Movement Behaviour Disorder Scores and Sense of 
Smell 
(i) Whole Group Analysis 
 
Analysis of RBD in PD patients showed that 55 patients (37 males 18 
females) had RBD and 57 patients (35 males and 22 females) did not. (table 
4.5).  There was no difference in mean or median UPSIT scores comparing 
both groups suggesting there is no relationship between loss of sense of 
smell and RBD (figure 4.17).  
 
Table 4.5 PD patients with or without RBD, gender in each group, UPSIT 
median, mean range and mean duration of PD. 
PD Patients 
with or without 
RBD 
Gender UPSIT 
(median) 
UPSIT 
(Mean) 
Range Mean 
duration 
of 
disease 
With RBD 
(N= 55) 
37 males 
18 females 
16 17 7-29 5.93 
Without RBD 
(N=57) 
35 males 
22 females 
16 17 6-31 5.28 
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Figure 4.17: Patients without or with RBD and UPSIT Scores 
57 patients did not have RBD compared to 55 patients who did have RBD (see figure 4.17).  Results 
show there is no difference in the mean and median UPSIT scores with both groups having an UPSIT 
mean of 17 and median of 16 of patients without or with RBD. 
 
Figure 4.18 shows no correlation between UPSIT scores and their RBD 
scores. 
 
 
 
Figure 4.18: UPSIT Scores and Patients with or Without RBD 
Correlation between UPSIT sores and all patients with or without RBD was not significant (  =-0.021, 
p=0.823.).  
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(ii) Sub-Group Description 
 
Table 4.6 shows symptoms experienced by all PD patients who either  do or 
do not meet the criteria for a diagnosis of RBD, and the number of PD 
patients with RBD who have mild/moderate microsmia, severe microsmia or 
anosmia.  From table 4.6, (excluding question 10 as all patients have PD), 
the most reported symptom was having ‘vivid dreams’ in patients who either 
met the criteria for a diagnosis of RBD or not (63 patients of which 47 
patients met the criteria for a diagnosis of RBD).  The symptom least 
reported by all patients was ‘things that fell down around the bed’ (17 
patients), although all these patients met the criteria for a diagnosis of RBD.  
Interestingly the symptom ‘the dream content mostly match my nocturnal 
behaviour’ (25 patients) was also only experienced by patients who met the 
criteria for a diagnosis of RBD.  
 
Table 4.6: Symptoms Experienced by PD Patients Who Meet the Criteria for 
a Diagnosis of RBD and Number of PD patients with RBD who have 
mild/moderate microsmia, severe microsmia or anosmia. 
Question  Symptom  
Mild/Moderate 
Microsmia 
N=3 
Severe 
Microsmia 
N=13 
Anosmia 
N=39 
Patients 
with RBD 
N=55 
1 
I sometimes have very vivid dreams. 
1 12 34 47 
2 
My dreams frequently have an 
aggressive or action-packed 
content. 
0 7 23 30 
3 
The dream contents mostly match 
my nocturnal behaviour. 
0 5 20 25 
4 
I know that my arms or legs move 
when I sleep. 
3 9 28 40 
5 
It thereby happened that I (almost) 
hurt my bed partner or myself. 
2 5 20 27 
6 
I have or had the following 
phenomena during my dreams 
    
6.1 
speaking, shouting, swearing, 
laughing loudly  
1 9 30 40 
6.2 
sudden limb movements, “fights” 
2 9 31 42 
6.3 
gestures, complex movements, that 
are useless during sleep, e.g., to 
wave, to salute, to frighten 
mosquitoes, falls off the bed. 
1 3 17 21 
6.4 
things that fell down around the bed, 
e.g., bedside lamp, book, glasses  
1 0 16 17 
7 
It happens that my movements 
awake me  
2 8 19 29 
8 
After awakening I mostly remember 
the content of my dreams well. 
0 8 28 36 
9 My sleep is frequently disturbed 2 8 18 28 
10 I have/had a disease of the nervous 
system (e.g., stroke, head trauma, 
parkinsonism) which? 
3 13 39 55 
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4.6 DISCUSSION 
 
 
4.6.1 The Link Between the Sense of Smell and Unified Parkinson’s 
Disease Rating Scale (UPDRS) Motor III Scores  
 
Results of the whole group analysis showed a non-significant very weak 
negative correlation between the severity of motor function (as measured by 
the UPDRS motor section III) score (see appendix 7) and sense of smell 
score (UPSIT)  =-0.012 (see figure 4.1).  This finding is in keeping with 
previous research.  For example; Haehner et al (2009), in a multicentre study 
using a comprehensive testing method in a large sample of PD patients (n = 
400) from 3 independent populations failed to find a correlation between 
olfactory loss and clinical severity as measured by means of the Hoehn and 
Yahr scale and the UPDRS.  Doty et al (1988), who tested 81 PD patients 
and 81 controls through the results of the factor analysis also unequivocally 
indicate that the olfactory dysfunction of PD is independent of disease stage, 
and motor function and finally, Hawkes et al (1997) who tested 96 PD 
patients and 96 controls using a standardised odour identification test, 
together with an evoked potential assessment with hydrogen sulphide also 
failed to find a correlation between olfactory loss and motor severity.   
 
However, other studies, which are particularly comparable to this present 
study, have reported significant associations between severity of motor 
symptoms, using the UPDRS lll motor scores and olfactory testing (using B-
SIT and UPSIT respectively) in PD (Cavaco et al 2015, Deeb et al 2010).  
However, it is worth highlighting, Deeb et al (2010) did not differentiate 
normal from abnormal odour identification and Cavaco et al (2015) study PD 
patients were consistently evaluated in “off” state (i.e., overnight without 
antiparkinsonian mediation), to reduce the confounding effect of medication.  
Therefore, we could argue that, in this present PhD study, evaluation of PD 
patients in the ‘’on’’ state (i.e., taking PD medication as prescribed to 
optimise control of symptoms) is more representative of a typical PD patient.  
However, most studies on the topic lack information regarding motor 
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symptom assessment circumstances of treated patients (i.e., “on” versus “off” 
medication) which raises an important point that motor assessment 
circumstances are an important methodological aspect that has somewhat 
been neglected by the literature, which may partially explain the variability of 
findings. However, this depends also on whether medication has an effect on 
sense of smell. 
 
On further sub-group analysis of the individual 14 UPDRS motor III domains, 
the results show there is a decline in smell ability alongside an increase in 
motor disability in the speech, facial expression, hand movement, arising 
from a chair and posture domains.  (See figures 4.2-4.6).  When each 
individual domain of the 14 UPDRS motor domains was further analysed 
within each sense of smell sub-group and showed correlation is significant in 
posture (  = -0.231 p=0.014), facial expression ( =-0.207 p=0.029) and 
arising from a chair (  =-0.190 p=0.045) (See table 4.1).  This agrees with 
figures 4.6, 4.3, and 4.5 and table 4.1 and is close to being significant in 
motor domains, hand movements ( =-0.166 p=0.080) and speech (  = -
0.166 p=0.085).  (See figures 4.4 and 4.2 and table 4.1).  Comparison 
between other studies cannot be made as this study appears to be the first to 
address the link between individual domains of  motor symptoms and sense 
of smell loss.  
 
4.6.1.1 The Link Between the Sense of Smell and Tremor Identified by 
the Unified Parkinson’s Disease Rating Scale (UPDRS) Motor III Scores  
This study also highlights that people with tremor dominant PD did not have a 
superior sense of smell.  (See table 4.4).  This reflects previous observations 
in a small sample size of 37 patients (Muller et al 2002) and a larger study 
(400 patients) conducted by Haehner et al (2009) (who used sniff sticks). 
However, this PhD study findings are contradicting the findings of Lijima et al 
(2011), (using odour identification sticks), Ondo and Lai (2005), (using UPSIT 
40) and Stern et al (1994) (using UPSIT), who all reported superior odour 
identification scores in patients with tremor dominant compared to akinetic-
rigid type PD.  
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Despite this, the findings in this present study highlight that individual motor 
domains may be linked to the degree of smell loss rather than the total 
UPDRS III motor domains.  
 
4.6.2. The Significance of The Outliers in UPDRS III Motor Scores 
 
As it is well known, outliers should be investigated carefully.  To understand 
why they appeared, each outlier was examined for any unusual traits that 
might be the cause of higher UPSIT 40 scores in this present study.  The 
most significant finding was that the PD patient who scored the highest 
UPSIT score (patient number 81 with an UPSIT score of 31) was the only 
patient in this study group to have mild olfactory loss and is, in fact, the only 
patient in this study since initial testing (May 2013) who has had their 
diagnosis reviewed by another expert and has now been diagnosed with 
PSP-P (June 2015).  This is a significant finding as previous studies have 
suggested that either microsmia is not present or is better preserved in PSP-
P (Silveria-Moriyama et al 2010, Wenning et al 1995, Doty et al 1993).  (See 
section 1.4.1.3.).  Indeed, Silveria-Moriyama et al (2010) suggests smell tests 
might differentiate PSP-P from PD, particularly when UPSIT scores are lower 
than 14/40 (a cut-off that provides a sensitivity of 97.3%).  This result 
supports that theory. 
 
4.6.3. The Stages of PD Severity and Sense of Smell 
The results of this study suggest that olfactory deficits (using smell 
identification) in PD are unrelated to disease severity (using Hoehn and Yahr 
staging) ( =-0.062, n=112, p=0.514) (see figure 4.16).  This has been 
observed by previous studies (Haehner et al 2009, Hawkes et al 1997, Doty 
et al 1988, Quinn et al 1987, Ward et al 1983).  However, a study by Tissingh 
et al (2001), who administered odour detection, discrimination, and 
identification tests to a partly de novo group of forty-one non-demented PD 
patients, (24 of whom had untreated early PD, and 18 healthy controls), 
highlighted that odour discrimination scores, (using ‘sniffin sticks’  whereby 
the patient needs to  identifying the sample that has a different odour) , (not 
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seen in detection or identification scores) were related to disease severity.  
This was consistent with other findings from neuropathological and 
electrophysiological studies on PD patients (Potagas et al 1998, Barz et al 
1997, Pearce et al 1995) and suggests that at least some aspects of olfactory 
dysfunction in PD (e.g., odour discrimination, which is considered to involve 
the more central olfactory structures, unlike odour detection that may be a 
consequence of peripheral defects in the olfactory pathway), may be 
secondary to on-going degenerative processes in PD.  This study is unable 
to support or refute this work as smell identification, rather than 
discrimination, was the method used for analysing smell loss in this study 
group (detailed in chapter 2.4.6). 
However, it is worth noting that, in this present PhD study, most patients are 
at stage 1 and stage 2 with poor representation of disease stage particularly 
at stage 4 (2 patients are categorised as stage 4) (see table 4.6). 
 
Therefore, there may be a sampling bias influencing median UPSIT scores 
due to poor representation of PD patients in certain Hoehn and Yahr stages.  
To address this there would need to be an even distribution of patients in 
each stages of Hoehn and Yahr which requires recruiting more PD patients.  
Ethical approval would need to be sought to address this (discussed in 
limitations of this study (see section 9.6) and therefore subsequent studies 
could further prove or disprove these findings. 
 
4.6.4. Rapid Eye Movement Behaviour Disorder Scores and Sense of 
Smell 
 
Idiopathic RBD is strongly linked to PD (Postuma 2014, Iranzo et al 2011, 
Postuma et al 2009, Plazzi et al 1998).  In fact, there is growing evidence to 
suggest that RBD precedes PD by years or even decades (Gao et al 2011, 
Claassen et al 2010, Postuma et al 2009, Monderer and Thorpy 2009, Iranzo 
et al 2006, Olson et al 2000). 
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Initial analysis of this present study shows 57 patients did not have RBD and 
55 patients did (see figure 4.17). This highlights that approximately 50% of 
PD patients in this study have a clinical diagnosis of RBD, using the RBD 
screening questionnaire (see appendix 11).  Generally, RBD is said to affect 
15 - 65% of patients with PD (Postuma et al 2009, De Cock et al 2007, 
Scaglione et al 2005, Olson et al 2000) but is rare in tauopathies such as 
Progressive Supra Nuclear Palsy (Boeve et al 2001).  Reasons for the 
variation in percentages of patients noted in individual studies could be due 
to the tools used to diagnose RBD.  For example, one theory is that, unlike 
the diagnosis of idiopathic RBD which can easily be made by conducting only 
a structured clinical interview, more than half of the RBD cases in patients 
with Parkinson's disease would be omitted using this technique (the 
sensitivity was poor at 33% with a specificity of 90%, in patients with PD) 
(Poryazova and Zachareive 2005).  Also, although the RBD screening 
questionnaire shows good internal consistency and a high sensitivity (96%) 
compared to the clinical interview, it has a low specificity (56%) (Stiasny-
Kolster et al 2007) and therefore patients with PD should ideally be examined 
by polysomnography (Schenck and Mahowald 2002).  This is particularly 
since there are mild forms of RBD in Parkinson's disease while the idiopathic 
forms always present with markedly severe clinical manifestations.  This may 
suggest that patients who have RBD in PD may be unaware of it (similar to 
patients not realising they have a reduced sense of smell). 
Therefore, polysomnography is the gold standard assessment for RBD in PD.  
However, on a practical note, polysomnography requires monitoring 
equipment, including time synchronized video recordings, specially trained 
technologists, bed availability in a sleep laboratory and clinicians who can 
interpret the data.  For a patient with PD they have an additional burden of 
possibly being too physically impaired to tolerate and undergo an adequate 
study.  Also, since the background EEG is often so abnormal in those with 
moderate to severe dementia, which can be a late symptom of PD, 
determining which periods represent REM sleep on polysomnography can be 
difficult if not impossible.  It is also worth noting, in some PD patients, the 
dream enactment behaviour is so infrequent and mild that a clinical 
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polysomnography is difficult to justify.  Therefore, although not ideal, a 
questionnaire such as the Rapid Eye Movement Behavior Disorder 
Screening Questionnaire was the only useful tool to measure this in this 
study.  Boeve (2010a) states that a diagnosis of probable RBD would be 
justified. 
As seen in table 4.7 and figure 4.17 there are no differences in the mean and 
median UPSIT scores with both groups of PD patients regardless if they had 
RBD or not (mean 17 and median 16).  Further analysis between UPSIT and 
RBD scores confirmed this was not statistically significant (  = -0.021 
p=0.823) (see figure 4.18).  This is surprising as pathogenically, PD shares 
many similar features with RBD.  Both conditions are characterized by 
reduced striatal dopaminergic mediation (Poryazova and Zachareive 2005).  
This raises the question why do not all PD patients in this study have RBD, 
particularly as stage 2 in the Braak classification (Braak et al 2003) affects 
the key areas for sleep control and eye movement (Trotti 2010, Benedito and 
Camarini 2001).  There appears to be no definitive answer to the question 
and this warrants further future analysis. Finally, table 4.8 highlights that 
(excluding question 10 in which all patients have PD) the two most common 
symptoms reported in patients with RBD are vivid dreams and sudden limb 
movements and the two least common symptoms are things falling down 
around the bed and complex movements.  
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4.7 SUMMARY 
 
 Whole group analysis in this study showed a non-significant negative 
correlation between the severity of motor function and sense of smell 
scores. 
 Examining the individual 14 UPDRS motor III domains, the results 
show there is a decline in smell ability alongside an increase in motor 
disability in the facial expression, arising from a chair and posture 
domains and is close to being significant in hand movements and 
speech domains.  
 Tremor dominant PD patients did not have a superior sense of smell 
compared to PD patients with akinetic-rigid type PD. 
 The PD patient who scored the highest UPSIT score (patient number 
81 with an UPSIT score of 31) was the only patient in this study group 
to have mild olfactory loss and is, in fact, the only patient in this study 
since initial testing (May 2013) who has had their diagnosis reviewed 
and has now been diagnosed with PSP (June 2015).   
 Olfactory deficits (using smell identification) in PD are unrelated to 
disease severity.  
 Loss of sense of smell is unrelated to RBD.   
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CHAPTER 5 
SENSE OF SMELL, NON-MOTOR SYMPTOMS AND QUALITY OF LIFE IN 
PARKINSON’S DISEASE 
 
 
5.1 OVERVIEW 
 
The non-motor symptoms of PD are an important aspect of nursing 
assessment and have a direct negative impact on health-related and 
perceived quality of life in PD (Santos-Garcia and de la Fuente-Fernández 
2013).  The main research question that will be addressed in this chapter is 
whether any other non-motor symptoms, highlighted in the non-motor 
symptom questionnaire, or any of the quality of life issues, raised in the 
PDQ39 questionnaire, correlate with loss of sense of smell.  
5.1.1. Non-Motor Symptoms Questionnaire and Sense of Smell  
James Parkinson recognised the implications and importance of key non-
motor symptoms, such as sleep dysfunction, cognitive and neuropsychiatric 
issues in 1817 (Parkinson 2002, Parkinson 1817).  However, it was almost 
150 years before the importance of the burden of non-motor symptoms on 
the lives of the people with Parkinson's and the carers became apparent 
(Chaudhuri et al 2006).  In clinical practice, most of these non-motor 
symptoms are not usually volunteered by patients.  Indeed, a recent study 
has shown that most of the non-motor symptoms remain undeclared to 
health care professionals, probably because patients are either embarrassed 
or unaware that such non-motor symptoms are due to PD (Bostantjopoulou 
et al 2013).  Therefore, it is important that there is systematic questioning by 
health care professionals.  
Non-motor symptoms are found in a substantial proportion of patients with 
PD (Bostantjopoulou et al 2013).  These symptoms consist of autonomic 
dysfunction, sensory complaints, neuropsychiatric disturbances, sleep 
disorders, fatigue, and many others (Chaudhuri et al 2011).  The use of the 
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validated non-motor symptoms screening questionnaire (Martinez-Martin et 
al 2007) to assess the non-motor symptoms of Parkinson’s disease can 
assist in the ability to recognise and manage these symptoms in clinical 
practice.  
There appears to be no research papers examining the link between the 
degree of loss of sense of smell and other non-motor symptom in PD 
patients.  Therefore, one of the aims of this chapter is to establish whether 
the degree of loss of sense of smell correlates with any other non-motor 
symptoms.  
5.1.2. PDQ39 Quality of Life Scores and Sense of Smell 
There appears to be a lack of research generally around reduced sense of 
smell and diminished quality of life, with only a few studies demonstrating the 
impact on reproductive behaviour (Stevenson 2010), decreased sexual 
arousal and testosterone levels in men (Gelstein et al 2011) and depression 
in those patients who develop anosmia (Hede’n Blomqvist et al 2004, 
Temmel et al 2002).  There are also a few studies on some disease specific 
conditions (Politis et al 2010, Deems et al 1991) of which PD is one such 
condition (Politis et al 2010).  In the Politis et al (2010) study, they found 
olfactory loss belongs to the top-five most prevalent motor and non-motor 
symptoms in early stage PD patients that have affected their quality of life.  
Furthermore, Miwa et al (2001) also highlighted in their research that 
patients' overall satisfaction with life correlated positively with smell scores.  
One of the aims of this chapter is to establish whether there is a correlation 
between the loss of sense of smell and any of the other quality of life scores. 
 
 5.2 AIM 
The aim of this chapter is to investigate whether the loss of sense of smell 
correlates with any non-motor symptoms or quality of life scores in PD 
patients. 
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5.3 OBJECTIVES  
(i) To establish whether the loss of sense of smell correlates with any of the 
non-motor symptoms highlighted in the non-motor symptoms questionnaire. 
(ii) To establish whether the loss of sense of smell correlates with any of the 
quality of life scores highlighted in the PDQ39 quality of life questionnaire. 
 
 
5.4. OUTLINE OF METHODS 
 
(i) The sense of smell was evaluated using the University of Pennsylvania 
Smell Identification Test (UPSIT) (as detailed in section 2.4.6). 
 
(ii) Non-motor symptoms were measured by the non-motor symptoms 
questionnaire, which provides a measure of 30 key non-motor symptoms 
seen in PD (as detailed in section 2.4.2). 
 
(iii) Quality of life was measured using the PDQ39 quality of life questionnaire 
(PDQ39) which provides an overall assessment of PD patients 39 quality of 
life issues (as detailed in section 2.4.3). 
 
 
5.5. RESULTS 
 
5.5.1. Profile of Non-Motor Symptoms in the PD Study Group 
 
The most prevalent non-motor symptoms and percentage of patients 
reporting them are shown in table 5.1.  A sense of urgency to pass urine 
(63%), getting up regularly at night to pass urine (61%) and constipation 
(54%) are the most prevalent top three non-motor symptoms experienced by 
PD patients in this study, irrespective of their sense of smell status. Table 5.2 
shows the most prevalent top five non-motor symptoms and number of males 
and females experiencing that symptom.  
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Table 5.1: Non-Motor Symptoms Questionnaire Results and Percentage 
of Each Symptom Reported.   
Symptom Percentage Patients 
Reporting Symptoms  
8   A sense of urgency to pass urine makes you rush to the toilet 63% 
9   Getting up regularly at night to pass urine 61% 
5   Constipation (less than three bowel movements a week) or            
having to strain to pass a stool 
54% 
26 Unpleasant sensations in your legs at night or while resting, and a 
feeling that you need to move 
52% 
12 Problems remembering things that have happened recently or 
forgetting to do things 
51% 
16 Feeling sad, ‘low’ or ‘blue’ 48% 
20 Feeling light-headed, dizzy or weak standing from sitting or lying 46% 
1   Dribbling of saliva during the daytime 44% 
23 Difficulty getting to sleep at night or staying asleep at night 44% 
15 Difficulty concentrating or staying focused 40% 
7   Feeling that your bowel emptying is incomplete after having been 
to the toilet 
38% 
25 Talking or moving about in your sleep, as if you are ‘acting out’ a 
dream 
38% 
17 Feeling anxious, frightened or panicky 36% 
19 Finding it difficult to have sex when you try 35% 
24 Intense, vivid or frightening dreams 34% 
2   Loss or change in your ability to taste or smell 33% 
3   Difficulty swallowing food or drink or problems with choking 32% 
18 Feeling less interested in sex or more interested in sex 32% 
10 Unexplained pains (not due to known conditions such as arthritis) 29% 
27 Swelling of the legs 29% 
21 Falling 27% 
13 Loss of interest in what is happening around you or in doing things 23% 
28 Excessive sweating 20% 
29 Double vision 20% 
4   Vomiting or feelings of sickness (nausea) 17% 
14 Seeing or hearing things that you know, or are told, are not there 16% 
22 Finding it difficult to stay awake during activities such as working, 
driving or eating 
16% 
6  Bowel (faecal) incontinence 7% 
11 Unexplained change in weight (not due to change in diet) 7% 
30 Believing things are happening to you that other people say are 
not 
2% 
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Table 5.2: Top Five Non-Motor Symptoms Questionnaire Results and 
Number of Males or Females Reporting that Symptom. 
Symptom Percentage Patients 
Reporting Symptoms  
Males Females 
8   A sense of urgency to pass urine makes you 
rush to the toilet 
63% 47 24 
9   Getting up regularly at night to pass urine 61% 43 25 
5   Constipation (less than three bowel movements 
a week) or having to strain to pass a stool 
54% 39 22 
26 Unpleasant sensations in your legs at night or 
while resting, and a feeling that you need to move 
52% 34 24 
12 Problems remembering things that have 
happened recently or forgetting to do things 
51% 44 13 
 
 (I) Sub-group analysis 
 
Further sub-group analysis was carried out to investigate the frequency of 
these non-motor symptoms in the three sub-groups of patients (according to 
the severity of loss of sense of smell), (i.e., mild/moderate, severe, anosmia) 
and link them with the percentage of PD patients (See table 5.3 A, B, C, D). 
 
Table 5.3 (A) highlights an increase in frequency of non-motor symptoms 
alongside the degree of smell loss and is reported in 12 out of the 30 non-
motor symptoms overall.  This is in support of the research hypothesis. 
However, when conducting a chi-square test of independence to examine the 
relation between the degrees of smell loss and each individual non-motor 
symptom, the only symptom to reach statistical significance is dribbling of 
saliva during the day (p=0.003). 
 
Furthermore, with the exception of the mild/moderate sense of smell group, 
(which only has a small number of the overall sample size), table 5.3 (B) also 
shows an increase in frequency of non-motor symptoms alongside the 
degree of smell loss.  This pattern is reported in 15 out of the 30 non-motor 
symptoms overall. However, none of these symptoms reached statistical 
significance.  
 
Table 5.3 (C) highlights only two symptoms which are more prevalent in 
those patients with severe microsmia than those with mild to moderate 
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microsmia or anosmia.  However, they were not statistically significant.  
Finally, Table 5.3 (D) highlights that only one symptom appears to be 
reported least by patients, despite the degree of olfactory deficit being worse, 
and this is unexplained pains.  This was also not statistically significant 
(p=0.159). 
 
Interestingly, if we exclude the mild/moderate sense of smell group (due to 
small sample size, n=10), 27 out of the 30 non-motor symptoms are more 
prevalent in patients with anosmia. 
 
(ii) Sense of Smell in Each Sub-group and Percentage of Patients 
Reporting Symptoms in Each Non-Motor Symptom 
 
Table 5.3(A): Non-Motor Symptoms that Increase Alongside the Degree 
of Smell Loss 
Non-Motor Symptom 
 
Mild/Moderate 
Microsmia 
(N=10) 
 
Severe 
Microsmia 
(N=27) 
Anosmia 
(N=75) 
Chi 
Square 
(P value) 
1 Dribbling of saliva during the daytime 20% 22% 55% 0.003 
2 Loss or change in your ability to taste or 
smell 
20% 33% 35% 0.628 
3 Difficulty swallowing food or drink or 
problems with choking 
30% 30% 34% 0.928 
12 Problems remembering things that have 
happened recently or forgetting to do things 
30% 52% 53% 0.371 
14 Seeing or hearing things that you know 
or are told are not there 
10% 15% 15% 0.809 
16 Feeling sad, ‘low’ or ‘blue’ 40% 44% 51% 0.856 
17 Feeling anxious, frightened or panicky 30% 30% 41% 0.645 
19 Finding it difficult to have sex when you 
try 
10% 26% 43% 0.059 
20 Feeling light-headed, dizzy or weak 
standing from sitting or lying 
40% 48% 49% 0.904 
24 Intense, vivid or frightening dreams 10% 22% 41% 0.141 
25 Talking or moving about in your sleep, 
as if you are ‘acting out’ a dream 
20% 33% 43% 0.295 
28 Excessive sweating 10% 11% 24% 0.226 
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Table 5.3 (B): Non-Motor Symptoms that Improve in Patients with 
Severe Microsmia 
Non-Motor Symptom 
 
Mild/Moderate 
Microsmia 
(10) 
(10) 
Severe 
Microsmia 
(27) 
Anosmia 
(75) 
Chi 
Square 
P value 
4 Vomiting or feelings of sickness 
(nausea) 
40% 11% 16% 0.154 
5 Constipation (less than three 
bowel movements a week) or 
having to strain to pass a stool 
60% 37% 59% 0.113 
6 Bowel (faecal) incontinence 10% 4% 8% 0.681 
7 Feeling that your bowel emptying 
is incomplete after having been to 
the toilet 
40% 26% 43% 0.293 
8 A sense of urgency to pass urine 
makes you rush to the toilet 
70% 52% 68% 0.360 
9 Getting up regularly at night to 
pass urine 
50% 44% 69% 0.078 
11 Unexplained change in weight 
(not due to change in diet) 
10% 4% 8% 0.681 
13 Loss of interest in what is 
happening around you or in doing 
things 
30% 15% 24% 0.447 
15 Difficulty concentrating or 
staying focused 
30% 19% 42% 0.722 
21 Falling 20% 15% 32% 0.176 
22 Finding it difficult to stay awake 
during activities such as working, 
driving or eating 
30% 7% 18% 0.212 
23 Difficulty getting to sleep at 
night or staying asleep at night 
50% 37% 46% 0.692 
26 Unpleasant sensations in your 
legs at night or while resting, and a 
feeling that you need to move 
80% 44% 51% 0.131 
27 Swelling of the legs 40% 19% 32% 0.296 
29 Double vision 20% 15% 22% 0.755 
 
 
Table 5.3 (C): Non-Motor Symptoms that are More Prevalent in Patients 
with Severe Microsmia 
Non-Motor Symptom 
 
Mild/Moderate 
Microsmia 
(10) 
(10) 
Severe 
Microsmia 
(27) 
Anosmia 
(75) 
Chi 
Square  
P Value 
18 Feeling less interested in sex or 
more interested in sex 
30% 37% 32% 0.824 
30 Believing things are happening 
to you that other people say are 
not 
0% 4% 1% 0.641 
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Table 5.3 (D): Non-Motor Symptom that are More Prevalent in Patients 
with Mild/Moderate Microsmia 
Non-Motor Symptom 
 
Mild/Moderate 
Microsmia 
(10) 
Severe 
Microsmia 
(27) 
Anosmia 
(75) 
Chi 
Square 
P Value 
10 Unexplained pains (not due to 
known conditions such as arthritis) 
50% 37% 24% 0.159 
 
 
Figure 5.1 Non-Motor Symptoms that either Increase or Decrease in 
Frequency with the Degree of Loss of Sense of Smell 
 
 
 
5.5.2. PDQ39 Quality of Life Scores and Sense of Smell 
 
(i) Analysis of the Overall Scores 
 
Initial analysis of quality of life overall scores showed that most of the scores 
are particularly clustered around the 5-40 scores; with few PD patients 
scoring over 40 (see figures 5.2 and 5.3).  This may suggest that this group 
of PD patients have, on average, a reasonable quality of life.  However, 
looking at the sense of smell (UPSIT score) and its relationship with PDQ39 it 
does appear to worsen slightly alongside worsening quality of life.  Figure 5.2 
shows a negative correlation, ( =-0.120), between quality of life (as 
measured by the PDQ39 quality of life questionnaire) and sense of smell 
score which is not statistically significant, (p=0.350). 
Table 5.3 A.  
Highlights an increase in frequency of 
non-motor symptoms alongside the 
degree of loss of sense of smell 
Number of non-motor 
symptoms that either 
increase or decrease in 
frequency with the degree 
of  loss of sense of smell. 
Table 5.3. B 
Highlights a decrease in frequency 
of non-motor symptoms in 
patients with severe microsmia 
compared to those with 
mild/moderate microsmia or 
anosmia.   
Table 5.3 D 
Highlights that only one symptom 
appears to be reported least by 
patients, despite the degree of loss 
of sense of smell  being worse.   
 
Table 5.3 C 
Highlights two non-motor 
symptoms that are reported more 
by PD patients  with severe 
microsmia  compared to those 
patients with  mild/moderate 
microsmi a or anosmia 
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Figure 5.2: UPSIT scores and Patients’ Quality of Life (PDQ39) Scores. 
Most of the scores are clustered around the 5-40 scores, with few PD patients scoring over 40.  The 
trend line appears to show worsening quality of life scores alongside the degree of loss of sense of 
smell, however this was not statistically significant ( =-0.120 p=0.350). 
 
(ii) Frequency of PDQ 39 Scores 
 
Figure 5.3 shows the distribution of PDQ39 scores within this study group 
The mean score is 23.26 and SD =14.254, median 21.025 and IQ range 
19.622. 
Figure 5.3: Frequency of Patients’ Quality of Life (PDQ39) Scores. 
Distribution of PDQ39 scores within this study group is positively skewed with one outlier.  The mean 
score is 23.26 and SD =14.254, IQ range 19.622. 
 
By examining the correlation between the individual PDQ39 themes and 
UPSIT score using Pearson’s correlation it was noted all (except bodily 
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discomfort) have a weak or very weak negative correlation except cognition 
which is statistically significant ( = -0.198 p=0.036), (see table 5.4).  
 
Table 5.4: PDQ39 Themes and Correlation of UPSIT 
 
PDQ39 Themes Correlation between UPSIT and 
Theme ( ) 
P value 
(i) Activities of Daily Living -0.110 0.250 
(ii) Emotional Wellbeing -0.087 0.360 
(iii) Stigma -0.048 0.618 
(iv) Communication -0.147 0.123 
(v) Bodily Discomfort 0.033 0.730 
(vi) Mobility -0.046 0.633 
(vii) Cognition -0.198 0.036 
(viii) Social Support -0.030 0.750 
 
(iii) Sub-Group Analysis  
 
To answer the research question as to whether PD patient’s PDQ39 quality 
of life themes, are clinically distinct depending on their degree of smell loss, 
further sub-group analysis has been carried out (see tables 5.5).  Although  
initially from table 5.5 quality of life seems to worsen alongside the degree of 
smell loss in the, (i) activities of daily living, (ii) emotional well-being, (iii) 
stigma, and (iv) communication themes (highlighted in purple), which implies 
that the degree of olfactory loss may well be associated with worsening of 
these themes, on further statistical analysis, using a Kruskal Wallis test 
showed there is no statistically significant differences between the three 
sense of smell sub-groups and their quality of life themes scores.  
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Table 5.5: Sense of Smell and PDQ 39 Quality of Life Themes and Mean 
Scores in Each Sub-group 
 
PDQ39 Themes Mild/Moderate 
Microsmia. 
Mean PDQ39 
Score 
Severe 
Microsmia. 
Mean 
PDQ39 
Score 
Anosmia. 
Mean 
PDQ39 
Score 
Kruskal 
Wallis 
Test  
P value 
(i) Activities of Daily 
Living 
19.56 27.29 32.16 0.497 
(ii) Emotional 
Wellbeing 
17.47 20.51 22.64 0.741 
(iii) Stigma 11.82 13.19 13.61 0.687 
(iv) Communication 14.14 16.64 23.08 0.546 
(v) Bodily Discomfort 38.31 30.83 34.86 0.825 
(vi) Mobility 32.75 26.85 32.93 0.546 
(vii) Cognition 23.12 21.29 29.75 0.206 
(viii) Social Support 11.65 7.08 7.09 0.311 
(ix) Total score for All 
Themes 
168.82 163.68 196.12  
 Purple supports the research question that the degree of smell loss worsens 
alongside the degree of quality of life issues. 
 Red neither supports nor refutes the research question that the degree of smell 
loss worsens alongside the degree of quality of life issues. 
 Green refutes the research question that the degree of smell loss worsens 
alongside the degree of quality of life issues. 
 
Once again, if we exclude the mild/moderate sense of smell group (due to 
small sample size, n=10), all the PDQ39 themes worsen alongside the 
degree of loss of sense of smell.   
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5.6. DISCUSSION 
5.6.1. Non-Motor Symptoms Questionnaire and Sense of Smell 
 
The most frequent non-motor symptoms reported by PD patients in this study 
were a sense of urgency to pass urine (63%), getting up regularly at night to 
pass urine (61%) and constipation (54%), irrespective of their sense of smell 
status (see table 5.1).  These results are consistent with an International 
study by Martinez-Martin et al (2007) who examined 545 PD patients and 
found nocturia (61.9%), urinary urgency (55.81%)  and constipation (52.48%) 
as the top three most prevalent non-motor symptoms and Bostantjopoulou et 
al (2013),  who enrolled one hundred sixty six PD patients and sixty six 
matched controls and also found that in the PD patients urinary urgency 
(54.3%), nocturia (51.8%) and constipation (45.7%) were the top three non-
motor symptoms. Similarly, nocturia and urinary urgency were the most 
frequent non-motor symptoms reported by Gallagher et al (2010).  
 
However, these findings were not mirrored in other studies, for example; 
Barone et al (2009) who performed a multicentre survey using a semi-
structured interview in 1,072 consecutive patients with PD found the most 
frequent non-motor symptoms were fatigue (58%), anxiety (56%) and leg 
pain (38%) and in the study of Cheon et al (2008) who evaluated 74 
parkinsonian patients and 54 family members. the most frequent non-motor 
symptoms were getting up regularly at night to pass urine (nocturia) in men 
and feeling sad, low or blue in women, followed by restless legs and 
constipation.  
 
Although the three most frequent non-motor symptoms highlighted in this 
study can be troublesome to the PD patient, and indeed are, the non-motor 
symptoms that appear to have a major impact on quality of life to the patients 
themselves, noted through many years of clinical observation in the clinical 
area of work, are feeling anxious, frightened or panicky (36%) and falling 
(27%) which are less prevalent in this study group than those reported by 
others (see table 5.1).  However, it is worth noting that all the above studies, 
including this PhD study did not look at PD patients with advanced disease 
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and therefore, in this subset of PD patients, non-motor symptoms may play 
an even greater role and may be more prevalent.  
   
Therefore, it is important to note that; (i) the most frequent symptoms 
experienced by PD patients are not necessarily the most significant 
symptoms that affect their quality of life (ii) the effect of these symptoms is 
very individual to each patient (one symptom not considered troublesome to 
one patient could be significantly troublesome to another) and (iii) the most 
frequently cited problems in this study may have other causes rather than 
PD.  For example, a sense of urgency to pass urine (63%) and getting up 
regularly at night to pass urine (61%) could well be associated with prostate 
problems in men, such as benign prostatic hyperplasia (BPH), which is a 
common progressive clinical disease of ageing men (Shrivastava and Gupta 
2012).  Indeed, a multicenter study showed 34% of men in the USA and 29% 
of European men aged 50–80 years had BPH (Nordling 2005).  Equally, an 
overactive bladder is another common cause of frequent urination affecting 
an estimated 50 to 100 million people worldwide (Miller and Sand 2005).  The 
prevalence of an overactive bladder is known to increase with age and is a 
major problem particularly for women (Robinson and Cardoz 2002).  
Epidemiological studies have implicated oestrogen deficiency in the aetiology 
of lower urinary tract symptoms, although the role of oestrogen replacement 
therapy remains controversial (Robinson and Cardoz 2002). 
 
Also, table 5.1 highlights the loss (or change) in ability to smell or taste was 
only reported by 33% of the study group.  This further supports that self-
reporting of smell dysfunction is regarded as too unreliable (Muller et al 2002, 
Doty et al 1988, Doty et al 1992, Hawkes and Doty 2009) as 100% of PD 
patients recruited for this study have varying degrees of smell loss.  This also 
contradicts the work of Hawkes and Doty (2009) who commented that those 
who are unaware of their olfactory dysfunction, probably have mild 
impairment, as in this study over 90% of the PD patients have either anosmia 
or severe microsmia (see figure 3.4). 
Regarding unexplained pains, there appears to be a significant amount of 
research on pain in PD, looking at a broad range of pain such as burning, 
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tingling, dystonic pain and central pain, although underlying mechanisms are 
not yet fully understood (for a comprehensive review of the literature see Fil 
et al 2013).  However, for the first-time Hara et al (2013) examined the link 
between impaired pain processing and its association with the sense of 
smell.  They examined forty-two patients (18 males and 24 females) with PD 
and 17 healthy control subjects (8 males and 9 females).  A thin needle 
electrode was used to stimulate epidermal Aδ fibers, and somatosensory 
evoked potentials (SEPs) recorded at the vertex.  Olfactory function was 
evaluated using the Odour Stick Identification Test.  They concluded that 
pain processing in PD patients was impaired under specific nociceptive 
stimulation of Aδ fibers and significant correlation with smell dysfunction was 
detected and suggest that this mechanism may involve the limbic system 
during PD pathology.  This present PhD study highlights that 29% of PD 
patients experience unexplained pains of which 50% of those patients had –
infact- mild to moderate microsmia, which does not support Hara et al (2013) 
findings. The conclusion therefore is that this PhD study neither confirms nor 
refutes Hara et al (2013) findings; this is mainly because this study was not 
designed specifically to test the link between sense of smell and pain.  
However, this warrants further analysis.  
 
With regards to falling, around 70% of people with PD who fall do so 
recurrently.  Recurrent fallers reported 4.7 to 67.6 falls per year confirming 
that recurrent falling is a substantial problem for PD patients (Allen et al 
2013).   
In this PhD study 27% of the PD patients had fallen (see table 5.1), although 
the researcher did not examine the frequency of falls.  The link between falls 
and olfactory dysfunction however has not been studied in PD, although, 
Sakamoto et al (2012) did find that the odour lavender reduced the risk of 
falls in elderly nursing home residents.  However, it is beyond the scope of 
this study to analyse this in depth and give justification for this finding.   
Although this PhD study does highlight those patients who did fall, it neither 
supports nor refutes the research question that the degree of smell loss 
worsens alongside falling (see table 5.2 B). 
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When analysing the link between degree of smell loss with individual non-
motor symptoms, table 5.3(A) highlights an increase in the reported 
frequency of non-motor symptoms alongside the degree of smell loss.  This 
is in support of the research hypothesis.  Furthermore, with exception of the 
mild/moderate sense of smell group, (which only has a small number of the 
overall sample size), table 5.3 (B) also shows an increase in frequency of 
non-motor symptoms alongside the degree of smell loss.  Meanwhile table 
5.3 (C) highlights only two symptoms which are more prevalent in those 
patients with severe microsmia than those with mild to moderate microsmia 
or anosmia.  Finally, Table 5.3 (D) highlights that only one symptom appears 
to be reported least by patients, despite the degree of olfactory deficit being 
worse, and this is unexplained pains.  Interestingly, if we exclude the 
mild/moderate sense of smell group (due to small sample size, n=10), 27 out 
of the 30 non-motor symptoms are more prevalent in patients with anosmia.  
Nonetheless, when conducting a chi-square test of independence to examine 
the relation between the degrees of smell loss and individual non-motor 
symptom, the only symptom to reach statistical significance is dribbling of 
saliva during the day (p=0.003). 
 
Due to the lack of a standard definition and criteria for diagnosing dribbling in 
PD patients, estimates of prevalence vary.  Previous studies showed that 
prevalence ranged from 84% (Ozdilek et al 2012) to 10% (Nicaretta et al 
2008).  This study’s prevalence rate is 44% (see table 5.1), which is sitting 
between the high and the low prevalence rates quoted by others.  
 
Factors possibly associated with dribbling of saliva in other studies were; (i) 
Severity of PD; For example, Rana et al (2012) conducted a retrospective 
chart analysis on 314 PD patients from six ethnic categories and concluded 
that PD patients at Hoehn and Yahr stage 4 were the most at risk.  This is not 
surprising as these patients have severely disabling PD (see appendix 10) 
and dribbling is often seen in patients at this stage in clinical practice. (ii) 
Male gender (Rana et al 2013, Cheon et al 2008, Scott et al 2000).  Indeed, 
Rana et al (2013) states males are twice more  likely to have dribbling of 
saliva than females, and highlights in his study that there is a clinically 
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significant link in males between the prevalence of drooling and dementia. 
(iii)  Ageing; For example, Kalf et al (2007) examined 63 PD patient’s 
questionnaires relating specifically to drooling and found mild and severe 
dribbling of saliva in patients differed signiﬁcantly in age (p = 0.03), the 
severe dribbling of saliva patients being on average 5.8 years older.  
Although this is not mirrored in all research with Rana et al (2012) finding no 
correlation between age and dribbling of saliva and (iv) Disease duration of 
PD (Rana et al 2012).  Although this is not mirrored in other research (Kalf et 
al 2007).  
 
Several factors may cause or increase dribbling of saliva in PD.  Mounting 
evidence suggests that hypersalivation is unlikely to induce dribbling of saliva 
(Proulx et al 2005).  In fact, the researcher recognises and observes this in 
clinical practice and it is more likely to result from pooling of saliva in the 
mouth, due to decreased frequency of swallowing and antecollis in PD 
patients (Pehlivan et al 1996). 
 
Although not previously considered, there may be a link between facial 
expression, dribbling of saliva and sense of smell (facial expression was 
statistically significant when examining the UPDRS 14 motor scores 
(p=0.029) (see figures 4.3 section 4.3.1).  The reason for this is that the 
muscles of the face in PD patients become more rigid and less animated 
(masklike facies) and the key to these movements is dopamine.  Therefore, 
there may be a direct link between dribbling, sniff vigour and reduced sense 
of smell as the muscles of the face are required and therefore the link can be 
proposed.  However, this study is not designed to test this hypothesis further. 
 
Regarding dribbling of saliva and posture, there may also be a link with loss 
of sense of smell (posture was significantly associated with sense of smell 
loss and UPDRS 14 motor scores (p=0.014) (see figures 4.6 section 4.3.1), 
because PD patients do not have the ability to use the muscles in the face 
adequately, (masklike facies), and therefore have poor lip seal.  
Consequently, if the patient is stooped forward this will cause dribbling and 
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therefore may have been a contributing factor.  Once again, this study was 
not designed to examine this hypothesis further.  
 
5.6.2. PDQ39 Quality of Life Scores and Sense of Smell 
 
The results of this present study showed a non-significant negative 
correlation between quality of life (as measured by the PDQ39 questionnaire) 
and UPSIT sense of smell scores.   Summary scores as well as the themes 
of the PDQ-39 were calculated according to the scoring algorithm (Jenkinson 
et al 1998) (see Appendix 9 and section 2.4.3) and sense of smell score 
(UPSIT)  =-0.120 (see figure 5.2).  When examining other research 
regarding quality of life and sense of smell this appears to be poorly explored 
in PD and this PhD study appears to be the first study to examine this.  
 
Examining the link between PDQ39 themes and sense of smell in the whole 
group, using Pearson’s correlation revealed all, (except bodily discomfort), 
have  weak or very weak non-significant negative correlations except 
cognition which is statistically significant ( = -0.198 p=0.036).  Interestingly, 
Doty et al (1989) tested 58 Parkinson's disease patients using UPSIT and 
modified Randt memory test and concluded that the olfactory disorder of 
parkinsonism is independent of the cognitive manifestations of the disease.  
However, this disagrees with section 3.6.6. (Cognitive Function and Sense of 
Smell) which used a spearman correlation on all MoCA and UPSIT scores of 
whole group which showed a positive correlation between cognition and 
UPSIT ( =0.213), which is statistically significant (p=0.024), (see figure 3.17 
section 3.6.6).  This supports the findings of Postuma and Gagnon (2010), 
Bohnen et al (2010) and Schrag et al (2000) who all found a positive 
correlation between odour identification scores and verbal memory in 
patients with PD who have olfactory loss (see section 1.2.6).  Indeed, Schrag 
et al (2000) conducted a population-based study on quality of life on 92 PD 
patients from 15 GP practices in London and found that cognition has in fact 
one of the greatest influences on quality of life in Parkinson’s disease.  
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A sub-group analysis of PD patients (using (i) mild/moderate microsmia, (ii) 
severe microsmia or (iii) anosmia categorisations) showed that quality of life 
seems to worsen alongside the degree of smell loss in the (i) activities of 
daily living, (ii) emotional well-being, (iii) stigma and (iv) communication 
themes (highlighted in purple). (Table 5.4) and therefore implies that the 
degree of olfactory loss may well be associated with these themes.  
 
However, further statistical analysis, using Kruskal Wallis test, highlights 
there is no statistically significant difference between all the quality of life 
themes and sense of smell in each sub-group.  It is important to note that the 
overall total scores are higher overall in the anosmia group and  lower in the 
severe group (see table 5.5).  This might be due to a sample size effect due 
to the small number of PD patients within the severe microsmia sub-group 
(27 PD patients in severe microsmia group compared to 75 patients in 
anosmia group). 
 
5.7. SUMMARY 
 
 The most frequent non-motor symptoms reported were a sense of 
urgency to pass urine (63%), getting up regularly at night to pass urine 
(61%) and constipation (54%). 
 The loss or change in ability to smell was only reported by 33% of the 
study group.   
 When examining the relation between the degrees of smell loss and 
individual non-motor symptoms, the only symptom to reach statistical 
significance is dribbling of saliva during the day (p=0.003). 
 A non-significant negative correlation between quality of life (as 
measured by the PDQ39 questionnaire) and loss of sense of smell 
was found in this study, suggesting quality of life does not correlate 
with the degree of sense of smell loss. This appears to be the first 
study to examine this. 
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CHAPTER 6 
 
ADDITIONAL CONFOUNDING FACTORS AFFECTING THE SENSE OF 
SMELL IN PD PATIENTS 
 
 
6.1. OVERVIEW 
 
Several confounding factors have been reported to affect the sense of smell 
in patients with PD.  Deliberations are particularly noted around the effects of 
medication, sniff vigour, environmental settings and handedness.  This 
chapter will address whether medication, sniff vigour, environment and 
handedness may affect the sense of smell in PD patients in this study. 
 
6.1.1. Anti-Parkinsonian Medication and Sense of Smell 
 
Several studies have explored whether Parkinson’s disease medications 
have any effect on the sense of smell (Doty et al 1992, Quinn et al 1987, 
Ward et al 1983, Ansari and Johnson 1975), including the potent dopamine 
agonist Apomorphine (Roth et al 1998).  Conclusions from these studies 
reported that olfactory function remains unaffected by anti-parkinsonian 
medication.  One of the aims of this chapter is to establish whether any PD 
medications worsen or improve PD patients’ ability of sense of smell in this 
study group.   
 
6.1.2. Sniff Vigour and Sense of Smell 
 
Sobel et al (2001) reported that suboptimal sniffing may contribute to the loss 
of sense of smell seen in PD.  This might be linked to fatigue.  Practically, 
this is said to equate to a mean reduction of around two to three points on the 
40-odour University of Pennsylvania smell Identification (UPSIT-40) test 
(Doty et al 1984).  To test this, each of the four booklets was examined 
regarding overall scores.  The theory is that if sniff vigour fatigues, like other 
motor symptoms of PD, then we would expect the scores on each 
146 
 
subsequent smell test booklet to worsen.  Patients were not encouraged to 
increase sniff vigour during the examination as this can improve scores 
(Sobel et al 2001). 
 
6.1.3. Environmental Setting and Sense of Smell 
 
The setting (environment) in which data is collected is one of the most 
important factors in conducting  research.  Bloor et al (2001) comment that 
the venue is important and should, ideally, be accessible, comfortable, 
private, quiet and free from distractions.  However, while a central location, 
such as clinical setting within a Trust might be ideal for some patients, other 
patients may be affected by any anxieties that affect them when they attend 
in a patient role and therefore, would much prefer their home environment 
(Bloor et al 2001).  For this reason, patients were offered the choice of 
attending a research room at a local Trust or to have their assessments 
completed at home.  This was firstly to establish whether this may have a 
direct effect on odour detection scores (UPSIT 40) and, secondly to ensure 
the researcher could capture enough PD patients to complete this study.  
Ultimately, the aim is to compare results in the two environments to establish 
whether this may have a direct effect on sense of smell (UPSIT 40).  This 
appears to have not been studied before in PD patients. 
 
6.1.4. Handedness and Sense of Smell 
 
Handedness may be a confounding factor affecting the sense of smell 
(Gottschlich and Hummel 2015).  This present PhD study re-investigates this 
subject as; (i) handedness is also said to play a large part in memory 
(Prichard et al 2013) and (ii) the memory part of the brain shares parts with 
the olfactory part of the brain, resulting in a connection between memory and 
olfactory sense (Witze 2006).  Investigating handedness, research showed 
that each hand is controlled by opposite hemispheres, so the left hand is 
controlled by the right hemisphere and the right hand by the left (Annett 
2006).  Handedness also determines which hemisphere of the person will be 
dominant.  Although over simplified right-handed people have dominant left 
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brains, so they can encode memories easier; the left brain enforces 
encoding.  Left-handed people have dominant right brains, so they can 
retrieve memories better because retrieval is enforced by the right brain.  
Ambidextrous people tend to have the best memory, because both sides of 
their brain are strong, and therefore they can retrieve and encode well 
(Propper et al 2005, Annett, 1970), followed by PD patients who are left-
handed (Annett 1970).  
 
 
6.2 AIM 
 
To investigate whether PD medications, sniff vigour, handedness and 
environment affect the sense of smell in patients with PD in this PhD study. 
 
 
6.3 OBJECTIVES  
(i) To confirm or refute whether different classes of PD medication and the 
timing of medication has an impact on the sense of smell. 
(ii) To establish whether sniff vigour fatigues during the UPSIT 40 smell test 
which may contribute to lower UPSIT scores seen in patients with PD in this 
study group. 
(iii) To establish whether the environment (in which the smell test was 
conducted) has an impact on sense of smell. 
(iv) To establish whether handedness has an impact on sense of smell. 
 
 
6.4. OUTLINE OF METHODS 
 
 
(i) Prescribing practice of the anti-parkinsonian medication was assessed by 
looking at the type of medication, duration of disease and timing of 
medication and whether there is a correlation with UPSIT scores. 
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(ii) Sniff vigour was analysed by comparing the four 40 UPSIT smell test 
booklets to see if there is a significant reduction in the number of correct 
answers as the PD patient goes through each smell booklet.  This is to 
establish if there is fatigability of sniff vigour. 
 
(iii) The effects of the environment in which the PD patient was tested (either 
in the patient’s own home or in hospital to test the sense of smell) was 
analysed to see if this affects mean UPSIT scores.   
 
(iv) Handedness was captured on the Odour Detection in Parkinson’s 
Disease Participants Questionnaire (see Appendix 14) and analysed to see if 
this might have influenced a PD patient’s ability to smell. 
 
 
6.5. RESULTS 
 
6.5.1. Type of Anti-Parkinsonian Medication and Sense of Smell 
 
Table 6.1 shows that the most prescribed medication is levodopa (87.5%).  
The UPSIT range is similar in each group.  The mean UPSIT is higher in 
those patients not taking a particular anti-parkinsonian medication compared 
to those that are except dopamine agonists. This shows PD patients either 
taking or not taking dopamine agonists both have a mean UPSIT score of 17.  
UPSIT median remains comparable with the mean by one-mark lower except 
in patients not taking a COMT inhibitor in which sense of smell score is two 
marks lower.  Standard deviation is spread more in PD patients not taking 
medication in all anti-parkinsonian medications.  None of the medications 
with regards to the sense of smell reached statistical significance between 
those taking certain anti-parkinsonian medication and those not taking it. 
(Table 6.1). 
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Table 6.1: Anti-Parkinsonian Medication and Sense of Smell in PD 
Patients.  
Variable Medication Percentage UPSIT 
Range 
UPSIT 
Mean 
UPSIT 
Median 
Standard 
deviation 
P 
value 
Patients either 
taking or not 
taking medication 
(N=112) 
Yes= 107 
No= 5 
95.5 
4 
6-31 
7-28 
17 
18 
17 
18 
5.494 
7.918 
0.334 
Levodopa 
 
Yes =98 
No=14 
87.5 
12.5, 
6-31 
7-28 
17 
19 
16 
18 
5.450 
6.359 
0.279 
COMT Inhibitor 
 
Yes=31 
No=81 
28 
72 
7-27 
6-31 
16 
18 
15 
16 
4.633 
5.867 
0.315 
Dopamine Agonist 
 
Yes=55 
No=57 
49 
51 
7-27 
6-31 
17 
17 
16 
16 
5.334 
5.851 
0.750 
MAO-B Inhibitor 
 
Yes=8 
No=104 
7 
93 
6-31 
10-27 
17 
19 
18 
18 
4.794 
5.739 
0.875 
The table shows name of anti-parkinsonian medication taken, number of Individual patients taking It, 
the overall percentage and UPSIT range, mean and median, standard deviation and P value. 
 
6.5.2. Duration of Disease 
 
PD disease duration (as a reflection of duration of taking PD medication) may 
be a confounding factor alongside the type of anti-parkinsonian medication 
taken.  Table 6.2 analyses this possibility.  Initial analysis of table 6.2 
suggests that disease duration combined with the use of anti-parkinsonian 
medication might affect olfaction as UPSIT scores are lower in patients taking 
medication than those who are not (except dopamine agonists) and are lower 
in patients with a longer duration of PD.  However, correlation between 
duration of disease and UPSIT showed a very weak negative correlation (
=-0.04344, n=112), which did not reach statistical significance (p=0.535). 
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Table 6.2: Anti-Parkinsonian Medication Taken and Number of 
Individual Patients taking it, Mean Duration of Disease and Standard 
Deviation. 
Variable Mean Duration of disease 
on medication 
Standard Deviation  
Patients either taking or not 
taking medication 
Yes = 107 
No = 5 
 
 
6 
1 
 
 
3.850 
0.593 
Levodopa 
Yes = 98 
No = 14 
 
6 
3 
 
3.929 
2.450 
COMT Inhibitor 
Yes = 31 
No = 81 
 
9 
4 
 
3.922 
3.152 
Dopamine Agonist 
Yes = 55 
No =57 
 
7 
4 
 
3.580 
3.777 
MAO-B Inhibitor 
Yes = 8 
No = 104 
 
6 
5  
 
2.386 
3.974 
 
6.5.3. Timing of Medication 
 
The degree of sense of smell loss may also be affected by the timing of the 
medication.  Figure 6.1 displays minutes since last PD medication taken and 
UPSIT scores.  Initial analysis of figure 6.1 highlights that most medication 
was taken between 60 to 120 minutes before testing a patient’s sense of 
smell.  Correlation between timing of the doses and UPSIT showed a weak 
negative correlation ( =-0.247) between the two which is statistically 
significant (p=0.010). (N=107). 
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Figure 6.1: UPSIT Scores and Minutes Since Last PD Medication Taken. 
Correlation between timing of the doses and UPSIT showed a weak negative correlation ( =-0.247) 
between the two which is statistically significant (p=0.010), (n=107). 
 
 
 
6.5.4. Levodopa vs Non-Levodopa Treatment 
 
As levodopa is the most prescribed medication in this study, dividing the 
study group into (i) patients taking levodopa and (ii) patients not on levodopa 
will now be analysed.  
 
Figure 6.2 illustrates ninety-eight patients’ UPSIT scores taking levodopa and 
minutes since last levodopa dose taken.  Correlation between timing of 
levodopa dose and UPSIT score showed a weak negative correlation 
between the two ( =-0.1875) which is statistically significant (p=0.015) 
(n=98). 
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Figure 6.2: UPSIT Scores of Patients on Levodopa and Minutes Since it was 
Last Taken. Correlation between timing of levodopa dose and UPSIT score showed a weak 
negative correlation between the two ( =-0.1875) which is statistically significant (p=0.015) (n=98). 
 
Further analysis of patients on a dopamine agonist and/or a MAO-B inhibitor 
(9 patients) appears to suggest that patients’ UPSIT scores worsen alongside 
the time since taking PD medication.  However, correlation between minutes 
since last PD medication taken and UPSIT was not statistically significant (
=-0.462 n=9, p=0.461).  
 
Figure 6.3: UPSIT Scores on Patients on a Dopamine Agonist and/or a MAO-
B inhibitor without Levodopa and Last Time Medication was Taken, Correlation 
between minutes since last PD medication taken and UPSIT using one-way anova was not statistically 
significant ( =-0.462, n=9, p=0.461).  
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6.5.5. Sniff Vigour and Sense of Smell  
 
Figure 6.4 divides patients smell (UPSIT) scores according to the total scores 
for each booklet to establish whether PD patients’ sniff vigour fatigues during 
the UPSIT 40 smell test (the overall total score for each booklet is 1,120).  
Each booklet has 10 different odours and is assessed continually until 40 
odours are sniffed.  Initial analysis suggests sniff vigour does not fatigue 
during the 40 UPSIT smell test.  On further statistical analysis using one-way 
ANOVA there was no statistically significant difference between each book (p 
=0.212). 
 
 
Figure 6.4: UPSIT Scores and Total Scores for Each Booklet.  (Booklet one=498 
points, booklet two=490 points, booklet three=444 points and booklet four=479 points). (N=112). 
On further analysis, there was no statistical significance between each book (p =0.212). 
 
This is further analysed by dividing patients into (i) anosmia, (ii) severe 
microsmia or (iii) mild to moderate microsmia (see figures 6.5-6.7).  Figures 
6.5 (PD patients with anosmia) and figure 6.7 (PD patients with mild to 
moderate microsmia) give the impression that sniff vigour does not worsen.  
On further statistical analysis this was confirmed using one-way ANOVA. 
(anosmic booklets p=0.693, mild to moderate microsmia booklet P=0.866).   
However, figure 6.6 (PD patients with severe microsmia) do have mild 
worsening of their sniff vigour, (as shown by the reduction in their sense of 
smell UPSIT scores).  However, on further statistical analysis using one-way 
ANOVA this again did not reach statistical significance (p= 0.546).  
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Figure 6.5: Total UPSIT Scores on Patients with Anosmia. (N= 75). 
 On further analysis, there was no statistical significance between each book (p =0.693). 
 
 
 
Figure 6.6: Total UPSIT Scores on Patients with Severe Microsmia (N= 27). 
On further analysis, there was no statistical significance between each book (p =0.546). 
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Figure 6.7: Total UPSIT Scores on Patients with Mild to Moderate Microsmia. 
(N=10). On further analysis, there was no statistical significance between each book (p =0.866). 
 
6.5.6. Environmental Setting and Sense of Smell 
 
Sixty patients (54%) were tested in clinic and 52 patients (46%) were tested 
at home.  Figure 6.8 shows that the median is slightly higher in patients 
tested in clinic (17) compared to those tested at home (16).  A Mann-Whitney 
U test was performed to provide further statistical analysis on the effects of 
the environment on the sense of smell; however, this did not reach statistical 
significance (p=0.746). 
 
Figure 6.8: UPSIT Scores and Environment in Which Patients Were Tested. 
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Whether these two groups differ in gender or age, which may affect the 
sense of smell, is further analysed in table 6.3.  Table 6.3 highlights that 
mean and median UPSIT is lower in patients tested at home.  The mean age 
is comparable.  However, gender differences are more marked in patients 
tested in clinic, with fewer women being tested.  This is not surprising as 
more men are recruited to this study. 
 
Table 6.3: Environment, UPSIT Mean, Median and Range, Mean Age, 
Gender and Mean UPSIT and Age of Each Gender. 
Environment UPSIT 
(Mean) 
UPSIT 
(Median)  
UPSIT 
(Range) 
Age  
(Mean) 
Gender  UPSIT 
(Mean) 
Age 
(Mean) 
 
Clinic 
(60 patients) 
+/- SD= 
17 
 
5.430 
17 6-27 70 Female=15  
Male=45  
19 
16 
70 
72 
Home  
(52 Patients) 
+/- SD= 
15 
 
5.781 
16 8-31 71 Female=25 
Male=27  
19 
16 
69 
71 
 
 
 
6.5.7. Handedness and Sense of Smell 
 
Figure 6.9 shows the number of patients either being (i) ambidextrous, (ii) left 
handed or (iii) right handed and total number in each group.  Most PD 
patients in this study are right handed and account for 84% of the whole 
study group. 
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Figure 6.9: Number of Patients Reporting Either being Ambidextrous, Left or 
Right Handed. 
 
To establish whether the handedness of a patient influences their olfactory 
loss, both figure 6.10 and table 6.6 show the mean, median and range of 
UPSIT scores for each group.  As shown in figure 6.10 and table 6.6 the 
range and median of patients who are right or left handed are similar.  
However, those PD patients who are ambidextrous have a much higher 
median and mean score although this result needs to be interpreted with 
caution due to the small sample size of ambidextrous patients (only 5) in this 
study. 
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Figure 6.10: UPSIT Scores and Handedness on All Patients Recruited to 
This Study. 
 
Table 6.4: Handedness, Number of Patients in Each Group, Range Mean 
and Median of UPSIT Scores. 
Handedness Number of 
Patients 
UPSIT 
(Range) 
UPSIT  
(Mean) 
UPSIT 
(Median)  
Ambidextrous 5 12-27 21 23 
Left 13 7-28 17 15 
Right 94 6-31 17 16 
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6.6 DISCUSSION 
 
6.6.1. Medication and Sense of Smell 
Type of Medication 
 
The most important class of medication, which may influence the sense of 
smell, could be levodopa.  This is because levodopa is a precursor of 
dopamine (the neurotransmitter significantly reduced in PD) and remains the 
most effective drug for treating PD for 5 decades (LeWitt and and Fahn 2016, 
Tomlinson et al 2010, Katzenschlager and Lees 2002).  
 
Table 6.1 shows that Levodopa is the most prescribed medication in this 
study group (n=98, 87.5%).  This is mirrored when examining olfaction and 
medication in PD research in general (Rosser et al 2008, Doty et al 1992, 
Quinn et al 1987, Ward et al 1983, Ansari and Johnson 1975), unless the 
study is specifically designed to look at another class of drug, such as the 
potent dopamine agonist Apomorphine (Roth et al 1998).  The next class of 
drug prescribed is dopamine agonists (n=55, 49%), followed by COMT 
inhibitors (n=31, 28%) then MAO-B inhibitors (n=8, 7%). 
 
From table 6.1 the mean and median UPSIT is similar in all patients taking 
levodopa, COMT Inhibitor, dopamine agonist and MAO-B inhibitors.  This 
might suggest that anti-parkinsonian medication does not improve olfaction. 
This has been frequently found in other studies (Rosser et al 2008, Huisman 
et al 2004, Hsia et al 1999, Koster et al 1999, Duchamp-Viret 1997, Wilson 
and Sullivan 1995, Doty et al 1992).  The rationale for this can be found in 
section 1.2.5. as dopamine is known to inhibit olfactory transmission in the 
olfactory bulb (Huisman et al 2004).  Indeed, correlation showed that 
regardless of the class of drug and whether (or not) PD patients were taking 
that class of drug; none reached statistical significance (see figure 6.1).  
This PhD study therefore supports previous research that PD medication 
does not improve olfaction.  This has been confirmed by others in both 
clinical practice and in the research laboratory.  For example, Rosser et al 
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(2008) tested olfaction in 19 older patients without a diagnosis of PD before 
and after administration of levodopa in a double-blind, placebo-controlled, 
randomized cross-over study.  They concluded that in contrast to what had 
been demonstrated in rats, levodopa did not improve olfaction, with even a 
trend for the reverse.  It is also important to acknowledge from Rosser et al 
(2008) study that the results of animal studies cannot be directly transferrable 
to the human situation.  Also, Ward et al (1983) in a comparison study of PD 
patients with closely matched controls found patients with PD had not only 
reduced scores in odour detection but olfactory impairment was not related to 
treatment.  Furthermore, Quinn et al (1987) examined 78 patients with PD 
and 40 age-matched controls also highlighted there was no significant 
correlation between olfactory threshold and current therapy with levodopa or 
anti-cholinergic drugs.  At a molecular level, both Huisman et al (2004) and 
Hsia et al (1999), noted that PD patients have a marked increase in 
dopaminergic neurons (which inhibit olfaction) in the olfactory bulbs which 
makes it understandable why olfaction is not improved in PD patients treated 
with L-dopa (see figure 1.3 section 1.2.5).  Therefore, loss of sense of smell 
may involve mechanisms that are not influenced by pharmacological 
manipulation of dopaminergic or cholinergic status. 
 
6.6.2. Disease Duration, Medication and Sense of Smell 
 
The duration of disease is similar in each group (see table 4.2), and disease 
duration is not a significant predictor of the degree of smell loss in this study.  
This has been shown by others (Hakymenze et al 2013, Haehner et al 2009, 
Hawkes et al 1997, Doty et al 1988, Quinn et al 1987, Ward et al 1983).  
However, this is not universal with other studies reporting disease duration is 
a predictor of the degree of smell loss (Cavaco et al 2015, Deeb et al 2010). 
 
When examining disease duration combined with the use of anti-
parkinsonian medication, UPSIT scores are lower in patients taking 
medication than those who are not, (except dopamine agonists) and is lower 
in patients with a longer duration of PD (see table 6.2).  However, 
interestingly patients who are on no medication had significantly higher 
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UPSIT score (UPSIT 22); the rationale for this is unclear but could be due to 
a sample size effect as only 5 patients out of the 112 were on no medication.  
This warrants future research to establish whether UPSIT scores worsen as 
the disease progresses in individual patients. 
 
However, correlation between duration of disease and UPSIT ( =-0.04344, 
n=112), did not reach statistical significance (p=0.535).  This is in support of 
previous research (Haehner et al 2009, Hawkes et al 1997, Doty et al 1988, 
Quinn et al 1987, Ward et al 1983).  
 
Nevertheless, these data must be viewed with caution as almost all patients 
will eventually end up on levodopa (plus or minus a COMT inhibitor).           
Therefore, the reason for a difference in mean duration of disease can simply 
be attributed to prescribing practice.  For example, levodopa traditionally has 
been prescribed later in the disease progression to avoid long-term side 
effects, such as levodopa induced dyskinesia.   
 
6.6.3 Timing of Medication and Sense of Smell 
 
Initial analysis of the degree of loss of sense of smell and the minutes since 
last or no PD medication taken suggests that UPSIT scores worsen 
alongside the increase in minutes since last or no PD medications taken (see 
figure 6.1).  Further analysis shows the correlation between minutes since 
last PD medication taken and UPSIT scores ( =-0.2634, n=112, p= 0.008) 
was significant at the 0.01 level (2-tailed).  
 
As levodopa is the most prescribed medication in this study figure 6.2 
illustrates that the UPSIT score of the ninety-eight patients taking levodopa is 
also worsening.  Further analysis shows the correlation between timing of 
levodopa dose and UPSIT scores ( =-0.1875, n=112, p= .015) again was 
significant at the 0.05 level (2-tailed).  Therefore, UPSIT scores worsen 
alongside the minutes since PD medication taken.  Whether this is due to the 
wearing off effect of the medication (when dopamine levels are reducing) as 
levodopa tends to be given every 240 minutes and takes approximately 45 
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minutes to be absorbed (when dopamine levels are at their peak) suggesting 
that PD medications might improve sense of smell.  This is beyond this 
present study to investigate further but warrants further analysis.  However, 
as dopamine is known to inhibit olfactory transmission in the olfactory bulb, 
(Hsia et al 1999, Koster et al 1999, Duchamp-Viret 1997, Wilson and Sullivan 
1995, Doty et al 1992) it would not be unreasonable to suspect that levodopa 
would worsen sense of smell loss.  Therefore, this PhD study does not 
support this finding. 
 
Finally, further analysis of patients on a dopamine agonist and/or a MAO-B 
inhibitor suggests that patients UPSIT scores worsen alongside the time 
since taking PD medication (figure 6.3).  However, correlation between 
minutes since last PD medication taken and UPSIT was not statistically 
significant at the 0.05 level (2-tailed) ( =-0.462 n=9, p= 0.211).  This may be 
a sample size effect as only 8% (9 patients) of patients in our study are on a 
dopamine agonist with or without a MAO-B inhibitor.  
 
6.6.4 Sniff Vigour and Sense of Smell 
 
This study suggests sniff vigour does not fatigue during the 40 UPSIT smell 
test (see figure 6.4).  Further analysis by dividing patients into (i) mild to 
moderate microsmia, (ii) severe microsmia or (iii) anosmia found initially that 
PD patients with severe microsmia have worsening UPSIT scores and 
therefore possible sniff vigour on booklet 3 but then improves on booklet 4 
(see figure 6.6).  It however, must be considered that the UPSIT scores on 
each booklet may well be influenced by the familiarity of smells presented in 
each booklet (see appendix 23).  Therefore, both (whole group and sub-
group) analysis showed that sniff vigour does not fatigue which was 
supported on further statistical analysis.  Therefore, this PhD study findings 
did not support Sobel et al (2001) research which suggests that suboptimal 
sniffing may contribute to the olfactory problems seen in PD. However, Sobel 
et al (2001) does state that sniff impairment is not the sole cause of the 
olfactory impairment in PD and increasing sniff volume only helped the worst 
of the performers and did not bring them to normal performance.  
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Interestingly, in our study olfactory function was significantly correlated with a 
subset of measures on the Unified Parkinson’s Disease Rating Scale 
(UPDRS) related to axial function, such as gait and postural instability, (see 
appendix 22), prompting speculation that impaired sniffing may be another 
motor symptom of PD.  However, the study was not designed to test this 
hypothesis, but it warrants further analysis.  
 
6.6.5. Environmental Setting and Sense of Smell 
 
The results of this PhD study suggest that the environment in which the smell 
test is conducted does not affect the sense of smell (see figure 6.8). 
 
When taking into consideration the difference in gender or age, which may 
affect the sense of smell, it appears mean UPSIT difference is insignificant in 
patients tested at home (see table 6.3).  The mean age is comparable, 
between the two groups.  However, gender differences are more marked in 
patients tested in clinic, with fewer women being tested.  This is not 
surprising as more men are recruited to our study.  However, mean gender 
UPSIT is consistently higher in females and may reflect the lower mean age 
of women tested in both clinic and at home or due to the ability of women 
understood to have a greater sense of smell (Lundstrom et al 2006, Dalton et 
al 2002, Brand and Millot 2001, Liu et al 1995, Cain 1982).  
 
6.6.6. Handedness and Sense of Smell 
 
Handedness is defined as the preferred hand used for a motor activity 
(manual preference) or the hand most skillful at performing a task (manual 
proficiency) (Henninger, 1992).  Approximately 90-95% of the population is 
right-handed (dextral) (Annett, 1970).  The remainder are left-handed 
(sinistral) or ambidextrous. Most PD patients in this PhD study are right 
handed and account for 84% of the whole study group (see figure 6.9).  
To establish whether the handedness of a patient influences their olfactory 
loss, figure 6.10 and table 6.6 show the range and the median of patients 
(who are right or left handed) are similar.  This supports Lubke et al (2012) 
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research who suggested that left or right handedness does not seem to play 
a substantial role in the processing of olfactory information (by using 
functional MRI to assess olfactory activation whilst sniffing the rose-like odour 
phenyl ethyl alcohol and the smell of rotten eggs).  
 
However, those PD patients who are ambidextrous have  much higher 
median and mean UPSIT scores.  This suggests PD patients who are 
ambidextrous may have a more preserved sense of smell although; this 
might be due to a sample size effect as only 5 patients were ambidextrous in 
our study.  There appears to be no other research to substantiate this. 
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6.7 SUMMARY 
 
 Levodopa is the most prescribed medication in this study group.  
 The association between duration of disease and degree of loss of 
sense of smell did not reach statistical significance.  
 Olfactory function may be affected by anti-parkinsonian medication or 
a confounder for disease stage.   
 None of the medications with regards to the sense of smell reached 
statistical significance between those taking certain anti-parkinsonian 
medication and those not taking it.  
 The environment in which the smell test is conducted does not affect 
the sense of smell.  This appears to have not been studied before in 
PD patients.  
 UPSIT score of patients taking levodopa decreased the further away 
from the time the medication was taken.  
 Correlation between minutes since last PD medication taken and 
UPSIT was statistically significant.  
 Correlation between sniff vigour (fatigue) and UPSIT was not 
statistically significant.  
 PD patients who are ambidextrous have higher median and mean 
UPSIT scores. However, this might be due to a sample size effect as 
only 5 patients were ambidextrous in our study.  
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CHAPTER 7 
THE PROFILE OF PERCEIVED SENSE OF SMELL AND PHANTOSMIA IN 
PD PATIENTS. 
 
 
 
7.1 OVERVIEW 
 
This chapter will address whether PD patients in this study group are aware 
of any impairment of their sense of smell (i.e. perceived sense of smell), or of 
any recovery/ fluctuation of their sense of smell.  It will also establish if any 
PD patients in this study group have phantosmia (persistent pleasant or 
disgusting smell) and whether any of the above affects UPSIT scores.  
Finally, the profile of the UPSIT 40 odours will be presented and 
number/percentage of patients answering correctly will be shown.  
 
7.1.2 Perceived Sense of Smell 
 
As previously stated (section 1.2.2.), PD patients frequently complain of 
impaired sense of smell years prior to the appearance of motor impairments 
(Wolters et al 2000, Hawkes et al 1999, Mesholam et al 1998, Hawkes et al 
1997).  However, although there have been few systematic studies, self-
reporting of smell dysfunction in PD patients is regarded as too unreliable as 
between 40% and up to 76% (Muller et al 2002, Doty et al 1988, Doty et al 
1992, Hawkes and Doty 2009) of PD patients with smell deficits on formal 
testing have failed to notice it.  This is certainly evident in the researcher’s 
clinical working area.  Although, according to Hawkes and Doty (2009) those 
patients who are unaware of their olfactory dysfunction, probably have mild 
impairment.  Regardless of this, the evidence so far highlights that simply 
asking a patient about their sense of smell is too unreliable and it must be 
properly measured.  Part of this chapter is designed to confirm or refute 
previous studies as to whether PD patients are aware of, or can with some 
accuracy, detect any impairment in their sense of smell and to what degree. 
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7.1.3 Recovery/Fluctuations of Sense of Smell 
 
James Parkinson (1817) reported autonomic dysfunction in PD.  Since then, 
a variety of fluctuating non-motor symptoms have been described.  These 
include changes in blood pressure (Fereshtehnejad and Lokk 2013), dyspnea 
(Wang et al 2014), and drenching sweats (Sage and Mark 1995).  These 
fluctuations are mainly associated with the “off” state but also with peak-of-
dose dyskinesia (Goetz et al 1986).  However, no study has mentioned either 
fluctuating or recovery sense of smell in PD.  Seiden and Duncan (2001) 
suggest that if the olfactory loss fluctuates (for example, in response to a 
variety of physical or environmental activities), this would suggest an 
obstructive or conductive loss secondary to nasal inflammation, such as 
allergic rhinitis.  On the other hand, it must be noted that less than 50% of 
patients with a conductive olfactory loss will report a history of fluctuation 
(Sieden and Duncan 2001).  Part of this chapter is designed to establish 
whether patients perceive their sense of smell recovers or fluctuates and 
whether this correlates with the degree of loss of sense of smell. 
 7.1.4 Phantosmia 
Phantosmia is the perception of a smell in the complete absence of any 
physical odour.  The perceived odour can range from pleasant to disgusting 
(Sandyk 1981).  Several types of phantosmia include: unirhinal (single 
nostril), episodic, and recurrent, where the activation of brain's GABAergic 
system seems to play a role in the inhibition of the unirhinal phantosmia 
(Levy and Henkin 2004).  Although the causes of phantosmia are uncertain, it 
often occurs with psychological and neurological disorders such as PD 
(Landis et al 2008).  
Phantosmia has not been extensively reported in PD and the first report 
appears to be briefly mentioned over 30 years ago, (Sandyk 1981).  
However, several more recent case reports showed that some patients have 
experienced phantosmia at the early stage of PD (Hirsch 2009, Singh and 
Schwankhaus 2009, Landis et al 2008).  Indeed, Landis et al (2008) 
proposed phantosmia as a new premotor manifestation of PD, but 
interestingly the disappearance of phantosmia in both patients within Landis 
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et al (2008) study coincided with the development of typical PD.  Also, a 
follow up study (Landis et al 2010) of 44 patients with idiopathic phantosmia 
concluded that idiopathic phantosmia improves or disappears in almost two 
thirds of patients after 5 years and it seems it is more likely a harmless 
symptom rather than a reliable predictor of early PD (Landis et al 2010).  Part 
of this chapter is designed to establish how many PD patients report 
phantosmia in this study group and whether this correlates with the degree of 
loss of sense of smell.  
 
7.1.5 UPSIT 40 Scores 
 
 
The UPSIT 40 test was administered in a designated research room at a 
local hospital Trust or at the patient’s own home.  On average the test took 
only 5 minutes to complete.  Part of this chapter is designed to establish 
which of the 40 odours are best detected by the 112 PD patients in this PhD 
study.  
 
7.2 AIM  
 
To investigate whether PD patients in this study group are aware of any 
impairment of their sense of smell (i.e. perceived sense of smell), or of any 
recovery/fluctuation of their sense of smell.  Also, to investigate the 
prevalence of phantosmia (persistent pleasant or disgusting smell) and 
whether any of the above affects UPSIT scores.  
 
7.3 OBJECTIVES  
 
Objectives of this chapter is to establish whether; 
 
(i) PD patients in this study group are aware of any impairment of their sense 
of smell (i.e. perceived sense of smell). 
  
(ii) Any evidence of phantosmia and whether phantosmia impacts on UPSIT 
scores. 
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(iii) Patients reporting a recovery or fluctuation of their sense of smell affects 
UPSIT scores.  
 
(iv) Finally, the profile of the 40 odours presented and number/percentage of 
patients correctly identifying each individual odour will be shown.  
 
 
7.4 OUTLINE OF THE METHODS 
 
 
(i) Perceived sense of smell, whether phantosmia is present and whether a 
patient reports a recovery in their sense of smell were all recorded on the 
Odour Detection in Parkinson’s Disease Participants Questionnaire (see 
appendix 14).  
 (ii) The sense of smell was evaluated using the 40 items University of 
Pennsylvania Smell Identification Test (UPSIT) (as detailed in section 2.4.6).  
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7.5.  RESULTS 
 
7.5.1. Patients Self Reporting Perceived Sense of Smell 
  
Figure 7.1 shows patient’s perceived (self-reported) sense of smell.  Thirty-
three patients reported a normal sense of smell. 
 
Figure 7.1: Patients Self-Reported Perceived Sense of Smell. 
 
Figure 7.2 shows median UPSIT scores for patients self-reporting sense of 
smell. Interestingly, the median UPSIT for those patients self-reporting a 
normal sense of smell is 18 (figure 7.2) which is higher than the median of 
patients self-reporting an absent (median =12.5) or decreased (median=16) 
sense of smell. 
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Figure 7.2: Patients Self-Reporting Sense of Smell and their UPSIT Scores. 
 
Further analysis of patients self-reporting normal sense of smell and their 
individual UPSIT scores can be seen in figure 7.3 which shows that 29 out of 
the 33 PD patients (self-reporting a normal sense of smell) had, in fact, a 
severe degree of sense of smell loss (UPSIT range 7-25, mean 16) without 
recognising it.  This highlights the need to test the sense of smell formally, 
using more objective means. 
 
 
 
Figure 7.3: Patients Self-Reported Normal Sense of Smell and UPSIT 
Scores.  
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Further analysis of the PD patients self-reporting number of years during 
which they experienced either a decreased or absent sense of smell is 
shown in table 7.1 (which breaks down years of smell loss into 5 yearly 
intervals).  
 
The tables 7.1 and 7.2 also highlights that self-reported decreased sense of 
smell was recognised by the patient from approximately I month to 60 years 
before and after diagnosis.  Table 7.1 also highlights that the longest record 
of loss of sense of smell (60 years) in a PD patient has only been diagnosed 
for 5 years.  Therefore, this person had sense of smell loss for 55 years prior 
to a diagnosis and had an UPSIT score of 18 (anosmic).  
The eight PD patients reporting smell loss for a significant amount of years 
prior to a diagnosis of PD (26-60 years) had a mean diagnosis of PD for 7 
years and all  had anosmia. 
 
Thirty-three PD patients reporting normal sense of smell had a diagnosis of 
PD ranging from 1-13 years and did have a slightly better UPSIT mean (20). 
However, a mean of 20 is still considered severe microsmia.  
 
Table 7.1 PD Patients Reporting Years of Smell Loss, Years Since Diagnosis 
of PD and Number of PD Patients and UPSIT Mean in each 5 Yearly 
Intervals. 
 Smell Loss (years 
involved) 
PD Years Number of 
Patients 
UPSIT (Mean) 
0 1-13 33 20 
0.1-5 1-14 34 16 
6-10 1-12 20 17 
11-15 2-12 6 14 
16-20 1-19 11 16 
21-25 0 0 0 
26-30 3-7 5 13 
31-35 0 0 0 
36-40 4-6 2 13 
60 5 1 18 
 
 
A Spearman’s correlation was run to determine the relationship between the 
perceived number of years since sense of smell reported as 
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normal/decreased or absent and the UPSIT mean.  This did not reach 
statistical significance ( =0.093, n=112, p= 0.328). 
 
Further analysis of these sub-groups per their age, gender, Hoehn and Yahr 
score, PD Years and whether they suffer from RBD is also shown in table 
7.2.  Table 7.2 highlights that age range appears comparable in each self-
reported perceived sense of smell group.  However, mean age is higher (73 
years) in patients self-reporting perceived absent sense of smell than the 
other two groups.  Female representation is also less in those patients 
reporting an absent sense of smell (20%) compared to those in the normal 
(39%) and decreased (42%) group. 
 
Hoehn and Yahr stage 1 appears to be represented more in patients self-
reporting perceived decreased sense of smell (25 patients).  This accounts 
for 22% of the 112 patients enrolled in this PhD study.  Fifty-five patients in 
total reported decreased sense of smell accounting for 49% of the whole 
study group.  
 
Analysing the mean duration for disease showed that mean years is slightly 
higher in those patients self-reporting perceived decreased sense of smell (6 
years).  This is in comparison to mean age of 5 years in those patients self-
reporting perceived normal or absent sense of smell. 
 
Analysing RBD, patients self-reporting perceived decreased sense of smell 
appear to represent more patients meeting the criteria for a diagnosis of RBD 
(30 out of 55) (55%) and represents 27% of the overall PD study group.  
However, when grouping patients with decreased or absent sense of smell 
(n=79) there appears to be a slight difference in those with or without RBD 
(with RBD 42=53%, patients without RBD 37=47%) which possibly concludes 
decreased or absent perceived sense of smell does not direct the clinician to 
the fact the patient may have RBD.  Equally of those reporting normal sense 
of smell (33), 20 patients did not have RBD (61%) and 13 (40%) did, further 
confirming that the sense of smell may not be correlated with RBD.  
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Further analysis using a chi-square test highlighted there is no association 
between RBD and perceived decreased sense of smell in this study group, 
(p=0.670). 
 
Table 7.2. Demographics and Clinical Characteristics of PD Patients Self-
Reporting Sense of Smell. 
 
Variable  Normal (N=33) Decreased (N=55) Absent (N=24) 
Self reported sense of smell  
(before or after a diagnosis of 
PD). 
Years involved 
Mean duration 
Median duration  
Overall percentage of patients 
in this study 
 
 
- 
- 
- 
29% 
 
 
1 month-60 years 
10 years 
7 years 
49% 
 
 
1-40 years 
13 years 
7 years 
22% 
Gender  
Males  
Females 
 
(N=20) (18%) 
(N=13) (11%) 
 
(N=32) (28%) 
(N=23) (21%) 
 
(N=20) (18%) 
(N=4) (4%) 
Age (years) 
Range  
Mean 
Median  
IQ 
 
49-86  
71 
71 
7 
 
51-84  
70 
70 
7.5 
 
62-83 
73 
73 
4.5 
Duration of Disease  
Mean 
Median 
IQ 
6months-13 years 
5 
3 
5 
1-16 years 
6 
6 
5.5 
1-19 years 
5 
4 
3 
Hoehn and Yahr Stage  
1 
2 
3 
4 
 
(N=14) (12.5%) 
(N=9 (8%) 
(N=9 (8%) 
(N=1) (.8%) 
 
 (N=26) (22%) 
(N=16 (14%) 
(N=12) (11%) 
(N=1) (.8%) 
 
(N=12) (11%) 
(N=8) (7%) 
(N=4) (4%) 
(N=0) 
RBD 
No 
Yes 
 
(N=20)  
(N=13)  
 
(N=25)  
(N=30)  
 
(N=12)  
(N=12)  
         Data are presented on means, medians, IQ ranges.  
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7.5.2. Patients Reporting Phantosmia (persistent pleasant or disgusting 
smell) and their UPSIT Scores 
 
Figure 7.4 shows that 102 (91%) PD patients reported no phantosmia and 10 
(9%) patients did. The length of time since diagnosis with those patients who 
reported phantosmia ranged from 0.5-8 years with a mean of 4.85 years (see 
table 7.3); their median UPSIT score is 19.5, with a range of 13-25 (see 
figure 7.5).  The length of time involved in PD patients reporting phantosmia 
ranged from 1-20 years with a mean of 5.25 years.  The median UPSIT score 
of 102 patients reporting no phantosmia is 16, with a range of 6-31 (see 
figure 7.5).  Initial analysis suggests that patients with phantosmia have a 
higher median UPSIT score and generally higher overall range of UPSIT 
scores, compared to those patients reporting no phantosmia.  However, a 
Mann-Whitney U test was performed which did not reach statistical 
significance (P=0.095).  
 
Figure 7.4: Number of Patients Self-Reporting No Phantosmia or 
Phantosmia. 
 
102 
10 
No Phantosmia                                        Phantosmia  
Number of Patients Self Reported No Phantosmia or Phantosmia  
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Figure 7.5: Patients Reporting No Phantosmia or Phantosmia and their 
UPSIT Scores. 
 
Table 7.3 PD Patients Phantosmia and the Year’s Prior to or Post Diagnosis 
of PD  
PD Years 
 
Years since Phantosmia noted 
5 5 
8 8 
7 1 
3 1 
7 20 
1 5 
0.5 2 
6 4 
4 1.5 
7 5 
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7.5.3 Patients Reporting Recovery of their Sense of Smell and their 
UPSIT Scores 
 
Eighty-three patients (74%) self-reported their sense of smell did not recover 
and 29 patients (26%) reported it did.  Initial analysis suggests that patients 
self-reporting, that their sense of smell recovers, do not have increased 
sense of smell when tested using UPSIT.  The median UPSIT score is 16 in 
both groups (see figure 7.6).  A Mann-Whitney U test was conducted which 
did not reach statistical significance (P=0.973). 
 
Figure 7.6: Patients Reporting Recovery of their Sense of Smell or not and 
Their UPSIT Scores. 
 
7.5.4 Individual Odours Presented and Number/Percentage of Patients 
Identifying Them 
 
Table 7.4 shows the odour presented, the number of patients who correctly 
identified the individual odour and the overall percentage.  As it can be seen, 
onion (71%) and leather (65%) were the two odours PD patients could 
identify the most and lemon (13%) and root beer (21%) were the two odours 
PD patients had difficulty identifying the most.  
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Table 7.4: Correct Odour Presented in UPSIT 40 and 
Number/Percentage of Patients Answering Correctly. 
Correct odour presented  Number of patients who 
answered correctly. 
Percentage of patients 
who answered correctly. 
Pizza 27 24% 
Bubble gum 45 40% 
Menthol 68 61%  
Cherry 46 41% 
Motor oil 47 42% 
Mint 45 40% 
Banana 40 36% 
Clove 56 50% 
Leather 73 65% 
Coconut 51 46% 
Onion 80 71%  
Fruit punch 32 29% 
Liquorice 36 32% 
Cheddar cheese 40 36% 
Cinnamon 53 47% 
Gasoline 28 25% 
Strawberry 46 41% 
Cedar 48 43% 
Chocolate 71 63% 
Gingerbread 56 50% 
Lilac  60 54% 
Soap 27 24% 
Peach 63 56% 
Root Beer 24 21% 
Dill Pickle 27 24% 
Pineapple 50 45% 
Lime 36 32% 
Orange 55 49% 
Wintergreen 45 40% 
Watermelon 57 51% 
Paint thinner 52 46% 
Grass 34 30% 
Smoke 72 64% 
Pine 53 47% 
Grape 45 40% 
Lemon  15 13% 
Soap 48 43% 
Natural Gas  50 45% 
Rose 51 46% 
Peanut  59 53% 
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7.6 DISCUSSION 
 
7.6.1 Patients Self Reporting Perceived Sense of Smell 
  
There has been an interest in analysing perceived sense of smell in PD as 
research suggests PD patients are unable to detect, with some clarity, their 
degree of smell loss (Muller et al 2002, Doty et al 1988, Doty et al 1992, 
Hawkes and Doty 2009).  In this present study, thirty-three patients (29%) 
reported a normal sense of smell but on formal testing had, in fact, anosmia 
or severe microsmia (see figure 7.1).  This is in support of previous research 
which highlights self-reporting of smell dysfunction are regarded as too 
unreliable as between 40% and up to 76% (Muller et al 2002, Doty et al 
1988, Doty et al 1992, Hawkes and Doty 2009) of PD patients with smell 
deficits on formal testing have failed to notice it.  Although, Hawkes and Doty 
(2009) commented that those who are unaware of their olfactory dysfunction 
probably have mild impairment, this study did not support this as only one out 
of the 33 patients had mild microsmia.  However, the evidence in this PhD 
study and that of others (Muller et al 2002, Doty et al 1988, Doty et al 1992, 
Hawkes and Doty 2009) highlights that simply asking a patient about their 
sense of smell is unreliable and it must be properly measured.  
 
Another important question was to discover how long this group of PD 
patients noticed either a decreased or absent sense of smell.  This was to 
establish if there was a clear prodromal stage of PD, as some PD patients 
complain of impaired sense of smell years prior to the appearance of motor 
impairments (Wolters et al 2000, Hawkes et al 1999, Mesholam et al 1998, 
Hawkes et al 1997).  Of those patients who were aware of a decreased 
sense of smell this ranged from I month to 60 years (see table 7.1).  This is in 
support of previous research in that estimates of prodromal phase duration 
vary considerably from 2 to 50 years (Hawkes 2008). In addition, those PD 
patients reporting complete absent sense of smell (anosmia) ranged from 1 
year to 40 years (see table 7.2).  Mean duration was 7 years in both groups 
(see table 7.2). Most researchers agree the pre-diagnosis period probably 
covers 4-6 years (7 years in this study).  This period fits the proposed 
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duration of 4.7 years from the onset of neuronal loss until the classic PD 
symptoms, as calculated from post mortem neuronal counts in the substantia 
nigra (Greffard et al 2006, Gonera et al 1997).  
 
Further analysis of these self-reported sub-groups per their age, gender, 
Hoehn and Yahr stage, PD years and whether they suffer from RBD 
highlighted that age range appears comparable in each self-reported 
perceived sense of smell group (see table 7.2).  Female representation 
appeared less in patients reporting an absent sense of smell which could 
support the theory that women have a better sense of smell than men 
(Silveria-Moriyama et al 2008, Lundstrom et al 2006 Schaal et al 2004, 
Dalton et al 2002, Brand and Millot 2001, Cain 1982), (as briefly described in 
section 1.2.7). 
 
Hoehn and Yahr stage 1 appears to represent more in patients self-reporting 
perceived decreased sense of smell (25 patients).  This accounts for 22% of 
the 112 patients enrolled in this PhD study.  Fifty-five patients in total 
reported decreased sense of smell accounting for 49% of the whole study 
group (see section 4.5.2).  The researcher could find no studies examining 
Hoehn and Yahr stage and patients self-reported smell loss.   
 
When analysing PD duration in years and PD patients self-reporting sense of 
smell, it appears that mean duration of disease is slightly higher in those 
patients self-reporting perceived decreased sense of smell (6 years) (see 
table 7.1) comparable to mean duration of 5 years in those patients self-
reporting perceived normal or absent sense of smell.  
 
Analysing RBD, patients self-reporting perceived decreased sense of smell 
(which did not reach statistical significance ( =0.093, n=112, p= 0.328)). 
appear to represent more patients meeting the criteria for a diagnosis of RBD 
(27% compared to 22%) but less in normal sense of smell (39% compared to 
61%), and equal to in anosmic patients (50% each) (see table 7.2).  The 
rationale for this is difficult to establish as the researcher was unable to 
confirm or refute these findings in any other research papers. 
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7.6.2 Patients Reporting Phantosmia (persistent pleasant or disgusting 
smell) and their UPSIT Scores 
 
In this PhD study 10 patients reported phantosmia (see figure 7.4, table 7.3), 
which equates to 9% of the study group.  Phantosmia has been reported as 
an uncommon form of smell disturbances in a variety of conditions involving 
the peripheral and central olfactory system, including, head trauma, temporal 
lobe epilepsy and stroke (Frasnelli et al 2004 Leopold 2002).  It appears from 
this PhD study results and available research that phantosmia is also 
uncommon in PD.  For example; despite a detailed report of phantosmia 
mentioned nearly 35 years ago, (Sandyk 1981), only a small number of case 
reports show that some PD patients have experienced phantosmia very early 
during the disease (Hirsch 2009, Singh and Schwankhaus 2009, Landis and 
Burkhard 2008).  Indeed, according to Landis and Burkhard (2008) idiopathic 
phantosmia, as an early sign of PD, remains probably a rather exceptional 
presentation, whereas most people with idiopathic phantosmia will not 
develop PD. Therefore, due to limited research, the prevelence of 
phantosmia in PD is probably rare but this may be due to lack of research in 
this area.  
 
The length of time involved with those patients who reported phantosmia 
before or after a diagnosis of PD ranged from 1-20 years with a mean of 5.25 
years overall and and an average of 6.1 years prior to a diagnosis of PD and 
2.9 years post diagnosis.  This neither supports nor refutes the findings of 
Hirsch (2009), Singh and Schwankhaus (2009) and Landis (2008) who report 
that some patients have experienced phantosmia very early (within the first 
couple of years) during the disease.  
 
Initial analysis suggests that patients with phantosmia have a higher median 
UPSIT score and generally higher overall range of UPSIT scores, compared 
to those patients reporting no phantosmia.  No study on PD, sense of smell 
and phantosmia could be found.  However, this is consistent with the 
published work of Smith and Seiden (1991) (which relates to head trauma 
and not PD).  This warrants further analysis, to exclude sample size effect, as 
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only 9% of patients in our study reported phantosmia.  However, this appears 
to be the first time this has been reported in PD patients, but a more evenly 
distributed percentage of patients reporting phantosmia would be required to 
substantiate this.  
 
7.6.3. Patients Reporting Recovery/Fluctuations of their Sense of Smell 
and their UPSIT Scores 
 
Eighty-three patients (74%) self-reported their sense of smell did not return 
and 29 patients (26%) reported it did (see figure 7.6).  Further examination of 
figure 7.6 suggests that patients self-reporting that their sense of smell 
returns do not have increased sense of smell when tested using UPSIT.  
Further statistical analysis by means of the Mann Whitney test showed no 
statistical significance (P=0.973). However, due to the small sample size (30 
PD patients) and that this PhD study is a cross sectional study rather than a 
longitudinal study this must be interpreted with caution).    Despite extensive 
research no papers could be found to support or refute these findings.  To 
the best of the researcher’s knowledge it appears that this is the first time this 
has been reported in PD patients.  Although Sandyk (1999) found treatment 
with AC pulsed electromagnetic fields on two PD patients improves olfactory 
function in conjunction with recurrent episodes of yawning, the rational 
behind this was difficult to establish.  
 
7.6.4.  UPSIT 40 Odours Presented and Number/Percentage of Patients 
Answering Correctly 
 
Table 7.3 shows that onion (71%) and leather (65%) were the two odours PD 
patients could identify the most and lemon (13%) and root beer (21%) were 
the two odours PD patients had difficulty identifying the most.  Interestingly, 
lemon was also an odour most readily misidentified by PD patients on the 
UPSIT test in a much earlier study (Hawkes et al 1999).  
 
Interestingly, most odourant’s also stimulate the trigeminal nerve (Fraznelli et 
al 2007, Doty et al 1978).  Therefore, even anosmic patients can distinguish 
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between odorants based on their trigeminally mediated sensitivity. However, 
despite this, anosmic patients show reduced trigeminal sensitivity when 
compared with healthy controls (Fraznelli et al 2007, Hummel et al. 2003, 
Walker et al 2001).  This suggests that, in addition to the known mutual 
interactions between the olfactory and the trigeminal chemosensory systems 
in healthy subjects (Livermore and Hummel 2004), even the absence or 
presence of a functioning olfactory system influences trigeminal perception.  
Anatomical and functional characteristics of the underlying mechanisms are 
largely unknown.  This study did not test patient’s trigeminal impact on 
odours and therefore this cannot be examined. 
Also, this study did not address whether certain odours are more difficult to 
detect in PD patients rather than controls.  However, interestingly in one 
study banana, licorice and dill pickle could distinguish PD subjects from 
controls with the greatest accuracy (Bohnen et al 2007).  These 3 odours 
also had stronger correlations with nigrostriatal dopamine denervation than 
the total UPSIT.  Another study found that the UPSIT odours pizza and 
wintergreen were best able to distinguish PD patients from controls (Hawkes 
and Shephard 1993), while pizza, mint, and licorice were optimal in another 
study (Silveira-Moriyama 2005).  Double et al (2003) reported that gasoline, 
banana, pineapple, smoke, and cinnamon were the odours most affected in 
Australians with PD using the 12-odour Brief Smell Identification Test (BSIT) 
Daum et al (2000) using the 12-odour Sniffin' Sticks test reported that 
licorice, followed by aniseed, pineapple, apple, turpentine, and banana, best 
separated PD patients from controls.  
This seems to highlight that olfactory impairment in PD is not confined to a 
subset of odours and therefore, at this present time, there is no convincing 
evidence for the concept of selective hyposmia in PD (Doty et al 1988, 
Boesveldt et al 1984). 
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7.7 SUMMARY 
 
The most significant findings from this chapter are; 
 
 PD patients need to be formally tested to establish their loss of sense 
of smell. 
 Self-reported decreased sense of smell was recognised by the 
patients from approximately one month to sixty years pre-and post 
diagnosis.  
 The mean self-reported loss of sense of smell pre-diagnosis period 
was 7 years in this study.  
 Female representation is less in those patients reporting an absent 
sense of smell which could support the theory that women have a 
better sense of smell than men, (within the limits of reliability of self-
reporting). 
 Decreased or absent perceived sense of smell does not suggest that 
the PD patient may have RBD. 
 The difference in UPSIT Scores between PD patients who self-
reported their sense of smell did or did not recover, did not reach 
statistical significance. This PhD study appears to be the first study to 
examine this.   
 Ten (9%) of the PD patients reported phantosmia, which highlights 
phantosmia is uncommon in PD and that the prevalence of 
Phantosmia in PD is unknown. 
 The difference in UPSIT scores between PD patients reporting 
phantosmia or not did not reach statistical significance. 
 Onion and leather were the two odours PD patients could identify the 
most and lemon and root beer were the two odours PD patients had 
difficulty identifying the most.  
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CHAPTER 8 BIOMARKERS IN PARKINSONS DISEASE 
 
 
8.1. THE USE OF BIOMARKERS IN PD 
 
Biomarkers are biological characteristics used to indicate or measure disease 
risk, presence of disease and disease progression (Atkinson et al 2001).  It is 
believed that the development of reliable biomarkers for PD would accelerate 
advances in research on the aetiology, pathophysiology, early diagnosis, 
disease progression and therapeutics of PD. 
 
PD pathology is now known to be much more widespread and includes Lewy 
bodies, not only in dopamine neurons but also cholinergic neurons of the 
nucleus basalis of meynert, norepinephrine neurons of the locus coeruleus, 
and serotonin neurons of the raphe as well as neurons of the olfactory 
system, cerebral hemisphere, spinal cord and peripheral autonomic system 
(Del Tredici and Braak 2012, Jellinger 2012).  Lewy bodies are insoluble 
intraneuronal inclusions that contain the misfolded protein alpha-synuclein in 
aggregated form (Dickson et al 2009, Norris et al 2004, Dickson 2001, 
Spillantini et al 1997).  They ultimately cause neuronal degeneration and 
death.  
 
Figure 8.1 shows (i) normal substantia nigra zona compacta which is 
involved earliest and most severely in PD (ii) substantia nigra in PD-in the 
same location and (iii) Lewy body inclusion (Agamanolis 2011).  
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(i) Normal Substantia Nigra Zona Compacta 
 
(ii) Substantia Nigra Zona Compacta in PD- same location 
 
                      Lewy Body 
(iii) Lewy Body inclusion 
 
            Lewy Body 
 
Figure 8.1: Substantia Nigra and PD Pathology (source Agamanolis, 2011). 
Pathological staging of PD proposed initially by Braak et al (2003), observed 
by others (Duda et al 2007, Muller et al 2005) and recently revised by 
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Halliday and McCann (2010) and Beach et al (2009) has suggested that the 
neuropathological changes in PD may begin in extranigral structures.  This 
includes the olfactory bulb or brainstem nuclei or even extra central nervous 
system structures (Halliday and McCann 2010, Beach et al 2009, Braak et al 
2003).  The non-dopaminergic pathology is associated with a variety of 
clinical features such as autonomic dysfunction, olfactory loss and sleep 
disorders.  These clinical features are said to precede the development of 
classical dopaminergic pathology (Braak et al 2003).  This has led to 
research targeting these areas as possible biomarkers (Del Tredici and 
Braak 2012, Jellinger 2012).  Figure 8.2 highlights the stylized representation 
of the Braak et al (2003) staging for Parkinson’s disease. 
 
 
 
Figure 8.2: Stylized Representation of the Staging for Parkinson’s Disease 
(with permission from Braak et al (2003). 
 
Braak et al (2003) through this neuropathological staging system suggests a 
characteristic spread of Lewy body pathology as the features of PD evolve. 
The initial sites are in the medulla oblongata and olfactory bulb with later 
infiltration of Lewy pathology, and finally in the cortical regions.  
 
Although there are clearly deviations from this design (Jellinger 2009, 
Halliday et al 2008, Zaccai et al 2008) and reasonable debate around Braak 
et al (2003) staging (Lim et al 2009, Lees 2009, Burke et al 2008, Kalaitzakis 
et al 2008, Dickson et al 2008, Parkkinen et al 2008, Attems and Jellinger 
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2008), predictable development of pathology does occur in many patients.  It 
would therefore be reasonable to propose that clinical features associated 
with different brain regions would also develop in an orderly fashion.  If this 
was the case in PD, understanding the order of onset of clinical and 
observable physiological features could guide screening strategies for pre-
motor PD. 
 
There are several potential biomarkers which can aid diagnosis and can be 
used as a biomarker for PD. For example,  
 
1. Non-motor features of PD (such as olfactory deficits, constipation, 
rapid eye movement sleep behaviour disorder (RBD) (Chaudhuri and 
Naidu 2008) as well as excessive daytime sleepiness (Gao et al 
2011).  
 
2. The most widely used test is neuroimaging using DAT SPECT and 
[18F]-fluorodopa PET scans (Piccini et al 1999, Marek et al 1996, 
Holthoff et al 1994) which assesses the integrity of the nigrostriatal 
system with ligands specific for dopamine (DA) metabolism or 
transport.   
 
3. Other examples of biochemical biomarkers include measuring alpha-
synuclein levels in blood or spinal fluid (El Agnaf et al 2006, Abdi et al 
2006), evidence of cardiac sympathetic denervation demonstrated by 
metaiodobenzylguanidine (MIBG) SPECT imaging of postganglionic 
sympathetic neurons (Fujishiro et al 2008, Orimo et al 2008, Courbon 
et al 2003, Braune et al 1999,  Braune et al 1998, Yoshita 1998) and 
alpha-synuclein accumulation in colonic neurons following colonic 
biopsy (Shannon et al 2012, Lebouvier et al 2010).  
 
4. Genetic biomarkers that confer a considerable risk of developing PD in 
the future (Healy et al 2008, Adams et al 2005, Lucking et al 2000, 
Polymeropoulos et al 1997) such as testing for mutations in the Parkin 
and LRRK2 genes are now commercially available.   
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8.2 PARKINSONS DISEASE STAGES 
 
Current research appears to have divided the natural history of PD into 
stages based on the presence of clinical, physiological, or risk markers of 
disease and a conceptual model known as the ‘Parkinson’s At-Risk 
Syndrome’ (PARS) pyramid has been devised which describes a hierarchical 
classification pyramid for patients who do not yet have clinical PD (Siderowf 
and Stern 2006, Stern 2004).  See Figure 8.3. 
 
Figure 8.3: The PARS Pyramid. (With permission from Stern 2004). 
 
In this conceptual model, there are 4 stages that precede clinically manifest 
PD: pre-physiological, pre-clinical, pre-motor and pre-diagnostic.  
 
8.2.1. Pre-Diagnostic Phase 
 
At the pre-diagnostic phase, patients have subtle parkinsonian features 
which may represent very early Parkinson’s disease, but these features can 
be seen, to a certain degree, in normal ageing as well (Louis and Bennett 
2007).  There is a potential role for imaging in the pre-diagnostic stage of PD, 
using dopamine transporter (DAT), single-photon emission computerized 
tomography (SPECT) imaging and glucose metabolism positron emission 
tomography (PET). (see appendix 24) 
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Appendix 24 highlights potential imaging biomarkers which are based on 
preliminary data in PD patients.  However, these do not serve as a stand-
alone definitive diagnosis as dopamine deficiency can occur in other 
diseases (Ravina et al 2005).  It is also worth highlighting that not all patients 
who meet the criteria for PD at this stage go on to develop Parkinson’s 
disease.  This is evident in clinical practice and recognised by others (Stern 
et al 2012). 
 
8.2.2. Pre-Motor Phase 
 
There is a developing consensus on the clinical features that make up the 
pre-motor phase of PD.  Although these pre-motor features are nonspecific 
with limited sensitivity/specificity for their clinical utility, it appears that pre-
motor biomarkers can be identified based on the known non-motor features 
of PD (such as olfactory deficits, constipation, rapid eye movement sleep 
behaviour disorder (Chaudhuri and Naidu 2008) as well as excessive 
daytime sleepiness (Gao et al 2011).  These are discussed below. 
 
8.2.3. Pre-Clinical Phase 
 
Pre-clinical PD refers to physiological changes that can be detected using 
biomarker techniques in the absence of any clinical features.  The most 
widely used test is neuroimaging using DAT SPECT and [18F]-fluorodopa 
PET scans (Piccini et al 1999, Marek et al 1996, Holthoff et al 1994) which 
assesses the integrity of the nigrostriatal system with ligands specific for 
dopamine (DA) metabolism or transport. 
 
The feasibility of neuroimaging with DATSPECT, [18F] dopa PET, [11C] 
dihydrotetrabenazine PET, and [18F] fluorodeoxyglucose PET to monitoring 
disease progression in PD has been extensively discussed (Ravina et al 
2005, Brooks et al 2003, Marek et al 2003, Brooks 2003, Morrish 2003).  
However, it is not within the scope of this thesis to discuss these techniques 
and equipment. 
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Appendix 25 shows a range of biomarkers highlighted in the literature for PD. 
However, all these biomarkers, as well as genetic testing, raises important 
ethical, professional and financial issues and concerns about the effects of 
such screening on the well-being of individual persons and groups and the 
ways in which it could harm people.  For example, to deny them access to 
health insurance, employment and education.  In fact, people cite fear of 
losing insurance as a major reason to avoid genetic testing (Lapham et al 
1996). 
 
8.2.4. Pre-Physiological Phase 
 
Finally, pre-physiological patients have no evidence suggestive of PD but 
possess traits, such as a genetic mutation that confer a high risk of 
developing PD in the future (Healy et al 2008, Adams et al 2005, Lucking et 
al 2000, Polymeropoulos et al 1997).  Genetic testing for mutations in the 
Parkin and LRRK2 genes is now commercially available.  These gene tests 
have the potential to make the diagnosis of preclinical PD at the time of birth 
because they identify a lifelong trait rather than an evolving pathological 
state.  The risk imparted by genetic factors varies depending on the gene 
involved. (See appendix 26).  
 
Healy et al (2008) suggest, over all, the two strongest risk factors for PD are 
having a family member who has a known genetic mutation and having a 
diagnosis of idiopathic rapid eye movement behaviour disorder . 
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8.3 IMPLICATIONS OF THE FINDINGS OF THIS PhD STUDY ON THE 
USE OF BIOMARKERS IN PD 
 
This study highlights that loss of sense of smell is common and profound in 
PD patients.  Testing for sense of smell is thus considered as a candidate 
biomarker for PD because of its high prevalence in PD patients.  This study 
also highlights that loss of sense of smell precedes the motor features of PD 
by a mean of 7 years and therefore testing sense of smell could be a useful 
biomarker to predict PD. 
 
The Odour identification testing using UPSIT 40 is the gold standard of smell 
identification tests for its reliability (reliability = 94%) (Doty et al 1989).  
However, the relatively low specificity (83.5%) (Silveira-Moriyama et al 2008) 
discovered during the literature review limits the diagnostic application of loss 
of sense of smell  because loss of sense of smell exists not only in PD, but 
also in other neurological diseases (Silveria-Moriyama et al 2010) as well as 
other medical conditions (Rombaux et al 2012, Jafek et al 1990, Douek et al 
1975) (see appendix 20) and related to medications (Doty et al 2008, 
Seiberling and Conley 2004, Schiffman and Graham 2000) (see appendix 
21).  
However, this study does highlight that once loss of sense of smell has 
developed it might help distinguish patients with idiopathic PD from other 
parkinsonian syndromes (Doty et al., 1993; Hawkes, 2003) as it was 
discovered that the only PD patient to have mild microsmia was later 
diagnosed with PSP.  However, although loss of sense of smell has the 
potential to distinguish PD from other parkinsonian syndromes, it is not being 
used as a formal testing guideline because there are not enough large-scale 
studies to show that it is accurate enough and even if this was the case, from 
the patient’s perspective there is no known treatment to improve the sense of 
smell.  Although, it could indirectly improve mortality rates by raising 
awareness of the profound loss of sense of smell in PD patients and the 
dangers that might face that person which could in turn reduce mortality rates 
caused by accidental food poisoning or fire.  
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In conclusion by combining sense of smell testing with other non-motor 
symptoms in PD such as autonomic dysfunction, depression, visual 
symptoms, and RBD, the specificity of loss of sense of smell as a biomarker 
for PD may be enhanced (Berg 2012).  Currently, a large-scale multicentre 
prospective longitudinal epidemiological and biomarker study of PD is 
underway looking specifically at the use of biomarkers in PD (Tracking 
Parkinson’s ProBand Study) (Grosset et al 2013).  It is the world's largest 
ever in-depth study of people with PD.  This study may help to establish an 
effective screening protocol for the early diagnosis of PD at the population 
level. 
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CHAPTER 9  
Conclusion 
 
9.1 THE BURDEN OF PARKINSONS DISEASE 
 
Approximately 127,000 people in the UK have been diagnosed with PD in 
2009 (Parkinson’s UK 2009) with a diagnosed projected prevalence of 
162,000 in 2020 (Parkinson’s prevalence in the UK 2012).  Such projections 
give impetus to the need for innovative early diagnosis and new treatments to 
prevent, delay onset, or alleviate symptoms of PD and other similar diseases 
(Kowal et al 2013).  However, a lack of treatment options for changing the 
trajectory of disease progression, in combination with an increasing elderly 
population, indicate a rising economic burden. 
 
The burden of illness associated with PD is related not only to the disease 
itself, but also to the progressive disability that patients experience as their 
disease advances.  Impairments in motor function cause problems with 
mobility and interfere with activities of daily living.  Problems with balance 
and gait can lead to falls and injuries, and the inability to perform everyday 
tasks.  Non-motor complications also increase over time and dementia, 
depression and other neuropsychiatric disorders are commonly reported 
comorbidities (Korczyn 2001, Huse et al 2005, Guttman et al 2003).  
Currently, over 500 people with a diagnosis of PD are registered on the PD 
local Trust database for which the researcher has shared responsibility for 
alongside the local consultant physician.  These patients have complex and 
progressive needs.  Home visits are often required for the more advanced 
cases and are costly in terms of time and expenses incurred.  Also, despite 
having reasonable rehabilitation facilities, such as a local day hospital and a 
dedicated neurology physiotherapist, demand far outweighs the capacity of 
these services.  
 
However, most services focus on motor symptoms of PD and the non-motor 
symptoms of PD have received little attention in clinical settings, particularly 
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when planning care, even though they can lead to greater disability, restrict 
the patient’s independence, limit social and recreational activities and lead to 
increased reliance on carers and the healthcare system (Lohle et al 2009, 
Wolters 2009, Global Parkinson’s Disease Survey Steering Committee 2002, 
Whetten-Goldstein et al 1997).  
 
With increases in life expectancy, finding ways of controlling the costs 
associated with PD is a major societal challenge.  It has been shown that 
costs increase as a patient’s condition becomes more severe, so slowing 
down PD progression is a major unmet need. 
 
In this present study, olfactory loss, on formal testing, was the most prevalent 
non-motor symptom seen in PD patients (100%).  Indeed, a recent study by 
Politis et al (2010) found that olfactory loss belongs to the top-five most 
prevalent motor and non-motor symptoms in early stage PD patients that 
have affected their quality of life.  Only pain is referred to as a more prevalent 
troublesome non-motor problem in their study.  Therefore, if it can be 
established that the loss of sense of smell correlates with any of the motor or 
non-motor symptoms, the potential benefits to PD patients will include a 
better understanding of the natural history of one of the non-motor features of 
PD, namely the sense of smell. 
 
Depending on the clinical features associated with the sense of smell, health 
care workers, particularly nurses, are in an excellent position to view PD 
patients holistically and interface with the specific disciplines, for example, 
physiotherapists, occupational therapists, speech and language therapists 
and dietitians, which may be needed over the disease course.  Nurses are 
also in an ideal position to monitor responses to medication and symptoms 
that arise such as motor fluctuations, constipation and speech problems (van 
Laar 2003, Fahn and Parkinson’s Study Group 2005).  Such evaluation skills, 
along with provision of appropriate therapy, are critical in minimizing the 
development of complications of PD and preventing undue loss of quality of 
life, not only for patients, but also for caregivers as well. 
 
196 
 
9.2. RESEARCH QUESTIONS  
 
The purpose of this study was to investigate whether patients with PD who 
have mild/moderate microsmia, severe microsmia or anosmia (as measured 
by the University of Pennsylvania Smell Identification Test (UPSIT)) were 
clinically different when comparing their natural history of PD in terms of 
motor, non-motor and quality of life symptoms.  These questions were 
prompted as little is known about PD patients with mild to moderate 
microsmia and whether they are clinically distinct from those with severe 
microsmia or anosmia. 
 
 
9.3 METHODOLOGICAL ASPECTS AND USE OF TOOLS IN THIS STUDY.  
 
Having now completed this PhD study, the researcher considers the choice 
of an open cross-sectional observational study to test whether varying 
degrees of the sense of smell worsen alongside motor and other non-motor 
symptoms seen in PD to be appropriate.  This is because the researcher was 
able to recruit a reasonable number of PD patients to study, thereby allowing 
the results to be generalisable  It was also relatively cheap to conduct such a 
study which is a major concern in today’s financial  climate within the NHS.  
The researcher also felt the data collected did, in the majority of cases,  
answer the specific question around sense of smell.  However, the 
researcher is keen now to re-test PD patients who presented with 
mild/moderate sense of smell loss (total number =9), to establish if their 
sense of smell loss deteriorates alongside the disease progression, as the 
motor domains do, to complete the one element that the researcher felt was 
missing from this study.  
 
Generally, the tools and scales used for this study were easy to use, but 
most were very subjective and for a more robust study more formal testing 
would be needed for example; polysomnography to test for RBD as the 
researcher felt it would be difficult for a PD patient to know if they had RBD if 
they slept alone, even accounting for bed clothes movement.  The researcher 
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also felt the PDQ39 required reasonable mathematical skills to complete the 
scoring system and was personally statistically difficult to calculate.  
 
9.3.1 Correlation between the Demographic Features of PD Patients in 
the study group and their Sense of Smell. 
 
Although there is a trend in reduction in the sense of smell as PD patients get 
older, which is mirrored in this study (p=0.026), the actual  loss of sense of 
smell in this sample of PD patients is consistently reduced and in most cases 
profound.  This indicates that loss of sense of smell seen in PD patients is 
unlikely to be due to simple ageing and supports Hawkes (2008) research.  
This obviously has implications for this group of patients and indeed the 
disease itself , such as quality of life issues and safety.  This  obviously 
needs careful consideration when planning care for PD patients. 
 
The majority of PD patients in this study were males (72) but this is not 
surprising as males are 1.5:1 more likely to get PD than females; although, 
the ratio is slightly higher at 1.8:1 in this study.  The reason behind this could 
purely be due to a convenient sample of PD patients on the local Trust 
database, although, the researcher doubts this is a significant source of bias, 
as prevalence and incidence rates agreed with the local PD population and 
the local Trust database.  However, it could be due to the concept of age-
increasing male to female ratios due to etiological changes with age in PD 
(Moisan et al 2016), as the mean age for this study population was 71 years.  
Therefore, sex-related risk/ protective factors may play a different role across 
the continuum of age at onset in PD (Moisan et al 2016).  However, a genetic 
linkage study has localised a PD susceptibility gene (autosomal dominant) to 
the X chromosome (2q36-37), a finding that could, potentially, explain the 
higher incidence of PD among men (Pankratz et al 2002).  Therefore, until 
more genome-wide association studies are preformed, it remains to be seen 
whether X linked factors play a role in PD and whether their effect is age 
dependent.  Despite this, whatever the cause of increased risk of PD among 
men, a search for its basis may provide new evidence as to the pathology of 
this condition.  
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Females outperformed men on the UPSIT smell test which was significant 
(p=0.024). Many studies reports this finding regardless if they have 
investigated PD or not (Fusari et al 2008, Doty et al 1984, Cain 1982).  Also, 
female representation is less in those patients reporting an absent sense of 
smell which could further support the theory that women have a better sense 
of smell than men.  
 
Therefore, having grounds to believe gender differences exist here; this 
needs to be considered when recruiting PD patients into smell studies and 
could be why there is sometimes a variation in loss of sense of smell 
between studies.  Although it is beyond this study, further research into 
gender differences and motor, non-motor and quality of life issues may 
produce some interesting results.   
 
There were only four current smokers in this study sample and although 
mean UPSIT of present smokers is less than ex-smokers and non-smokers, 
results need to be interpreted with caution as there may be a sample size 
effect.  Therefore, this finding is difficult to generalise.  Also, the number of 
years since stopping smoking did not correlates with an improvement in 
sense of smell in the forty-seven ex-smokers which may suggest that 
smoking causes long-term irreversible effects on the sense of smell.  
However, due to the fact this study is an open cross-sectional observational 
study and not a longitudinal study this would again be difficult to justify.  It 
would also be difficult to measure due to the profound smell loss seen in 
most PD patients in this study sample.  However, as smokers are reported to 
have lower risk of developing PD and there are only 4 current smokers in this 
study this could support the theory that smokers have a lower risk for 
developing PD (Burton et al 2013, Huang et al 2010, Hawkes et al 2007, 
Hawkes et al 2009, Allam et al 2004).  The potential mechanisms underlying 
this association remain debated and it is unknown whether it is truly causal or 
a consequence of preclinical disease (Ritz and Rhodes 2010).   
 
Perceived ability to be aware of loss or change in ability to taste was not 
affected by the patient’s sense of smell (p=0.111), which highlights that taste 
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problems do not co-exist with loss of sense of smell.  However, it is worth 
highlighting that most PD patients cannot detect loss of sense of smell and it 
needs to be formally tested.  This may also be true of taste which needs 
consideration when examining these results.  Also, when examining when 
taste problems occurred and when PD was diagnosed, 20 out of the 30 
patients reported taste loss 1-18 years (mean 9 years) before a diagnosis of 
PD.  This finding does not support Fernando et al (2005) research who 
suggested that if loss or change in ability of taste does occur it is probably a 
late feature of PD.  
 
Duration of PD in this study ranged from 6 months to 19 years and it was 
particularly interesting to discover that loss of sense of smell was present to a 
relatively high degree, and in some cases profound, even in initial stages of 
the disease process, suggesting that loss of sense of smell is or can be 
affected before any motor manifestations.  
 
This study showed there was a positive correlation between loss of sense of 
smell and cognition during whole group analysis (p=0.024) and when 
comparing PD patients with mild impaired cognitive function or normal 
cognitive function (p=0.049).  The reasons for this are not fully understood 
and the implications to the individual PD patients are not transparent. 
However, what is evident in clinical practice (and in the research) is most PD 
patients do go on to develop dementia.  Overall, the incidence rate of 
dementia in patients with PD is consistently estimated at approximately 100 
per 100,00 patient years, a rate almost five- to six-fold higher than controls 
without PD (Hobson and Meara 2004) and a cumulative incidence of 
dementia in PD is reported to be as high as 80 percent (Aarsland et al 2003).  
The prevalence rate amongst the PD patients at a local Trusts database is 
approximately 43%.  However, most importantly, in practice, dementia is a 
key part of survival in PD and must be planned for in services for this 
condition (Buter et al 2008).  However, it would be unwise to assume those 
patients with anosmia will eventually develop dementia from this study as this 
warrants further in-depth research.   
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9.3.2 Correlation Between Traditional (Cardinal) PD Motor Symptoms 
and Sense of Smell; Implications for Clinical Practice 
 
No correlation between the motor function (as measured by the UPDRS III) 
score (whole group analysis) and sense of smell in PD was found in this 
study.  However, interestingly individual domain analysis revealed that a 
negative correlation was significant in posture, (p=0.014) facial expression 
(p=0.029) and arising from a chair (p=0.045).  This is an interesting finding, 
but the association is difficult to validate.  It appears no previous studies have 
linked posture, facial expression or arising from a chair to loss of sense of 
smell and the only reasonable theory is that due to poor posture and reduced 
facial expression, sniff vigour might be compromised. Arising from a chair 
may also be linked to posture and this is often seen in clinical practice and is 
therefore not an unreasonable assumption.  However, at this stage, the 
implications that directly help a PD patient is to be mindful that these motor 
domains may highlight a PD patient has a more profound loss of sense of 
smell. This however, warrants further investigation. 
 
Also, PD patients with tremor dominant PD did not have a superior sense of 
smell, compared to patients with akinetic –rigid type PD. (Whole group 
analysis p=.920; Individual sub-group analysis p=-0.366).  This mirrors 
previous observations by Haehner et al (2009) who tested 400 patients by 
means of ‘Sniffin Sticks’, and Ondo and Lai (2004) Who tested patients 
sense of smell using UPSIT 40.  Although Ondo and Lai (2004) found the 
subgroup of tremor-dominant PD with a family history of tremor had less loss 
of sense of smell loss than those without a family history (p=0.0007) or those 
with regular PD (p=0.0350).  However, the research findings of Lijima et al 
(2011) who tested 90 patients with PD using a 12 odour stick identification 
test specifically for the Japanese population noted that people with tremor 
dominant PD had a better sense of smell (p=0.05).  The reason behind this 
could not be explained as tremor is still poorly understood from a 
pathophysiological basis and in practice PD tremor treatment is a clinical 
challenge.  It appears only surgery (lesion or high frequency stimulation) of 
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discrete deep brain targets consistently provides symptomatic long-lasting 
alleviation. This is a procedure not often seen in practice.  However, it did 
highlight that olfactory dysfunction in this PhD study is more prevalent than 
the cardinal sign of a resting tremor (approximately 70%) of PD patients 
(Alves et al 2008), and similar to rigidity and bradykinesia (approximately 
90% and 100% respectively) (Alves et al 2008, Hawkes et al 1999. Hoehn 
and Yahr 1967).   
  
The results of this study also suggest that olfactory deficits (using smell 
identification) in PD are unrelated to factors such as disease stage (Hoehn 
and Yahr) and therefore disease severity.  This is supported by others using 
DatSPECT scans (Marek and Jennings 2009, Panzacchi et al 2008).  Also, in 
this PhD study, the loss of sense of smell can be profound even in the initial 
stages of PD.  This suggests therefore, that loss of sense of smell is helpful 
in diagnosis at pre-clinical stage; however, it is not clear if it changes with 
disease progression.  
 
Finally, RBD in this study does not correlate with the degree of smell loss.  
This is surprising as RBD and PD are both alpha-synuclein pathologies and 
both loss of sense of smell and RBD are both pre-motor biomarkers of PD 
(Chaudhuri and Naidu 2008).  Also, it is known that RBD arises in the Pons, 
which is stage two of Braak staging in PD (Braak et al 2003). 
 
9.3.3 Correlation Between PD Non-Motor Symptoms and Sense of 
Smell; Implications for Clinical Practice 
 
An important finding is that despite all the PD patients in this study having 
varying degrees of loss of sense of smell, change in ability to smell or taste 
was only reported by 33% of the study group on the NMS questionnaire even 
though on the screening questionnaire 70.5% reported a loss of sense of 
smell.  Although it is difficult for patients to retrospectively recognise a 
reduction in their sense of smell, it does highlight that self-reporting of smell 
dysfunction is too unreliable even from one questionnaire to another in the 
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same study. It also re-enforces the fact that sense of smell must be formally 
tested.  
The link between pain and its association with the sense of smell in this study 
does not support the work of Hara et al (2013) who found a significant 
correlation with smell dysfunction.  What is evident in clinical practice 
however, is patients’ rarely volunteer pain as a symptom of their PD.  To 
establish if there is a link between pain and PD a more specific questionnaire 
would need to be administered rather than a general question as shown in 
the NMS questionnaire.  
 
Of all the 30 non-motor questions asked dribbling of saliva during the day 
showed a negative correlation ( = -0.256) with loss of sense of smell which 
was statistically significant (p=0.003).  The rationale as to the cause of this 
has been discussed in chapter 5.  However, it is important to mention that 
drooling is a major non-motor complaint in many patients suffering from PD, 
44% of patients reporting it in this study and it is not uncommon for it to be a 
disabling social problem for many PD patients.  Drooling also increases the 
risk of aspiration pneumonia, skin maceration, and infection, (Meningaud et 
al 2006).   
 
Whole group analysis highlighted that quality of life did not deteriorate 
alongside the loss of sense of smell.  However, when examining the 
individual themes there was a negative correlation between cognition and 
UPSIT scores (p=0.036). 
 
 
 
9.3.4 Additional Confounding Factors and their Impact on Sense of 
Smell testing in PD Patients: Implications for Clinical Practice  
 
This study supports previous research that PD medication does not improve 
loss of sense of smell regardless of how long a person was diagnosed and 
what class of medication they were taking.  This has been found in other 
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studies (Hsia et al 1999, Koster et al 1999, Duchamp-Viret 1997, Wilson and 
Sullivan 1995, Doty et al 1992). 
 
Interestingly, correlation between duration of disease and UPSIT did not 
reach statistical significance (p=0.535).  This is in support of previous 
research which also suggested that there is no correlation between disease 
duration and loss of sense of smell (Haehner et al 2009, Hawkes et al 1997, 
Doty et al 1988, Quinn et al 1987, Ward et al 1983).  This is an interesting 
finding as other known symptoms of PD in particular motor symptoms, such 
as bradykinesia and rigidity, progressively worsen.  Therefore, these findings 
may suggest that olfactory loss is not a motor symptom of PD but it is beyond 
the scope of this study to give this theory any justice.   Also, this study did not 
confirm or refute whether impaired sniffing may be another motor symptom of 
PD. 
 
The effects of the environment on the sense of smell did not reach statistical 
significance (p=0.746).  This appears to have not been studied before in PD 
patients. 
 
PD patients who are ambidextrous have a much higher median and mean 
UPSIT scores.  However, due to the small sample size in the ambidextrous 
group (5 patients) statistical analysis was not possible. 
 
9.3.5 Perceived Recovery or Fluctuations in Sense of Smell. 
Phantosmia and UPSIT 40 Odours Presented 
 
Self-reported decreased sense of smell was recognised by the patients from 
approximately I month to 60 years pre-and post-diagnosis.  This highlights 
that the loss of sense of smell is often recognised before the onset of the 
motor symptoms of PD as evidenced by the fact that seventy-nine PD 
patients correctly detected a reduced sense of smell before being formally 
tested. 
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Comparison of UPSIT scores between PD patients reporting phantosmia or 
not did not reach statistical significance. Equally, UPSIT scores between PD 
patients self-reporting their sense of smell did or did not return, did not reach 
statistical significance.  Despite extensive research no papers could be found 
to support or refute these findings.  However, this study demonstrates that 
only ten (9%) of the PD patients reported phantosmia, which confirms 
phantosmia as an uncommon symptom in PD.  
 
This PhD study further highlights that most PD patients cannot smell 
common food substances.  For example, 87% of PD patients could not smell 
lemon, 76% could not smell pizza and 64% could not smell cheddar cheese 
(see section 3.6.4 table 3.30). 
 
Appropriate counselling with patients and their family members is important 
in the management of olfactory deficits.  This may be particularly crucial in 
the elderly patient that lives alone. 
 
9.3.6 Loss of Sense of Smell in PD and Risk and Safety Implications 
  
There are two major risk and safety concerns particularly relevant in PD 
patients associated with the reduced or absent sense of smell findings in this 
study, these are; increased risk of hazards (such as fire) and food poisoning. 
 
(i)  Fire Risk 
In this study, 36% of PD patients were unable to detect smoke and 55% of 
PD patients were unable to detect gas leaks (which is potentially a significant 
fire risk).  The inability to smell smoke and therefore detect fires and the fact 
that people over the age of 65 (Taylor et al 2004),  which most PD patients 
are (Rao et al 2006, Simuni 2007) puts this client group as having one of the 
greatest risk of being involved in a fire.  Undoubtedly, when exploring older 
decades and fire risks this has been documented over several centuries.  For 
example, a study of fire casualties (Hall 1997) highlighted that  elderly people 
are involved in a disproportionate number of house fires and gas poisonings 
and the fire statistics of Great Britain (2012-2013), highlight the risk of dying 
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in a fire for elderly people (65 and over) is over twice as high as the average 
for all ages.  Given the well-documented increase in olfactory dysfunction 
with increasing age, this may be a factor in the increased risk of fire-related 
deaths in this population.  Obviously, many other factors may also apply, and 
further research is needed to conclusively identify a contributory role of 
olfactory dysfunction. 
 
Risk is also said to be further impacted by the patient’s gender, with women 
being at higher risk (Taylor et al 2004, Santos et al 2004).  However, this is 
seen in the very old (80 and over) (National Statistics Online 2012-2013).  
This is not surprising as women tend to out-live men (National Statistics 
Online 2011-2013). 
 
It is important for the nurse to educate and advise the patient with an 
olfactory disorder regarding safety issues (e.g. use of smoke and carbon 
monoxide detectors in the home).  Home fire and safety visits are a free 
service via the fire service in the United Kingdom and fire detectors are also 
installed free of charge. 
 
(ii) Food Poisoning 
The findings in this PhD study highlight that most PD patients cannot detect 
food substances.  For example, 76% of PD patients could not detect pizza 
and 87% of PD patients could not detect lemon (see table 7.3).  This means 
that the nurse should teach PD patients to focus on checking visually for 
spoilt food, being more vigilant with regards to expiry dates on food items and 
being more vigilant when cooking food particularly ensuring that heat sources 
are off. 
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9.4 LIMITATIONS OF THE PRESENT PhD STUDY 
 
There were several limitations to the present PhD study: 
 
 Although sample size calculations have been carried out and simple 
statistical analysis has been conducted, the researcher believes this 
study does not represent the whole spectrum of PD patients because 
the mean age for this study group is 71 years.  This is predominately 
due to demographics of the area (as discussed in section 3.1.2).  
Therefore, this study does not represent younger onset PD patients. 
Second, those patients with mild/moderate microsmia represent only 
9% of PD patients in this study.  This was due to the sub-group 
analysis of the UPSIT scores as suggested by Doty (2003) which 
ultimately led to comparing three sub-groups of unequal distribution. 
 
 Although initial analysis of some of the variables that might affect the 
sense of smell suggests evidence of interesting and original findings, 
these may be due to a sample size effect.  To address this issue, a 
larger percentage of patients with mild/moderate microsmia would 
need to be recruited into this study.  This would require ethical and 
trust research and development approval and assessment of over 200 
more Parkinson’s disease patients to increase the mild/moderate 
group to 30 patients, if our study is to have a more even distribution. 
 
 As an open cross-sectional study, it does not capture whether odour 
detection progresses alongside the natural history of PD and this 
warrants further longitudinal analysis to measure changes in the sense 
of smell over time. 
 
 For more credibility, patients would need to have a battery of tests 
such as a polysomnography to confirm RBD, a full ear, nose and 
throat examination to exclude any other pathology which might be 
causing their reduced sense of smell, autonomic tests to highlight any 
dysfunction and further psychophysical tests to assess olfactory 
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function.  However, it is beyond this thesis to complete these 
assessments from both a resource and time constraint perspective.  
This would also increase the burden on the patients recruited for this 
study and may cause significant issues with ethical and trust research 
approval. 
 
 Some aspects of our study relied on self-reported data in the form of 
questionnaires.  The researcher had to take what patients said at face 
value.  The researcher is aware self-reported data contain potential 
sources of bias.  For example, remembering or not remembering 
experiences or events that occurred at some point in the past, such 
as, how long they had noticed their sense of smell had been 
compromised or overstating or understating effects of PD on their 
quality of life.  The researcher, on occasions, had to seek further 
clarity on these issues. 
 
 With regards to literature review, access to online journal articles was 
denied or otherwise limited.  This caused some frustration and was 
time consuming for the researcher.  Also, some of the odours were 
culturally bias as the booklets used were American (root beer and dill 
pickle). If the PD patient volunteered that they had not smelt any odour 
before such as root beer the researcher explained it smelt like 
germolene, black liquorice or even celery.  However, the researcher is 
further reassured in the fact that both these odours had a distinct smell 
unlike other odour possibilities presented on that particular page. 
 
 The PD patients in this study were not in the ‘off state’ when they were 
examined.  It could be argued that addressing and reducing any ‘off 
periods’ is more representative of a typical PD patient and therefore 
data collected in this present study is more realistic (particularly when 
examining the motor state).  However, most studies on the topic lack 
information regarding motor symptom assessment conditions of 
treated patients (i.e., “on” versus “off” medication) which raises an 
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important methodological aspect that has somewhat been neglected 
by the literature, which may partially explain the variability of findings. 
 
 Due to the small sample size of those PD patients with mild/moderate 
microsmia, and the concern that data presented could be due to 
sample size effect (rather than an original finding); in hind sight, it 
could be suggested  that two sub-groups [which are those PD patients 
with anosmia (UPSIT scores 6-18) and those PD patients with varying 
degrees of microsmia (mild/moderate/severe) (UPSIT scores 19-31)] 
may have addressed this issue and added better clarity to the overall 
results and add better understanding of the relationship between 
sense of smell and the motor and non-motor symptoms of PD.  
 
 Finally, from a practical point of view, seeking ethical approval has 
been mentioned in previous reports and this was particularly 
challenging.  Also, data collection was time consuming, but keeping to 
a strict time-table enabled this to be done in a timely manner.  The 
researcher has also managed to continue to stay focused on 
completing the study although, at times, this has been personally 
challenging. 
 
 
9.5 IMPLICATIONS FOR PROFESSIONAL AND PERSONAL 
DEVELOPMENT 
 
From a more professional nursing development perspective, so far, this study 
has, as well as enriching the researcher’s knowledge and understanding of 
Parkinson’s disease, the non-motor symptoms, biomarkers and clinical 
stages,  enabled the researcher to have a greater understanding of the use 
of Microsoft office, including excel and sky drive and the ability to work with 
software such as IBM SPSS Statistics. 
 
This study has also enabled the researcher to look more critically and 
analytically at other aspects of her professional role and to have the 
confidence to be more proactive due to increased knowledge. 
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9.6 SUMMARY  
 
This study has enabled the researcher to explore how prevalent loss of 
sense of smell is in PD and how it might be a predictor of clinical features, in 
particular its association with the motor, non-motor and quality of life 
symptoms in PD patients.  
 
Testing a patient’s sense of smell is an easily applied assessment tool 
capable of evaluation during PD patient reviews.  The outcomes that this 
study may generate will allow the application of new knowledge to practice 
through publicising and disseminating (raising awareness) how the sense of 
smell impacts on the motor, non-motor and quality of life of PD patients; the 
aim is to improve the overall care of the PD patient.  
 
Therefore, the importance of assessing loss of sense of smell PD is that by 
determining a PD patient’s sense of smell with a simple test at the outset 
may help to provide important information, such as;  (i) the range of clinical 
features that are likely to be encountered in this patient, (ii) providing very 
important prognostic information for this person (iii)  provide a supportive 
diagnostic tool for PD  (iv) planning nursing goals and (v)  highlight dangers 
or hazzards the individual PD patient might not be aware of and (vi) improve 
safety and quality of lifeThis can only help in our understanding of PD. 
Potential benefits to nursing are, by raising awareness of the prevalence and 
implications of smell loss in PD, nurses can ensure coping mechanisms have 
been employed to improve safety and well-being and, where appropriate, 
refer to other members of the multi-disciplinary team.  It may also help to 
provide very important prognostic information about the sense of smell in PD.  
This is particularly relevant to specialist nurses working with patients and 
their carers.  This can only help in our understanding of PD.  This may then 
support the need to review the Parkinson’s Disease National Institute for 
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Health and Clinical Excellence Guideline (2006) on treatment and 
management for Parkinson’s disease. 
 
9.7 FUTURE DIRECTIONS 
 
Olfactory loss at clinical level shows profound impairment of smell function, 
which means that this symptom may improve the diagnostic error rate and 
may need to be considered as part of the brain bank criteria.  Hawkes et al 
(1999) pointed out that there needs to be evidence that the olfactory system 
is consistently and severely involved to a degree of equalling or exceeding 
that of the classical motor symptoms of tremor, rigidity and bradykinesia.  
Evidence to support this is presented in this research. However, there is a 
need for further research to: 
 represent younger onset PD patients to cover the whole spectrum of 
PD symptoms which can vary according to age of onset.  
 have a larger sample size of patients with mild/moderate loss of sense 
of smell recruited into a new study to establish whether those patients 
are clinically distinct. 
 perform a further longitudinal study in order to measure changes in the 
sense of smell over time. 
 establish whether PD patients are tested during the ‘on’ or ‘off’ 
(particularly when examining the motor state) and sense of smell. 
 In hindsight, a two rather than 3 sub-groups [i.e., those with anosmia 
(UPSIT scores 6-18) and those with varying degrees of microsmia 
(mild/moderate/severe) (UPSIT scores 19-31)] would added better 
clarity to the overall results and add better understanding of the 
relationship between sense of smell and the motor and non-motor 
symptoms of PD. 
 finally, the researcher intends to publish the results of this PhD in 
nursing, neurological and movement disorder journals.   
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APPENDIX 1 
 
    Holland & Rees: Nursing: Evidence-Based Practice Skills 
A framework for critiquing qualitative research articles 
Aspect  Questions  
Focus  What topic is the concern of this article? Is 
this an important topic? The focus here will 
be broader than that of quantitative 
research and may emphasise experience of 
a condition or situation.  
Background  How does the researcher argue that the 
topic is worthwhile? How widespread or big 
a problem is it? Is the seriousness of the 
topic reinforced by the previous studies? Is 
there a thorough review of the literature 
outlining current knowledge on this topic? 
The background may make the qualitative 
approach a logical choice.  
Aim  What is the statement of the aim of the 
data collection? This usually begins with the 
word ‘to’ and may concentrate on an 
exploration of a situation, e.g. ‘The aim of 
this study is to explore the lived experience 
of chronic illness.  
Methodology or Broad approach  Within a broad qualitative approach is it 
phenomenological, ethnographic, grounded 
theory, or broad qualitative design? Does 
this match the statement of the aim?  
Tool of data collection  What was the method used to collect the 
data? Had this tool been used in previous 
studies of this type? A qualitative tool will 
not be piloted to check accuracy but may 
be used firstly on a small scale to give the 
researcher experience of its use in this 
situation. There may be mention of 
credibility where the researcher attempts to 
give clear details on the circumstances and 
environment in which data gathering took 
place. The descriptions of such things as 
individual interviews may be extensive to 
allow you to feel almost as though you 
were there. Do you feel this tool worked 
well or might an alternative have been 
more effective?  
Method of data analysis and 
presentation  
This is one of the most important steps in 
qualitative approach where the researcher’s 
understanding emerges inductively from 
the data and their interpretation of what is 
going on with those involved. To make 
sense of large amounts of text the 
researcher may mention specific systems 
for analysing the data either in the form of 
computer programs such as NUDIST and 
NVivo, or systems designed by other 
qualitative analysts such as Colaizzi or Van 
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Manon. There may be reference to 
immersion in the data where the researcher 
reads over and over the details of what 
people have said or done. Codes to 
categorised themes may be mentioned and 
illustrations of the way this was done may 
be presented to form an ‘audit trial’ to allow 
you to follow the way the researcher 
managed the data from transcript to coded 
themes. The data will be in the form of 
observed descriptions or verbal comments 
and statements from those involved. These 
may be quite powerful in their description 
of feelings and emotions where the 
researcher is attempting to provide 
evidence of ‘credibility’ so we can believe in 
the accuracy of the findings and the 
interpretation of them.  
Sample  Here the numbers of participants will be 
low, perhaps under 10 and often not more 
than 20. Data collection may have stopped 
once ‘saturation’ was reached, that is, 
where no new categories emerged from the 
findings. Were there inclusion and exclusion 
criteria stated? Were these reasonable 
given the research question and the nature 
of the sample? Do the selection criteria limit 
to whom the results may apply? What 
method was used to select who got into the 
study (the sampling strategy)? Is this 
appropriate for this research question and 
approach? Does the sample suffer from any 
kind of bias?  
Ethical considerations  Did an ethics committee (LREC, or in US an 
Institutional Review Board ‘IRB’) approve 
the study? Was informed consent gained 
and mention made of confidentiality? Could 
the study be said to be ethically rigorous?  
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APPENDIX 2 
 
     Holland & Rees: Nursing: Evidence-Based Practice Skills  
A framework for critiquing quantitative research articles 
Aspect  Questions  
Focus  What topic is the concern of this article? 
Can you identify measurable ‘variables’ in 
the title or researcher’s statement 
concerning their main interest? Is this an 
important topic for research?  
Background  How does the researcher argue that the 
topic is worthwhile? How widespread or big 
a problem is it? Is the seriousness of the 
topic reinforced by the previous studies? Is 
there a thorough review of the literature 
outlining current knowledge on this topic? 
Are the key variables defined and an 
attempt made to consider how they can be 
measured? E.g. definitions of ‘pain’ or 
‘anxiety’ and descriptions of scales 
frequently used to measure them.  
Aim  What is the statement of the aim of the 
data collection? This usually begins with the 
word ‘to’, e.g. ‘The aim of this study is ‘to 
examine/determine/ 
establish/compare/etc’. If it is a randomised 
control trial there may be a hypothesis.  
Methodology or Broad approach  Within a quantitative approach, is it a 
survey, experimental (RCT), or correlation 
study? Does seem suitable given the aim of 
the study?  
Tool of data collection  What was the method used to collect the 
data? Had this been used in previous 
studies and so may be regarded as reliable 
or accurate? If not, was it piloted? Is there 
any mention of reliability or validity? Is 
there a rationale given for the choice of 
tool? Could an alternative tool have been 
considered?  
Method of data analysis and 
presentation  
Is the method of processing and analysing 
the results described in the methods 
section, such as statistical process through 
SPSS computer analysis, and are the results 
clearly presented in the results/findings 
section? Does the researcher clearly explain 
any statistical techniques or methods of 
presentation such as tables, graphs, pie 
charts?  
Sample  On how many people, events, or things are 
the results based? If questionnaires were 
used, what was the response rate? If it was 
a randomised control trial, what was the 
dropout rate? Is either of these likely to 
have an impact on the results? Were there 
inclusion and exclusion criteria stated? 
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Were these reasonable given the research 
question and the nature of the sample? Do 
they limit to whom the results may apply? 
What method was used to select who were 
included in the study (the sampling 
strategy)? Does the sample suffer from any 
kind of bias?  
Ethical considerations  Did an ethics committee (LREC, or in US an 
Institutional Review Board ‘IRB’) approve 
the study? Was informed consent gained 
and mention made of confidentiality? Could 
the study be said to be ethically rigorous?  
Main Findings  What did they find in answer to their aim? 
What were the large results that relate to 
the aim of the study?  
Conclusion and Recommendations  Did they give a clear answer to their aim? If 
they stated a hypothesis, did they say if 
this was supported or rejected? Were clear 
recommendations made (who should do 
what, how, now)?  
Overall strengths and limitations  What would you say were the aspects of 
the study they did well? What aspects were 
less successful? Did they acknowledge any 
limitations to the study?  
Application to practice  How do the results relate to practice? 
Should any changes be considered?  
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APPENDIX 3 
LIST OF PRESENT UK DRUGS USED TO TREAT PD 
 
The major classes of drugs currently available for the treatment of 
Parkinson's disease in the UK 
Levodopa preparations Standard release 
 
Slow release 
 
Rapid release 
Levodopa/benserazide 
Levodopa/carbidopa 
Levodopa/benserazide 
Levodopa/carbidopa 
Levodopa/benserazide 
Dopamine agonists Non-ergot 
 
 
Pramipexole 
Ropinirole 
Rotigotine 
Apomorphine 
 
Catechol-O-methyltransferase 
inhibitors 
 Entacapone 
 
Monoamine oxidase B 
inhibitors 
 Selegiline 
Rasagiline 
Other NMDA antagonist 
Anticholinergics 
Amantadine 
Benzhexol 
Benztropine 
Biperiden 
Orphenedrine 
Procyclidine 
 
Drugs for Parkinson's disease (Fung et al 2001) 
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APPENDIX 4 
FEMALE AND MALE PERCENTILES 
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APPENDIX 5 
 
LIST OF SOME SUSPECTED DRUGS CAUSING PARKINSONISM 
List of neuroleptic drugs available in the UK  
Generic name  Trade name  
Amisulpride  Solian  
Chlorpromazine hydrocloride  Chloractil/Largactil  
Clozapine  Clozaril, Denzapine  
Flupenthixol  Depixol  
Fluphenazine hydrochloride  Modecate/Moditen/Motival (includes 
nortriptyline)  
Haloperidol  Dozic/Haldol/Serenace  
Methotrimeprazine/Levomeprom
azine  
Nozinan  
Olanzapine  Zyprexa  
Oxypertine  Oxypertine  
Pericyazine  Neulactil  
Perphenazine  Fentazin, Triptafen 
(Perphenazine+amitriptyline)  
Pimozide  Orap  
Pipotiazine  Piportil  
Prochlorperazine  Stemetil  
Promazine hydrochloride  Promazine  
Quetiapine  Seroquel  
Risperidone  Risperdal  
Sulpiride  Domatil/Sulpitil/Sulpor (Sulparex is 
discontinued)  
Thioridazine  Melleril  
Trifluoperazine  Stelazine  
Zuclopenthixol acetate  Clopixol  
Zotepine  Zoleptil 
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Other drugs that can cause drug-induced parkinsonism  
Generic name  Trade name  Used to treat  
Amiodarone  Cordarone X  Heart problems  
Cinnarizine  Stugeron  Nausea and vomiting, 
motion sickness, 
vertigo, dizziness, 
tinnitus, vascular 
disease and Raynaud’s 
syndrome, high blood 
pressure, abnormal 
heart rhythm, angina 
pectoris, panic attacks, 
manic depression and 
migraine  
Fluphenazine  Motival, Motipress  A combination of 
antidepressant and with 
nortriptyline 
antipsychotic drug  
Lithium  Camcolit, Li-Liquid, 
Liskonum, Priadel  
Depression  
Methyldopa  Aldomet  High blood pressure  
Metoclopramide  Maxolon  For sickness and 
indigestion. Also 
included in some 
medicines used 
migraine such as 
Paramax (with 
paracetamol) and 
Migramax (with aspirin)  
Prochlorperazine  Stemetil  Dizziness and nausea  
Tranylcypromine  Parnate  Depression 
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APPENDIX 6 
 LONE WORKERS POLICY  
�Points for Managers 
• Make informal inspections to make sure the workplace is safe and the lone 
worker is working safely 
• Ask yourself if you would feel safe in that situation 
• Check that all equipment is properly maintained and appropriate records 
are kept 
• Make sure all relevant risk assessments and safe working procedures are 
produced and readily at hand 
• If hazardous substances are in use, make sure the relevant Manufacturers 
Safety Data Sheet(s) is/are easily available (e.g. in a laboratory) and ensure 
a COSHH assessment has been completed and is up to date 
• Make sure that lone workers are fully aware of all of the relevant Trust 
guidance/policies 
• Check the signing in book for out of hours to make sure that the workers 
are signing in and out 
• Make sure that you have a reliable system for contacting the lone worker 
and checking that the individual is safe e.g. calling a pre-determined 
telephone extension at agreed times. Additionally, if a worker is using radio 
or mobile phone, then a prior check on reception in the area of work is 
essential. In areas of poor mobile phone reception, a satellite phone may be 
required instead 
• Consider what emergency situations could arise and ensure that you have 
the 
procedures in place to cater for them 
• Talk informally with the lone workers to find out whether they have any 
health and/or safety concerns about working alone 
�Points for Staff 
Out-of-Hours 
• Make sure someone knows when you leave for the workplace and when 
you arrive e.g. on Trust site(s), patient’s home etc. the location and when you 
anticipate leaving 
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• Do not do anything that you feel may put you in danger. If you are at all 
unsure what to do, or feel that the work requires more than one person to be 
done safely contact your Manager and request advice/assistance 
• Report any adverse incident, including ‘no harm events’, to your Manager 
using the 
Trust’s AIR form 
• Make sure you know and follow the relevant risk assessments, safe 
working procedures and guidelines for the work, including those relating 
specifically to the lone working situation 
• Make sure you know the appropriate accident and emergency procedures 
and that you know where the nearest telephone extension is  
• If you are injured or become ill try to stay calm, remember your training and 
contact the emergency services 
• Check any equipment you will be using to ensure that it is in safe working 
order 
• Check the workplace on arrival to make sure that it is safe to work there. 
You should do this, even if you have been there before, since there may be 
changes [e.g. different chemicals in use, a new/additional domestic animal at 
a patient’s home/phone reception etc.] which alter the level of risk 
• Check reception for your mobile phone or radio before starting work and 
regularly during it. 
�Visit to a home 
Together with the Manager the lone worker must: 
• Undertake a risk assessment of the work activity to be carried out 
• Make contact with subject to arrange suitable visit time and to explain the 
purpose and content of the visit and answer any initial queries they may have 
• Establish transport and routes to ensure there is adequate information on 
safe routes/parking and, if using public transport, have information on 
timetables etc. Be aware of any social tensions in the area to be visited 
• Ensure that there is communication with the Manager e.g. mobile 
phone/pager 
• Have a clear itinerary of the visit including appointment times and the 
names, addresses and contact numbers of the individual(s) being visited and 
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that arrangements are in place for communicating with the Manager. This 
must include an agreed procedure for making contact following the procedure 
to ensure the Manager knows the lone worker is safe. 
• Become familiar with procedures for what to do in the event of an 
emergency 
• Ensure that the Trust identification badge is shown to the patient on arrival 
at their home 
• At the home note where the door(s) potentially allowing for a rapid exit, 
should this become necessary 
• Leave the house if at any point if you feel uncomfortable or threatened 
• When appropriate, arrange a debriefing session with the Manager following 
the visit to discuss if the control measures in place were adequate. 
� Transport 
Personal vehicle 
Staff have responsibility for their own vehicle and for producing MOT, 
insurance and driving licence documents to the relevant manager. Staff 
should: 
• Make sure the vehicle being driven is regularly serviced, tyres/oil/fuel 
checked and filled 
• Consider access to a national breakdown service 
• Plan route in advance 
• Inform colleagues of destination and expected time of arrival and departure 
• Carry change/phone card/mobile ‘phone/pager 
• Keep possessions out of site 
• Keep a map handy in case you have to stop for directions 
• If returning to the vehicle after dark ensure parked in a well - lit area 
• Have your key ready on returning to the vehicle 
• Reverse into a parking space, ensuring easy exit from the space on your 
return 
• ‘De-personalise’ the vehicle e.g. do not make it obvious a female 
drives/rides the vehicle, or you are a supporter of a particular football team 
etc 
Car/van etc – 
• Keep doors locked and windows closed wherever possible 
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• Do not pick up hitchhikers 
• Always lock the car/van etc and keep everything in the boot 
Taxis 
• Avoid all unlicensed taxi cabs. In case a licensed cab is unavailable carry 
the number of a reputable company. Where possible book taxis in advance, 
do not get into a cab that you have not asked for. 
Train 
• Wait on the platform where it is well lit and there are plenty of people 
• Stand well back from the platform edge 
• Avoid compartments and try to sit with other people 
• If you feel threatened or there is an incident act immediately, alert guard or 
driver, pull emergency alarm 
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APPENDIX 7 
 
Unified Parkinson's Disease Rating Scale (UPDRS) 
 
Ref No.                         /         Date:        /    /20_  
 
The information you give will be treated in complete confidence.  
 
111 MOTOR EXAMINATION  
18. Speech  
0 = Normal.  
1 = Slight loss of expression, diction and/or volume.  
2 = Monotone, slurred but understandable; moderately impaired.  
3 = Marked impairment, difficult to understand.  
4 = Unintelligible.  
19. Facial Expression  
0 = Normal.  
1 = Minimal hypomimia, could be normal "Poker Face".  
2 = Slight but definitely abnormal diminution of facial expression  
3 = Moderate hypomimia; lips parted some of the time.  
4 = Masked or fixed facies with severe or complete loss of facial expression; 
lips parted 1/4 inch or more.  
20. Tremor at rest (head, upper and lower extremities)  
0 = Absent.  
1 = Slight and infrequently present.  
2 = Mild in amplitude and persistent. Or moderate in amplitude, but only 
intermittently present.  
3 = Moderate in amplitude and present most of the time.  
4 = Marked in amplitude and present most of the time.  
21. Action or Postural Tremor of hands  
0 = Absent.  
1 = Slight; present with action.  
2 = Moderate in amplitude, present with action.  
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3 = Moderate in amplitude with posture holding as well as action.  
4 = Marked in amplitude; interferes with feeding.  
22. Rigidity (Judged on passive movement of major joints with patient 
relaxed in sitting position. Cogwheeling to be ignored.)  
0 = Absent.  
1 = Slight or detectable only when activated by mirror or other movements.  
2 = Mild to moderate.  
3 = Marked, but full range of motion easily achieved.  
4 = Severe, range of motion achieved with difficulty.  
23. Finger Taps (Patient taps thumb with index finger in rapid succession.)  
0 = Normal.  
1 = Mild slowing and/or reduction in amplitude.  
2 = moderately impaired. Definite and early fatiguing. May have occasional 
arrests in movement.  
3 = Severely impaired. Frequent hesitation in initiating movements or arrests 
in ongoing movement.  
4 = Can barely perform the task.  
24. Hand Movements (Patient opens and closes hands in rapid succession.)  
0 = Normal.  
1 = Mild slowing and/or reduction in amplitude.  
2 = Moderately impaired. Definite and early fatiguing. May have occasional 
arrests in movement.  
3 = Severely impaired. Frequent hesitation in initiating movements or arrests 
in ongoing movement.  
4 = Can barely perform the task.  
25. Rapid Alternating Movements of Hands (Pronation-supination 
movements of hands, vertically and horizontally, with as large an amplitude 
as possible, both hands simultaneously.)  
0 = Normal.  
1 = Mild slowing and/or reduction in amplitude.  
2 = Moderately impaired. Definite and early fatiguing. May have occasional 
arrests in movement.  
3 = Severely impaired. Frequent hesitation in initiating movements or arrests 
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in ongoing movement.  
4 = Can barely perform the task.  
26. Leg Agility (Patient taps heel on the ground in rapid succession picking 
up entire leg. Amplitude should be at least 3 inches.)  
0 = Normal.  
1 = Mild slowing and/or reduction in amplitude.  
2 = Moderately impaired. Definite and early fatiguing. May have occasional 
arrests in movement.  
3 = Severely impaired. Frequent hesitation in initiating movements or arrests 
in ongoing movement.  
4 = Can barely perform the task.  
27. Arising from Chair (Patient attempts to rise from a straight-backed chair, 
with arms folded across chest.)  
0 = Normal.  
1 = Slow; or may need more than one attempt.  
2 = Pushes self up from arms of seat.  
3 = Tends to fall back and may have to try more than one time, but can get 
up without help.  
4 = Unable to arise without help.  
28. Posture  
0 = Normal erect.  
1 = Not quite erect, slightly stooped posture; could be normal for older 
person.  
2 = Moderately stooped posture, definitely abnormal; can be slightly leaning 
to one side.  
3 = Severely stooped posture with kyphosis; can be moderately leaning to 
one side.  
4 = Marked flexion with extreme abnormality of posture.  
29. Gait  
0 = Normal.  
1 = Walks slowly, may shuffle with short steps, but no festination (hastening 
steps) or propulsion.  
2 = Walks with difficulty, but requires little or no assistance; may have some 
festination, short steps, or propulsion.  
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3 = Severe disturbance of gait, requiring assistance.  
4 = Cannot walk at all, even with assistance.  
30. Postural Stability (Response to sudden, strong posterior displacement 
produced by pull on shoulders while patient erect with eyes open and feet 
slightly apart. Patient is prepared.)  
0 = Normal.  
1 = Retropulsion, but recovers unaided.  
2 = Absence of postural response; would fall if not caught by examiner.  
3 = Very unstable, tends to lose balance spontaneously.  
4 = Unable to stand without assistance.  
31. Body Bradykinesia and Hypokinesia (Combining slowness, hesitancy, 
decreased arm swing, small amplitude, and poverty of movement in general.)  
0 = None.  
1 = Minimal slowness, giving movement a deliberate character; could be 
normal for some persons. Possibly reduced amplitude.  
2 = Mild degree of slowness and poverty of movement which is definitely 
abnormal. Alternatively, some reduced amplitude.  
3 = Moderate slowness, poverty or small amplitude of movement.  
4 = Marked slowness, poverty or small amplitude of movement. 
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APPENDIX 8 
Date 8th January 2013. Version 2 
Non-motor symptoms questionnaire 
Reference.............. Date: .................  
Have you experienced any of the following in the last month? 
All the information you supply through this form will be treated with confidence and 
will only be used for the purpose for which it has been collected. Information 
supplied will be used for monitoring purposes. Your personal data will be processed 
and held in accordance with the Data Protection Act 1998. Developed and validated 
by the International PDnon-motorGroup. 
Non-movement problems in Parkinson’s 
The movement symptoms of Parkinson’s are well known. However, other problems 
can sometimes occur as part of the condition or its treatment. It is important that the 
doctor knows about these, particularly if they are troublesome for you. 
A range of problems is listed below. Please tick the box ‘Yes’ if you have 
experienced it during the past month. The doctor or nurse may ask you some 
questions to help decide. If you have not experienced the problem in the past month 
tick the ‘No’ box. You should answer ‘No’ even if you have had the problem in the 
past but not in the past month.                                                         
                                                                                                                  Yes   No 
1 Dribbling of saliva during the daytime.                                                   □  □ 
2 Loss or change in your ability to taste or smell.                                      □  □ 
3 Difficulty swallowing food or drink or problems with choking.             □  □ 
4 Vomiting or feelings of sickness (nausea).                                              □  □ 
 
5 Constipation (less than three bowel movements a week) or having  
to strain to pass a stool                                                                                □  □  
6 Bowel (faecal) incontinence.                                                                    □  □ 
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                                                                                                                 Yes   No 
                                                                                                                 
7 Feeling that your bowel emptying is incomplete after having been  
to the toilet.                                                                                                 □   □ 
8 A sense of urgency to pass urine makes you rush to the toilet.               □   □ 
9 Getting up regularly at night to pass urine.                                             □   □ 
10 Unexplained pains (not due to known conditions such as arthritis).     □   □ 
11 Unexplained change in weight (not due to change in diet).                  □   □ 
12 Problems remembering things that have happened recently or 
 forgetting to do things.                                                                              □   □ 
13 Loss of interest in what is happening around you or in doing things.  □   □ 
Yes No 
14 Seeing or hearing things that you know or are told are not there.        □   □ 
15 Difficulty concentrating or staying focused.                                         □   □ 
16 Feeling sad, ‘low’ or ‘blue’.                                                                  □   □ 
17 Feeling anxious, frightened or panicky.                                                □   □ 
18 Feeling less interested in sex or more interested in sex.                        □   □ 
19 Finding it difficult to have sex when you try.                                        □   □ 
20 Feeling light-headed, dizzy or weak standing from sitting or lying.     □   □ 
21 Falling.                                                                                                   □   □ 
 
22 Finding it difficult to stay awake during activities such as working,  
driving or eating.                                                                                         □   □ 
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                                                                                                                  Yes   No 
23 Difficulty getting to sleep at night or staying asleep at night.            □   □ 
24 Intense, vivid or frightening dreams.                                                  □   □ 
25 Talking or moving about in your sleep, as if you are ‘acting out’   
a dream.                                                                                                    □   □ 
26 Unpleasant sensations in your legs at night or while resting, and  
a feeling that you need to move.                                                              □   □ 
27 Swelling of the legs.                                                                            □   □ 
28 Excessive sweating.                                                                             □   □ 
29 Double vision.                                                                                     □   □ 
30 Believing things are happening to you that other people say are not. □   □ 
 
Chaudhuri KR, Martinez-Martin P, Schapira AHV, Stocchi F, 
 Sethi K, Odin P et al (2006) 'An international multicentre pilot study of the first comprehensive self-completednon-
motorsymptoms questionnaire for Parkinson’s disease: The NMSQuest study' Mov Disord; 21(7):916-923. 
 
All the information you supply through this form will be treated with confidence and will only be used 
for the purpose for which it has been collected. Information supplied will be used for monitoring 
purposes. Your personal data will be processed and held in accordance with the Data Protection Act 
1998. Developed and validated by the International PDnon-motorGroup. 
 
© Parkinson’s UK, August 2011. Parkinson’s UK is the operating name of the Parkinson’s Disease Society of the United 
Kingdom. A company limited by guarantee. Registered in England and Wales (00948776). Registered office: 215 Vauxhall 
Bridge Road, London SW1V 1EJ. 
A charity registered in England and Wales (258197) and in Scotland (SC037554). B117 
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APPENDIX 9 
 
 
Ref No.               /     Date:      /    /20_  
 
The information you give will be treated in complete confidence.  
 
HEALTH SERVICES RESEARCH 
UNIT 
DEPARTMENT OF PUBLIC HEALTH AND PRIMARY CARE 
UNIVERSITY OF OXFORD  
 
 
 
 
 
 
 
PDQ-39 
 
 
Parkinson's Disease 
Quality of Life Questionnaire 
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DUE TO HAVING PARKINSON’S DISEASE, how often have you experienced 
the following, during the last month? Please tick one box for each question 
 
                        Never      Occasionally     Sometimes    Often           Always                                                                                                                                                                                           
1. 
 
 
Had difficulty doing the leisure 
activities which you would like 
to do? 
  
2. 
 
 
Had difficulty looking after your 
home, e.g. DIY, housework, 
cooking? 
  
3. 
 
 
Had difficulty carrying bags of 
shopping? 
 
  
4. 
 
 
Had problems walking half a 
mile? 
 
  
5. 
 
 
Had problems walking  
100 yards? 
 
  
6. 
 
 
Had problems getting around 
the house as easily as you 
would like? 
  
7. 
 
 
Had difficulty getting around in 
public? 
 
  
8. 
 
 
Needed someone else  
to accompany you when you 
went out? 
  
9. 
 
 
Felt frightened or worried about 
falling over in public? 
Please check that you have ticked one box for each question before going on to the 
next page 
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Due to having Parkinson’s disease, how often during the last month have you ….              
Please tick one box for each question 
              Never     Occasionally    Sometimes    Often  Always 
  
10. 
 
 
Been confined to the house 
more than you would like? 
  
  
11. 
 
 
Had difficulty washing 
yourself? 
  
  
12. 
 
 
Had difficulty dressing 
yourself? 
  
  
13. 
 
 
Had problems doing up 
buttons or shoe laces? 
  
  
14. 
 
 
Had problems writing 
clearly? 
  
  
15. 
 
 
Had difficulty cutting up 
your food? 
  
  
16. 
 
 
Had difficulty holding a drink 
without spilling it? 
  
  
17. 
 
 
Felt depressed? 
  
  
18. 
 
 
Felt isolated and lonely? 
  
  
19. 
 
 
Felt weepy or tearful? 
  
Please check that you have ticked one box for each question 
before going on to the next page 
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Due to having Parkinson’s disease, how often during the last month have you …. 
Please tick one box for each question 
                 Never     Occasionally    Sometimes     Often      Always 
 
 
 
Please check that you have ticked one box for each question before going on to the 
next  page 
 
 
 
 
 
 
  
20. 
 
 
Felt angry or bitter? 
  
21. 
 
 
Felt anxious? 
  
22. 
 
 
Felt worried about  
your future? 
  
23. 
 
 
Felt you had to conceal your 
Parkinson's from people? 
  
24. 
 
 
Avoided situations which 
involve eating or drinking in 
public? 
  
25. 
 
 
Felt embarrassed in public due 
to having Parkinson's disease? 
  
26. 
 
 
Felt worried by other people's 
reaction to you? 
  
27. 
 
 
Had problems with your close 
personal relationships? 
  
28. 
 
 
Lacked support in the ways 
you need from your spouse 
or partner?   
If you do not have a spouse 
or partner, please tick here 
  
29. 
 
 
Lacked support in the ways 
you need from your family 
or close friends? 
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Due to having Parkinson’s disease, how often during the last month have you ….                                    
Please tick one box for each question 
                    Never    Occasionally     Sometimes     Often   Always 
  
30. 
 
 
Unexpectedly fallen asleep 
during the day? 
  
  
31. 
 
 
Had problems with your 
concentration, e.g. when 
reading or watching TV? 
  
  
32. 
 
 
Felt your memory  
was bad? 
  
  
33. 
 
 
Had distressing dreams  
or hallucinations? 
  
  
34. 
 
 
Had difficulty with your 
speech? 
  
  
35. 
 
 
Felt unable to communicate 
with  
people properly? 
  
  
36. 
 
 
Felt ignored by people? 
  
  
37. 
 
 
Had painful muscle cramps 
or spasms? 
  
  
38. 
 
 
Had aches and pains in your 
joints or body? 
  
  
39. 
 
 
Felt unpleasantly hot  
or cold? 
  
 
Please check that you have ticked one box for each question 
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APPENDIX 10 
HOEHN AND YAHR STAGING  
Ref No.               /     Date:      /    /20_  
 
STAGE 0 = No signs of disease.  
 
STAGE 1 = Unilateral disease.  
 
STAGE 2 = Bilateral disease, without impairment of balance.  
 
STAGE 3 = Mild to moderate bilateral disease; some postural instability; 
physically independent.  
 
STAGE 4 = Severe disability; still able to walk or stand unassisted.  
 
STAGE 5 = Wheelchair bound or bedridden unless aided. 
Key stage 0= No signs of disease. 
 
Further Explanation 
 
Stage 1. Unilateral involvement only, usually with minimal or no functional 
impairment. 
Stage 2.  Bilateral or midline involvement, without impairment of balance. 
Stage 3. First sign of impaired righting reflexes. This is evident by 
unsteadiness as the patient turns or is demonstrated when he is pushed from 
standing equilibrium with the feet together and eyes closed. Functionally the 
patient is somewhat restricted in his activities but may have some work 
potential depending upon the type of employment. Patients are physically 
capable of leading independent lives, and their disability is mild to moderate. 
Stage 4 Fully developed, severely disabling disease; the patient is still able 
to walk and stand unassisted but is markedly incapacitated. 
Stage 5 Confinement to bed or wheelchair unless aided.  
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APPENDIX 11 
Ref No.               /     Date:      /    /20_  
 
The information you give will be treated in complete confidence.  
 
 
RBD Screening Questionnaire 
  Question Answer 
English     
1. I sometimes have very vivid dreams. yes/no 
2. 
My dreams frequently have an aggressive or action-packed 
content. 
yes/no 
3. The dream contents mostly match my nocturnal behaviour. yes/no 
4. I know that my arms or legs move when I sleep. yes/no 
5. 
It thereby happened that I (almost) hurt my bed partner or 
myself. 
yes/no 
6. I have or had the following phenomena during my dreams:   
6.1.  speaking, shouting, swearing, laughing loudly yes/no 
6.2.  sudden limb movements, “fights” yes/no 
6.3. 
 gestures, complex movements, that are useless during sleep, 
e.g., to wave, to salute, to frighten mosquitoes, falls off the bed 
yes/no 
6.4. 
 things that fell down around the bed, e.g., bedside lamp, book, 
glasses 
yes/no 
7. It happens that my movements awake me. yes/no 
8. 
After awakening I mostly remember the content of my dreams 
well. 
yes/no 
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Ref No.               /     Date:      /    /20_  
 
The information you give will be treated in complete confidence.  
 
 
RBD Screening Questionnaire 
  Question Answer 
9. My sleep is frequently disturbed. yes/no 
10. 
I have/had a disease of the nervous system (e.g., stroke, head 
trauma, parkinsonism, RLS, narcolepsy, depression, epilepsy, 
inflammatory disease of the brain), which? 
yes/no 
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APPENDIX 12 
 
The University of Pennsylvania Smell Identification Test, a 40-odorant forced-
choice self-administered "scratch and sniff" test of olfactory function. This test 
is the most widely used test of olfactory function in the world, being available 
commercially as "The Smell Identification Tests." 
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APPENDIX 13 
 
 
  
314 
 
APPENDIX 14 
 
Date 8th January 2013.   Version 2 
 
Odour detection in Parkinson's disease. 
Participant Questionnaire 
 
Ref No.               /     Date :      /    /20_  
 
The information you give will be treated in complete confidence.  
 
Q1. Age:            years 
 
Q2. Are you?  Male   Female  
 
Q3. Describe your sense of smell 
 
Normal    Decreased      Absent  Other  please specify  
 (If you answer normal please move on to Q7) 
…………………………………………………..……………………………………. 
………………………………………………………………………………………… 
Q4 If you have a smell problem when did it begin? 
………………………………………………………………………………………… 
Q5 Does your sense of smell ever return? Yes   No   
 
Q6 Have you ever been bothered by a persistent smell? Yes  No  
If yes when did it begin ……………………. 
Please describe the odour……………………………………………… 
……………………………………………………………………………... 
Q7 Do you have a problem with your sense of taste?  Yes         No  
 (If you answer no please move on to Q9).  
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 If yes when did it begin ……………………. ………….. 
 
Q8 If you do have a problem with your sense of taste would you consider it to 
be?   
Mild    Moderate      Severe    
 
Q9 Have you ever smoked?  Yes   No  (If you answer no 
please move on to Q11)  
Q10 Do you currently smoke Yes  No    
How many years? ……………………… How many packs per day? ……….  
 
Q11. Do you have any sinus conditions (sinusitis, sinus infection, prior sinus 
surgery)?  
 Yes  No  
 
1. Q12.  Have you ever had serious or severe trauma for example resulting 
in loss of consciousness, a fracture or hospitalisation to your nose or 
sinuses 
 Yes   No  
If yes please specify 
…………………………………………………………………………………………
…………………………………………………………………………………………
. 
 
Q13. Are you: right handed?  left handed?  ambidextrous?  
 
Q14. Do you currently have a cold?   Yes   No
  
 
 
Q15. Do you have any other recognised causes for loss of sense of smell? 
      Yes   
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Details 
……………………………………………………………………………….… 
.………………………………………………………………………………………
… 
        No   
 
Q16. Do you have any history of neurological disease other than Parkinson’s 
disease? 
Stroke   Dementia    Other   details: 
…………………………………………………………………………… 
.………………………………………………………………………………………
……………………………… 
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THANK YOU FOR YOUR TIME IN COMPLETING THIS QUESTIONNAIRE 
 
 
Q17. UPDRS Score (Motor): 
………………………………………………………………………… 
 
 
Q18. Non-motor PD Score: 
…………………………………………………………………………… 
 
 
Q19. MOCA Score : 
………………………………………………………………………………………… 
 
 
Q20. UPSIT Score : 
…………………………………………………………………………………………
. 
…………………………………………………………………………………………
…………………………………………………………………………………………
……………… 
 
Q21. PDQ 39 Score : 
…………………………………………………………………………………………
…………………………………………………………………………………………
……………… 
 
Q22. RBD Score: 
…………………………………………………………………………………………
…………………………………………………………………………………………
……………… 
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Q23. Hoehn and Yahr Score: 
…………………………………………………………………………………………
……… 
 
Q24. Parkinson’s Disease Duration: 
…………………………………………………………………………………………
……… 
 
Q25. Current PD Medications: 
…………………………………………………………………………………………
……… 
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
……………………… 
Other medications 
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
……………………………………… 
Q 26. Timing of last PD medication dose: 
…………………………………………………………………………………………
.. 
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
….. 
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APPENDIX 15 
Ethical Approval 
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APPENDIX 16 
Date 8thJanuary 2013. Version 2 
Invitation letter 
LETTER TO PARKINSON’S PATIENTS.  
Dear ………………………….. 
I am writing to ask if you are willing to take part in a research study. This will only take about 
an hour of your time. The research study will give us information on whether the degree of 
loss of smell function is related to Parkinson’s disease severity and progression. The findings 
of this research study could lead to better management of the condition. The information 
sheet enclosed with this letter gives an explanation of the study.  
 
If you are willing to take part you can either attend Christchurch outpatients’ clinic to have a 
smell test and a memory test or I can arrange to see you in your own home. This can be 
done entirely at your convenience.  Several other questionnaires mentioned in the 
information sheet can be done in the comfort of your own home. There are no drugs or other 
treatments involved. Further information can be obtained from me, as indicated in the 
information sheet.  
If you have Parkinson’s disease, and you are willing to take part, please complete the form 
below and return it to me in the pre-paid envelope. I will contact you within two weeks of 
receiving your reply. You can change your mind later if you so wish.  Not taking part in the 
study, or a later change of mind will not affect your medical care or legal rights. 
 
Thank you for taking the trouble to consider this request. 
 
Yours sincerely, 
 
Ms C Thompson 
Consultant Nurse. Parkinson’s disease 
Royal Bournemouth and Christchurch NHS Foundation Trust   
CUT………………………………………………………………………………………………………  
 
I am willing to take part in the smell test research 
 
NAME…………………………………………………………………………………………………... 
 
CONTACTNUMBER…………………………………………………………………………………. 
 
ADDRESS…………………………………………………………………………………………….. 
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APPENDIX 17 
Date 8th January 2013 Version 2 
PARTICIPANTS INFORMATION SHEET 
 
Plain English Title 
Do people with Parkinson’s disease “who have either normal sense of smell, 
or a reduced sense of smell or no sense of smell” differ clinically from each 
other?   
 
Full Title  
An observational study to investigate whether individuals with PD who have 
either 
normosmia, hyposmia or anosmia are clinically different when comparing 
them to the 
natural history of PD in the motor, quality of life, disease stage and non-motor 
domains. 
 
Invitation Paragraph 
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it 
will involve. Please take time to read the following information carefully and 
discuss it with others if you wish. Ask if there is anything that is not clear or if 
you would like more information. Take time to decide whether you want to 
participate or not. 
 
Thank you for reading this. 
 
What is the purpose of the study? 
Sense of smell is commonly reduced or even absent in patients with 
Parkinson’s disease I am conducting the study as part of an educational 
project to find out whether people with Parkinson’s disease who have either 
normal, reduced or no sense of smell are clinically different either from the 
motor (slowness of movement tremor rigidity) or non-motor (e.g. dribbling of 
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saliva, speech or swallowing problems, depression sleepiness etc) 
symptoms. This could help us formulate guidelines for the long-term 
management of Parkinson’s disease. 
 
Why have I been chosen? 
You have been asked to take part in the study because you have Parkinson’s 
disease.   
 
Do I have to take part?   
Your participation in this research is entirely voluntary. It is up to you to 
decide whether or not to take part. If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If 
you decide to take part you are still free to withdraw at any time and without 
giving a reason.  A decision to withdraw from the study at any time or not to 
take part will not affect the standard of care you receive or have any adverse 
effects on your treatment. 
 
What will happen to me if I take part? 
If you agree to take part in our study we will only require about an hour of 
your time. After a few preliminary questions, I will explain what to expect. You 
will be asked to complete a participant’s questionnaire to see if you fulfil the 
criteria to be included in the study.  You will then sign a consent form and I 
will complete a short memory test. A simple smell test will then be performed 
consisting of 40 different smells via a scratch and sniff booklet. You will not 
be given any drugs or other treatments for the purpose of this research. If 
you are taking any medications I will not ask you to change these in any way. 
The testing can either be performed at Christchurch Hospital out patient’s 
department or in the comfort of your own home. Four other short 
questionnaires will then be given to you to complete at your convenience and 
one we complete together. These are simple questionnaires presently used 
in clinical practice to measure your motor and non-motor symptoms. 
However, I can assist with completing them all with you if required. 
 
What do I have to do?  
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Your participation in the research will be very brief (about an hour). 
Therefore, this research will have very little impact on your time and no 
impact on your lifestyle. I will explain the simple procedures to you before 
performing the tests, as described in the paragraph above. 
 
What are the possible risks and disadvantages of taking part?   
There is a potential risk of nausea and headaches during the smell test. If 
you are sensitive to any smells that may cause these side effects please 
inform me prior to the test. If during the test you feel nauseated or develop a 
headache please let me know and the test will be abandoned and side 
effects dealt with appropriately. The only disadvantage to you would be the 
donation of an hour of your time.  
 
 
What are the possible benefits of taking part? 
You are not likely to benefit personally from taking part in the research. 
However because the research will give us a better understanding as to 
whether the sense of smell and the progression of Parkinson’s disease may 
be linked this could influence our understanding and treatment of individual 
Parkinson’s disease patients.     
 
 Will my taking part in the study be kept confidential? 
Your participation in the study will be entirely confidential. Once I have taken 
the necessary measurements from all your results they will be stored 
anonymously. 
 
What will happen to the results of the research study? 
The results will be analysed and published, if accepted, in movement 
disorders and neurology journals. If you wish to see a copy of any 
publications you can obtain one from Cindy Thompson Consultant nurse in 
Parkinson’s disease. It is likely that the publications will take place one year 
after the study is completed. Because all the information is anonymous your 
name will not appear in any form of publication. 
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Who is conducting, organising and funding the research?  
This research is being conducted as part of an educational project 
undertaken by Cindy Thompson Consultant nurse in Parkinson’s disease. It 
is being jointly organised and supported by Bournemouth University and the 
Royal Bournemouth and Christchurch Hospitals NHS Trust. The resources to 
support the research are coming from the professional development and 
education budgets at the Royal Bournemouth and Christchurch Hospitals 
NHS Trust. The student involved in this research and the supervisors will 
receive no additional payments for conducting the tests or performing the 
analysis.  
 
Will my General Practitioner (GP) be informed? 
Yes. Your GP will be informed that you will be participating in the study. If 
any results impact on you Parkinson’s control or condition they will be 
notified. 
 
Who has reviewed the study? 
The proposed research has been reviewed by South Central. Southampton B 
REC 
 
 
Contact information 
Further information can be obtained from Cindy Thompson at Christchurch 
Hospital, Fairmile Road, Christchurch, BH23 2JX. Telephone No: 01202 
705320, Fax number 01202 705320, E-mail address: 
cindy.thompson@rbch.nhs.uk 
Thank you for taking the trouble to read this information sheet.   
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APPENDIX 18 
 
Date 8th January 2013.   Version 2 
 
CONSENT FORM  
Title of Project 
Plain English Title 
Do people with Parkinson’s disease who have either normal sense of smell, a 
reduced sense of smell or no sense of smell clinically different?   
Full Title  
An observational study to investigate whether individuals with PD who have 
either  
normosmia, hyposmia or anosmia are clinically different when comparing 
them to the 
natural history of PD in the motor, quality of life, disease stage and non- 
motor 
domains. 
 
Name of Researcher: Cindy Thompson 
                                                                                                            Please 
initial box 
1.  I confirm that I have read and understood the information sheet dated         
     …………….for the above study and have had the opportunity to ask 
questions 
 
2. I understand my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal 
rights being affected.  
 
3. I understand that sections of any medical notes may be looked at by 
responsible individuals from the research team or from regulatory 
authorities where it is relevant to my taking part in research. I give 
permission for these individuals to have access to my records 
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4.  I agree for my GP to be informed that I am participating in our study                        
 
5. I agree to take part in the above study 
 
 
 
 
________________________                ________________           
__________ 
Name of patient/participant                      Date                                 Signature 
 
 
________________________                ________________           
__________ 
Name of researcher taking consent          Date                                 Signature 
 
One copy for patient, one copy for researcher and one copy to be kept with 
hospital notes. 
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APPENDIX 19 
 
Date 8th January 2013. Version 2 
Letter to GP  
Ms C M Thompson 
Consultant Nurse Parkinson’s Disease 
Christchurch Day Hospital 
Fairmile Road  
Christchurch  
Dorset BH23 2JX 
                      An observational study to investigate whether individuals with 
PD who have either normosmia, hyposmia or anosmia are 
clinically different when comparing them to the natural history of 
PD in the motor, quality of life, disease stage and non-motor    
domains. 
Patients Name………………………………………………………………… 
Address………………………………………………………………………… 
Date of birth…………………………………………………………………… 
Hospital Number……………………………………………………………… 
Dear Doctor ………………………………… 
This patient is participating in the above study on whether patients with 
Parkinson’s disease who have either normosmia, hyposmia or anosmia 
clinically different? The study will involve several questionnaires and 
assessment tools designed to record both motor and non-motor 
symptoms in Parkinson’s disease as well as a 40 scratch and sniff test. 
None of these tests are invasive and are used in clinical practice. 
It does not involve any changes in standard treatment. A copy of the 
patient’s information sheet is enclosed.  
With kind regards 
Yours sincerely  
 
Cindy Thompson 
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APPENDIX 20 
Representative Medical Conditions that Affect the Senses of Smell or 
Taste. 
Parkinson’s disease 
Alzheimer's disease 
Bell's palsy 
Epilepsy 
Head trauma 
Korsakoff's syndrome 
Multiple sclerosis 
Tumors and lesions 
Cancer 
Chronic renal failure 
Liver disease including cirrhosis 
Niacin (vitamin B3). B12 and zinc deficiency 
Sjogren syndrome 
Zinc deficiency 
Adrenal cortical insufficiency 
Cushing's syndrome 
Diabetes mellitus 
Hypothyroidism 
Turner's syndrome 
Allergic rhinitis 
Bronchial asthma 
Influenza infections 
Adapted and updated from Mann (2002) and Nordin and Bramerson (2008) 
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APPENDIX 21 
Common Drugs that can affect the Sense of Smell or Taste.  
Class of Drugs Examples  
Drugs to Treat Cancer Cisplatin 
Doxorubicin  
Methotrexate 
Antihistamines Chlorpheniramine maleate 
Loratadine 
Terfenadine  
Drugs to Treat Infections  Ampicillin 
Trimethoprim,  
Tetracycline 
Metronidazole Drugs to Treat Arthritis and Pain   Colchicine 
Dexamethasone 
Hydrocortisone 
Muscle Relaxants and Drugs to Treat 
PD 
Levodopa 
Baclofen 
Drugs to Improve Mood or Treat 
Epilepsy 
Amitriptyline  
Carbamazepine 
Clozapine 
Fluoxetine 
Phenytoin 
Cardiac medications  Acetazolamide 
Adenosine 
Captopril 
Clonidine 
Diltiazem 
Propranolol 
Spironolactone 
Drugs to Lower Cholesterol or Lipids 
in blood 
 
Cholestyramine 
Fluvastatin sodium 
Lovastatin 
Pravastatin sodium 
 Drugs for Asthma and Breathing 
Problems 
 
 
Albuterol sulfate 
Flunisolide 
Metaproterenol sulfate 
Terbutaline sulphate 
Other  Antifungals, smoking cessation aids, 
radiotherapy to head, vasodilators 
 
Adapted from Doty et al (2008) and Schiffman and Graham (2000) 
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APPENDIX 22 
UPSIT scores associated with the 14-motor examination  
UPDRS Motor examination 
Speech  Number of 
Patients 
UPSIT Range UPSIT Mean 
0 46 6-28 18 
1 52 7-31 16 
2 13 11-27 16 
3 1 23 23 
4 0 0 0 
Facial 
Expression 
Number of 
Patients 
UPSIT Range  UPSIT Mean 
0 8 18-27 22.5 
1 48 7-28 17 
2 41 6-27 16 
3 13 10-13 15 
4 2 17-27 22 
Tremor at Rest Number of 
Patients 
UPSIT Range UPSIT Mean 
0 39 7-27 17 
1 34 8-31 16 
2 26 6-29 17 
3 13 10-27 18 
4 0 0 0 
Action/Postural 
Tremor 
Number of 
Patients 
UPSIT Range UPSIT Mean 
0 70 6-28 17 
1 40 8-31 17 
2 1 27 27 
3 1 23 23 
4 0 0 0 
Rigidity Number of 
Patients 
UPSIT Range UPSIT Mean 
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0 32 7-27 18 
1 55 7-31 17 
2 24 6-28 16 
3 1 27 27 
4 0 0 0 
 
Finger Taps Number of 
Patients 
UPSIT Range UPSIT Mean 
0 34 8-31 19 
1 53 6-27 16 
2 24 7-27 18 
3 1 27 27 
4 0 0 0 
Hand 
Movements 
Number of 
Patients 
UPSIT Range UPSIT Mean 
0 59 8-31 18 
1 40 6-27 16 
2 12 7-27 16 
3 1 12 12 
4 0 0 0 
Rapid Hand 
Movements 
Number of 
Patients 
UPSIT Range UPSIT Mean 
0 68 8-31 18 
1 34 6-27 15 
2 10 7-27 20 
3 0 0 0 
4 0 0 0 
Leg Agility Number of 
Patients 
UPSIT Range UPSIT Mean 
0 45 6-31 17 
1 55 7-29 17 
2 11 10-28 19 
3 1 11 11 
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4 0 0 0 
Arising from 
Chair 
Number of 
Patients 
UPSIT Range UPSIT Mean 
0 64 6-29 18 
1 29 7-27 17 
2 13 11-18 14 
3 6 8-31 17 
4 0 0 0 
 
 
 
 
 
 
Posture Number of 
Patients 
UPSIT Range UPSIT Mean 
0 31 7-27 20 
1 62 6-31 16 
2 14 8-23 15 
3 4 12-21 16 
4 1 27 27 
Gait Number of 
Patients 
UPSIT Range UPSIT Mean 
0 48 6-29 18 
1 50 7-31 17 
2 13 13-23 15 
3 1 16 16 
4 0 0 0 
Postural Stability Number of 
Patients 
UPSIT Range UPSIT Mean 
0 45 7-29 16 
1 48 6-27 18 
2 16 10-27 17 
3 3 13-31 17 
4 0 0 0 
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Body 
Bradykinesia and 
Hypokinesia 
Number of 
Patients 
UPSIT Range UPSIT Mean 
0 6 8-25 19 
1 45 6-31 17 
2 52 7-27 17 
3 8 11-27 15.5 
4 1 27 27 
 
 
 The higher the score the higher the disability. So generally 0= abcent or 
normal and 4= severe, marked or unable. 
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APPENDIX 23 
                         
Smells presented in each booklet 
 
 
Booklet 1 
Pizza 
Bubble Gum 
Menthol 
Cherry 
Motor oil 
Mint 
Banana 
Clove 
Leather 
Coconut 
 
 
Booklet 2 
Onion 
Fruit punch 
Liquorice 
Cheddar 
cheese 
Cinnamon 
Gasoline 
Strawberry 
Cedar 
Chocolate 
Gingerbread 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Booklet 3 
Lilac  
Soap 
Peach 
Root Beer 
Dill Pickle 
Pineapple 
Lime 
Orange 
Wintergreen 
Watermelon 
 
 
 
 
 
 
 
 
 
 
 
 
  
Booklet 4 
Paint thinner 
Grass 
Smoke 
Pine 
Grape 
Lemon  
Soap 
Natural Gas  
Rose 
Peanut  
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APPENDIX 24 
Neuroimaging Markers for PD.  
 
 
Imaging 
Modality  
Ligand and Target Changes in PD 
patients   
Value  References 
SPECT DaTSCAN, B-CIT 
 
Dopamine transporter 
Reduced binding in 
striatum of PD 
patients 
Helpful in diagnosis at 
preclinical stage but 
not clear if it changes 
with disease 
progresses. 
Booij et al 1997 
Marek and Jennings 
2009 
Panzacchi et al 
2008 
PET DTBZ, AV133 
 
Vesicular monoamine 
transporter 
Reduced in striatum 
of PD patients  
Showing encouraging 
results. Less sensitive 
to drugs but warrants 
further study. 
Hsiao et al 2014 
Okamura et al 2010 
PET F-DOPA 
 
Aromatic L-amino acid 
decarboxylase 
Reduced in striatum 
of PD Patients  
Helpful at preclinical 
stage but expensive 
and could be affected 
by levodopa 
Brooks et al 2003 
Morrish et al 1998 
PET Flurodeoxyglucose 
 
Glucose metabolism 
PD-specific network 
pattern 
Not disease specific 
but may prove useful. 
Alternative to SPECT. 
Boehm et al. 2011 
 
PET Raclopride 
 
D2 receptors 
Altered receptor 
numbers 
Has potential 
implications for 
models of basal 
ganglia function in PD. 
More studies needed. 
Strafella et al 2005 
PET PK11195 
 
Peripheral 
benzodiazepine 
receptors/activated 
microglia 
Increased brain 
inflammation in PD-
patients  
Possible early 
biomarker. Remains 
stable after two years. 
Longitudinal and pre-
diagnostic studies 
needed. 
Gerhard et al 2006 
SPECT MIBG 
Sympathetic terminals 
in the myocardium 
Reduced cardiac 
innervation in PD 
patients 
Helpful in preclinical 
stage but needs more 
studies 
Fujishiro et al 2008 
Orimo et al 2008  
 
Optical 
coherence 
tomography 
Retinal morphology Reduced innervation 
of retina in PD 
patients 
Could be used for 
evaluating 
progression. 
Inzelberg et al 2004 
 
Magnetic 
resonance 
imaging/ 
diffusion tensor 
imaging 
Fractional anisotropy Nigral-specific 
pattern in PD 
patients 
Could be used as a 
biomarker but lacks 
standardization and 
validation. 
More studies needed. 
Peran et al 2010 
Nigral 
ultrasound 
Unknown  
(nigral iron?) 
Nigral-specific 
pattern in PD 
patients 
Reliability still a matter 
of debate. 
More studies needed. 
Walter et al 2003 
Belaidi and Bush 
2016 
 
336 
 
APPENDIX 25 
 
Biomarkers in PD 
 
 
 
 
Study Number of 
cases  
Years 
follow-
up 
Assessment Results Years noted 
prior to a 
diagnosis of 
PD 
Olfaction HAAS (men 
only) 
Ross et al 
2008 
35 8 BSIT e Relationship of 
olfactory loss not 
seen before 4 years 
Within 4 
years 
 Haehner et al 
2007. (follow-
up study from 
Sommer et al 
2004) 
30 4 Sniff sticks and 
SPECT 
7% developed PD 
compared to 1.6% 
general population 
Within 4 
years 
 Stiasny-
Kolster et al 
2005 
30   _ Sniff sticks and 
SPECT 
4 diagnosed with PD 7-6 years 
but hard to 
verify as bed 
partners 
assessment 
 Ponsen et al 
2004 
hyposmic = 
40 
normosmic 
= 38 
asymptomati
c relatives 
2 A combination of 
olfactory 
detection, 
identification, 
and 
discrimination 
tasks. 
Plus, SPECT 
scan 
 
10% hyposmic 
patients developed 
PD. No normosmic 
patients did.   
? 2 years  
 Berendse et al 
2001 
25 hyposmic 
23 
normosmic 
relatives of 
PD patients 
_ SPECT Scan 
B SIT  
4 /25 developed IPD 
0/23 no signs of PD 
Possibly 3 
 Montgomery 
et al 1999 
80 first 
degree 
relatives  
100 controls 
-  22.5% relatives had 
abnormal sense of 
smell compared to 
9% controls 
? 
asymptomati
c carrier 
state or risk 
of PD 
Daytime 
Sleepiness 
HAAS Abbot 
et al 2005 
43  
 
8 Self-reporting Risk of PD in men 
with EDS vs men 
without EDS (p = 
0.004). 
0.5-4.9 
years 
 Gao et al 2011 770 4-10 Self-reporting 
hours of daytime 
napping 
 4-10 years 
RBD Classen et al 
2010 
 27 RBD 15  Clinical 
Diagnosis 
9 Developed PD 15-50 years 
 Iranzo et al 
2006 
44 RBD 2  Clinical 
diagnosis 
7 Developed PD 6-18 years 
 Postuma et al 
2009 
 93 RBD _ Clinical 
diagnosis 
19 Developed PD Mean = 11 
years 
 Olson et al 
2000 
 93 RBD  5  Clinical 
diagnosis. 
Medical records 
25 had parkinsonism 3 years in 
PD 
Constipation   HAAS 
Abbot et al 
2001 
96 24  Self-reported 
bowel 
movements 
Infrequent bowel 
movements increase 
risk of PD  
Mean = 12 
years  
 Savica et al 
2010 
196 _ Medical records 
review  
Constipation and 
laxative use 
Could be 
greater than 
20 years 
 HPFS men 
only 
Gao et al 2011 
156 6  Self-reported 
bowel 
movements 
Infrequent bowel 
movements increase 
risk of PD. Risk 4.88 
6 years plus 
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 NHS women 
only 
Gao et al 2011 
402 24  Self-reported 
bowel 
movements 
Infrequent bowel 
movements increase 
risk of PD. 
Risk 2.15 
No 
association 
beyond 6 
years 
Depresion Shiba et al 
2000 
196 8-87  Medical records 
review 
1.9 (1.1–3.2) Within 5 
years 
 Gonera et al 
1997 
60PD 
58 controls 
10 
years 
preced
ing 
diagno
sis 
Medical notes 29 PD 
15 controls 
4-6 years 
Neurological 
Imaging 
Hiker et al 
2005 
31 Mean 
64 
month
s 
(18f) dopa PET These data suggest 
that the 
neurodegenerative 
process in PD 
follows a negative 
exponential course 
and slows down with 
increasing symptom 
duration, 
contradicting the 
long-latency 
hypothesis of PD. 
5.6 years 
 Morrish et al 
1998 
32 39 
month
s 
(18f) dopa PET 
and UPDRS x2 
occasions 
Estimation of mean 
rate of progression 
varies according to 
the sensitivity of a 
functional imaging 
method to clinical 
severity. 
7 years 
Alpha 
synuclein 
levels in blood 
or spinal fluid 
El Agnaf et al 
2006 
34 PD 
27 Controls 
_ Blood samples 52% of PD and 
14.8% showed 
dramatic increase in 
oligomeric alpha-
synuclein 
_ 
 Abdi et al 
2006 
10PD 
10AD 
5DLB 
10 Controls 
_ Changes in 
spinal fluid 
1,090 new 
proteins 
identified 
Three confirmed 
candidate markers 
found for PD but not 
decreased in all 
patients. No single 
marker could detect 
difference in 
conditions but 
increases when two 
dimensions used.  
_ 
Cardiac 
sympathetic 
denervation 
Fujishiro et al 
2008 
4 controls 
11 DLB 
14 PD 
- Biopsy anterior 
left ventricle 
Cardiac sympathetic 
innervation 
significantly less in 
PD (P < 0.01) and 
increases with 
disease duration. 
- 
Cardiac 
sympathetic 
denervation 
Orimo et al 
2008 
20 patients 
with 
incidental 
Lewy body 
disease 
(ILBD), 
10withPD, 
20withmultip
le system 
atrophy 
(MSA) 
and10 
control 
subjects 
- Both cardiac 
tissues and 
paravertebral 
sympathetic 
ganglia were 
obtained 
May represent the 
pathological 
mechanism 
underlying a 
common 
degenerative 
process in PD. 
- 
 Courbon et al 
2003 
8PD 
10 PD with 
Autonomic 
Failure 
10 MSA 
- (1231) MIBG Sensitive test in 
diagnosis autonomic 
failure in PD but not 
differentiating PD 
and MSA. 
- 
 Braune et al 
1998 
10 PD 10 
autonomic 
failure 
 (1231) MIBG Cardiac uptake of 
MIBG significantly 
lower in PD. 
- 
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 Yoshita 1998 25 with PD 
24 other 
parkinsonian 
disorders 
20 controls  
 (1231) MIBG Cardiac uptake of 
MIBG significantly 
lower in PD. 
- 
Colonic 
Biopsy  
Shannon et al 
2012 
3 2.5 
years 
before
_ 
Colonic biopsy Alpha synuclein 
pathology 
 - 
 Lebouvier et al 
2010 
29PD 
10 Controls 
_ UPDRS III 
ROMEIII 
Colonic biopsy’s 
x4 
Lewy body 
pathology 21/29 of 
PD Patients. 0/10 in 
controls. Useful pre-
mortem to 
demonstrate the 
presence of Lewy 
pathology in the 
colon at initial 
stages of disease.  
- 
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APPENDIX 26 
Genes Invoved so far in PD 
LOCUS 
NAME 
GENE 
SYMBOL  
PROTEIN 
PRODUCT 
MODE OF 
INHERITANCE 
% OF 
AFFECTED 
INDIVIDUALS 
REFERENCES 
PARK2 PRKN Parkin Recessive 50% early onset 
PD 
Kitada et al 
(1998). 
Lucking et al 
(2000). 
PARK6 PINK1 PTEN-induced 
putative kinase1i 
Recessive 1-7% early 
onset PD 
Valente et al 
(2004). 
PARK7 DJ-1 Protein DJ-1 Recessive Rare. Early 
onset PD  
Bonifati et al 
(2003). 
PARK8 LRRK2 Leucine-rich 
repeat kinase 2 
Dominant 2%* Funajama et al 
(2002). 
Paisan-Ruiz et 
al (2004). 
Zimprich et al 
(2004). 
PARK1/4 SNCA Alpha-synuclein Dominant Rare. Late PD 
and early onset 
PD, dementia 
Polymeropoulos 
et al (1997). 
 
Farrer (2006). 
 In white populations, the frequency of LRRK2 mutations is 5% in those with 
a family history of PD and in 1.5% in those with sporadic PD.  Other 
populations can vary widely. 
For a review of all other genes involved in the pathogenesis of PD which are 
autosomal recessive, causing atypical features of parkinsonism, autosomal 
dominant with unclear pathology or those found to be an important risk factor, 
can be seen in Schulte and Gasser (2011) review. 
 
 
 
 
 
 
 
